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Glucocorticoids can act upon vascular cells to alter contractile function, influence
structure and modulate the inflammatory response to vascular injury. Tissue-specific
glucocorticoid availability is modulated by the isozymes of 11 (3-hydroxysteroid
dehydrogenase which inter-convert active glucocorticoids and their inactive
metabolites. 11 (THydroxysteroid dehydrogenase activity in the vascular wall may
contribute to local feedback regulation of inflammation, especially since pro¬
inflammatory cytokines up-regulate lipHSDl and down-regulate 11(3HSD2 in
cultured human aortic smooth muscle cells. It was hypothesised that inflammatory
mediators enhance local glucocorticoid generation by 11 P-hydroxysteroid
dehydrogenases in intact vascular tissue with resultant impairment of endothelial cell
function.
11 P-Reductase and dehydrogenase activities were detected in intact mouse aorta and
iliofemoral arteries in vitro, and in the perfused mouse hindquarter in vivo. 11 (3-
reduction was the predominant reaction direction. Use of mice with genetic
inactivation of either lipHSDl or 11PHSD2 demonstrated that 11PHSD2 acts as an
exclusive dehydrogenase. lipHSDl exhibited bidirectional activity in intact arteries
in vitro but was shown to be a predominant reductase in vivo. These studies confirm
the predominant regeneration of glucocorticoids by the 11 P-hydroxysteroid
dehydrogenases within the vessel wall and suggest that these isozymes play an
important role in modulating intra-vascular glucocorticoid signalling.
lipHSDl activity in cultured murine aortic smooth muscle cells was up-regulated
following incubation with the pro-inflammatory cytokine IL-ip. By contrast, there
was no such effect of inflammatory mediators on 11PHSD activity in intact aortic
rings in vitro. Systemic in vivo LPS administration resulted in a modest increase in
11 P-reductase activity in aortic rings ex vivo, but did not alter 11 P-reductase activity
in the perfused hindquarter in situ. These data suggest that up-regulation of
llpHSDl reductase is unlikely to be a significant accompaniment of vascular
inflammation in healthy arteries in vivo. However, the possibility remains that
11PHSD1 is up-regulated in pathological conditions associated with intense cell
proliferation, such as vessel injury or atheroma.
Consequent changes in glucocorticoid levels within vessels during inflammation
would be relevant as glucocorticoids directly influence many aspects of vascular
structure and function, including the vascular response to inflammation and/or injury.
To examine the effects of variations in glucocorticoid availability on endothelial cell
function, forearm venous occlusion plethysmography studies were conducted in
healthy volunteers following acute manipulation of circulating glucocorticoid levels.
Short term changes in systemic glucocorticoid concentrations did not significantly
alter endothelial cell vasomotor or fibrinolytic function in the human forearm. The
explanation for these negative findings may lie in the exquisite lipHSD system,
central to this thesis, whereby, despite fluctuations in circulating glucocorticoid
concentrations, vascular intracellular glucocorticoids levels are tightly regulated.
In conclusion, the studies presented in this thesis demonstrate that the isozymes of
lipHSD modulate local glucocorticoid concentrations within intact murine
vasculature. However, glucocorticoid metabolism by the 1 lpHSDs in healthy murine
arteries is not altered by inflammatory mediators. Finally, acute systemic variations
in glucocorticoid availability do not impair endothelial cell vasomotor or fibrinolytic
function in humans in vivo.
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Glucocorticoids may interact directly with cells of the blood vessel wall to
contribute to their well-established link with the development of cardiovascular
disease. Glucocorticoids can act upon vascular cells to alter contractile function,
influence structure and modulate the inflammatory response to injury. Local vascular
glucocorticoid availability is regulated by the isozymes of 11 (Lhydroxysteroid
dehydrogenase (llpHSD), which inter-convert active glucocorticoids and their
inactive metabolites. It has been suggested that regulation of lipHSD activity
contributes to local feedback regulation of inflammation as pro-inflammatory
cytokines alter lipHSD activity and expression in cultured human aortic smooth
muscle cells, favouring increased local glucocorticoid concentrations. However, the
influence of cytokines on lipHSD activity in intact arteries, and the consequences of
altered glucocorticoid availability on endothelial function in vivo have not been
established. The hypotheses that inflammatory mediators regulate local vascular
glucocorticoid action through effects on the lipHSDs and that alterations in
glucocorticoid availability influence endothelial function are explored in this thesis.
Given the importance of systemic and local glucocorticoid action on vascular
function, a comprehensive understanding of these steroids is required. The following
chapter reviews glucocorticoid physiology and pathophysiology with particular
emphasis on the importance of metabolism by the lipHSDs within the blood vessel
wall. The direct effects of glucocorticoids on vascular function are then reviewed in
detail. Finally, the hypotheses and aims of the thesis are described.
1.1 Glucocorticoids
1.1.1 Hormone structure, synthesis, regulation and metabolism
Glucocorticoids (corticosterone in rodents and Cortisol in man), originally named for
their effects on carbohydrate metabolism, are members of the steroid hormone family
synthesised from the common precursor cholesterol. All steroids hormones are
derived from the cyclopentanoperhydrophenanthrene structure comprising a
cyclopentane ring and three cyclohexane rings, and the unique properties of each
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individual steroid are determined by the presence of different chemical groups at
specific positions on the molecule (Figure 1.1).
Glucocorticoids are synthesised from cholesterol in the zona fasciculata (and, to a
lesser extent, the zona reticularis) of the adrenal cortex. Steroid biosynthesis within
the adrenal cortex is catalysed by a series of cytochrome P450 (CYP) enzymes
(Figure 1.2), which reside in the membranes of the endoplasmic reticulum and
mitochondria. The major active glucocorticoid in mice is corticosterone, rather than
Cortisol, as these animals lack the adrenal 17a-hydroxylase enzyme required for
Cortisol synthesis. Glucocorticoids are not stored in the adrenal gland but are
synthesised de novo and released when required.
Glucocorticoid synthesis and release is regulated by numerous ncuro-endocrine
signals (eg physical stress, pro-inflammatory cytokines) which act via the
hypothalamic-pituitary-adrenal axis. The hypothalamus, in response to stimulation,
releases corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP)
into the hypothalamic-hypophyseal portal capillary system. The stimulation of CRH
receptors on corticotrophs within the anterior pituitary gland results in rapid release
of adrenocorticotrophic hormone (ACTH) into the systemic circulation. ACTH,
formed from the processing of pro-opiomelanocortin (POMC) in the anterior
pituitary, is secreted in a pulsatile fashion and acts on the adrenal cortex to stimulate
synthesis of glucocorticoids and other adrenocortical steroids (Axelrod & Reisine
1984). Glucocorticoids themselves inhibit ACTH synthesis through inhibition of
CRH and AVP synthesis in the hypothalamus and by preventing POMC transcription
and processing in the anterior pituitary. In this manner, glucocorticoids provide
negative feedback to the hypothalamic-pituitary-adrenal axis to maintain
physiological circulating glucocorticoid levels. Glucocorticoid biosynthesis is also
subject to diurnal variation, as a results of diurnal changes in ACTH pulse frequency
and amplitude, with plasma levels highest just prior to waking and reaching a nadir
prior to sleep (Dallman et al. 1993).
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Figure 1.1 Steroid ring structure
The basic steroid ring structure comprising a cyclopentane ring and three
cyclohexane rings. Conventional labeling identifies the four carbon rings by letters,
and the individual carbon atoms by numbers. Chemical groups are designated
according to the number of the carbon atom to which they are attached.
4
ch3 ch3
Figure 1.2 Adrenocortical glucocorticoid biosynthesis
Steroid biosynthesis within the adrenal cortex from the precursor cholesterol is
catalysed by a series of cytochrome P450 enzymes. The major active glucocorticoid
in rodents is corticosterone as they lack adrenal 17a-hydroxylase.
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Plasma glucocorticoids are largely found bound to corticosteroid-binding globulin
(CBG) and albumin, with only 5-10% circulating in the free unbound state
(Hammond et al. 1990). Only free steroids are able to diffuse across the capillary
basement membrane and cell membrane to bind to the intracellular glucocorticoid
receptor, hence these binding proteins act to buffer available glucocorticoid. At high
physiological glucocorticoid concentrations, the binding proteins may become
saturated and this phenomenon may amplify the diumal variations in circulating
levels of free glucocorticoids.
Inactivation of glucocorticoids is mediated by a complex process of conversion to
inactive metabolites in the liver followed by renal excretion. This pathway,
illustrated in Figure 1.3, includes inter-conversion with inactive 11-
dehydrocorticosterone (or cortisone in man) by the isozymes of 11 (3-hydroxysteroid
dehydrogenase (lipHSD), reduction by 5a/p-reductases, 3a-hydroxysteroid
dehydrogenase (3aHSD) and 20a/p-hydroxysteroid dehydrogenases, followed by
oxidation by 21-oxidase and, finally, conjugation to either glucuronic acid or
sulphates to facilitate urinary excretion. Whilst the 11-keto metabolites formed by
lip-dehydrogenation of glucocorticoids (11-dehydrocorticosterone in rodents and
cortisone in man) are biologically inert, some of the other intermediate products of
glucocorticoid metabolism (eg 5a-tetrahydrocorticosterone) have the capacity to bind
and activate the glucocorticoid receptor (Mclnnes et al. 2004).
1.1.2 Glucocorticoid action
Classical glucocorticoid action is mediated through the binding of glucocorticoids to
intra-cellular corticosteroid receptors. There are two distinct cytosolic corticosteroid
receptors: glucocorticoid (GR; type II corticosteroid receptors) and mineralocorticoid
(MR; Type I corticosteroid receptors) receptors, both of which are members of the
steroid/thyroid hormone receptor super family of ligand-activated transcription
factors (Parker 1993). Although only one gene for GR has been identified, several




Figure 1.3 Pathway of glucocorticoid metabolism
Glucocorticoids are inactivated through conversion to inactive metabolites by
reduction, oxidation, hydroxylation and conjugation. The enzymes catalysing these
reactions are indicated. A = 11-dehydrocorticosterone; B = corticosterone; HSD =
hydroxysteroid dehydrogenase.
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Although glucocorticoids are able to bind to both MR (whose normal ligands are
mineralocorticoids, such as aldosterone) and GR, pre-receptor metabolism of
glucocorticoids by the enzyme 11 (3-hydroxysteroid dehydrogenase prevents illicit
occupation of MR in mineralocorticoid sensitive tissues. Thus, physiological
glucocorticoid effects are predominantly mediated by binding to GR rather than MR.
There are exceptions to this, for example in the hippocampus, where MR is not
protected by 11PHSD2 and is activated by both glucocorticoids and
mineralocorticoids (Sheppard & Funder 1987b; de Kloet et al. 1998).
Following diffusion of unbound glucocorticoid across the capillary basement
membrane and across the cell membrane, ligand binding leads to dissociation of GR
from inhibitory heat shock proteins, GR receptor phosphorylation and activation,
dimerisation and translocation to the nucleus where the glucocorticoid receptor
complex binds to specific palindromic DNA sequences known as glucocorticoid
response elements (GREs). GREs are located in the promoter region of target genes
(Yamamoto 1985) and activation of these elements by activated GR interferes with
components of the transcription machinery, leading to stimulation or repression of
gene transcription. Activated GR may also indirectly influence gene transcription
through cross-talk with other transcription factors, including the pro-inflammatory
transcription factors AP-1 and nuclear factor-icB (NF-kB) (Marx 1995). Functional
antagonism between GR and subunits of both NF-kB and AP-1 can disrupt pro¬
inflammatory gene activation and interfere with inflammation-mediated signalling
pathways.
In addition to the classical mechanisms of glucocorticoid action, there is increasing
evidence that glucocorticoids exert specific "non-genomic" effects. Examples exist
of rapid glucocorticoid effects (for example, on phospholipase A2 and
phosphoinositide-3-kinase-mediated eNOS release) that are mediated by GR but are
transcription-independent (Limbourg et al. 2002; Hafezi-Moghadam et al. 2002).
Some of the non-genomic effects of glucocorticoids are thought to be mediated by as
yet uncharacterised membrane-coupled receptors (Bartholome et al. 2004).
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1.1.3 Physiological effects of glucocorticoids
Glucocorticoids influence many body systems directly, and also indirectly, though
modulation of other hormone systems. They influence metabolic and homeostatic
processes as well as exerting effects on the cardiovascular system, the immune
system, the central nervous system, the reproductive system, the eye, bone, muscle
and during growth and development.
The abundant actions of glucocorticoids first came to light upon identification of
phenotypes of adrenocortical excess and insufficiency. Addison's disease, a state of
adrenocortical deficiency, is characterised by hypoglycaemia, weight loss, anorexia
and postural hypotension (Addison 1855). By contrast, Cushing's syndrome of
glucocorticoid excess results in numerous clinical manifestations including
depression, central adiposity, insulin resistance, hypertension and dyslipidaemia
(Cushing 1912).
1.1.3.1 Effects on metabolism
Glucocorticoids regulate hepatic and peripheral metabolism of carbohydrate, fat and
protein. These steroids increase blood glucose concentrations by inhibiting peripheral
glucose utilisation, stimulating hepatic gluconeogenesis and reducing insulin
secretion. Peripheral glucose uptake is inhibited through repression of translocation
of the glucose transporter GLUT4 to the cell membrane (Rizza et al. 1982).
Gluconeogenesis is stimulated by glucocorticoids as they promote availability of
gluconeogenic substrates, by enhancing skeletal muscle catabolism and lipolysis
(Exton 1979), and increase the expression of gluconeogenic enzymes such as
phosphoenolpyruvate carboxykinase (PEPCK; Sasaki et al. 1984). Glycogen
production is enhanced by glucocorticoids through increased synthesis by glycogen
synthase and reduced metabolism by glycogen phosphorylase (Stalmans & Laloux
1979). Glucocorticoids also alter fat metabolism by stimulating lipolysis, which
releases free fatty acids into the circulation, and by promoting differentiation of pre-
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adipocytes to adipocytes (Hauner et al. 1987). Indeed, glucocorticoid excess is
associated with redistribution of body fat from the peripheral to the visceral
compartments (Rebuffe-Scrive et al. 1988). These various effects of glucocorticoids
on carbohydrate and fat metabolism are highly dependent on the caloric state of the
individual, however. In general terms, glucocorticoids promote the mobilisation of
substrate from peripheral fat and protein stores in times of starvation, through
lipolysis and muscle catabolism, whilst fostering the accumulation of abdominal
adipose, and hence obesity, under conditions of caloric excess (Dallman et al. 2004).
Glucocorticoid excess, by promoting skeletal muscle catabolism, is associated with a
proximal myopathy. Additionally, glucocorticoid excess can also cause osteoporosis,
by inhibiting intestinal calcium absorption and increasing renal calcium excretion
(Canalis 1996), and by inhibiting new bone formation (Manolagas 2000). Finally,
glucocorticoids exert adverse effects on connective tissue through inhibition of
fibroblast function and extracellular matrix synthesis (Pratt & Aronow 1966).
1.1.3.2 Effects on immunity and inflammation
Glucocorticoids modulate many facets of the immune system and are perhaps best
known for their potent anti-inflammatory actions, which account for their most
common therapeutic applications. Inflammation is a tightly controlled process
(Nathan 2002), involving recruitment and activation of cells of the immune system in
response to infection or injury. Cytokines are secreted proteins which regulate almost
every aspect of the inflammatory response through effects on cell growth,
differentiation and activation (Borish & Steinke 2003). Pro-inflammatory cytokines
such as tumour necrosis factor a (TNFa) and interleukin lp (IL-ip), produced
predominantly by macrophages and antigen presenting cells, bind to cell surface
receptors thereby activating multiple interacting signal transduction pathways
including the receptor tyrosine kinases, mitogen-activated protein kinases (MAPK),
janus kinases and other kinase pathways involved in nuclear factor-xB (NF-kB)
activation. Transcription factors such as NF-kB and activator protein-1 (AP-1) then
translocate to the nucleus, bind to DNA and induce inflammatory gene transcription.
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The final responses to stimulation by the cytokines TNFa and IL-1 (3 include
neutrophil and T-lymphocyte activation, and the induction of endothelial cell
adhesion molecules to facilitate trafficking of granulocytes to the appropriate site. A
potent stimulus for pro-inflammatory cytokine expression is lipopolysaccharide
(LPS), a component of gram-negative bacterial cell walls. LPS becomes bound to
circulating LPS-binding protein, an acute phase protein, which aids docking of LPS
at dimmers of toll-like receptors (TLR4) on the cell surface of macrophages.
Activation of TLR4 receptors leads to the initiation of NF-kB, IRF3 and MAPK
kinase pathways, complex signalling cascades resulting in expression of many pro¬
inflammatory cytokines (including TNFa and IL-1(3), chemokines and immediate
early transcription factors (Wells et al. 2005). LPS-induced inflammation is potently
suppressed by the cytokines IL-4 and IL-13, secreted by T-helper lymphocytes (Hart
etal. 1999).
During inflammation, circulating glucocorticoid levels are elevated as a result of
HPA axis activation (Munck et al. 1984). Inflammatory stimuli such as TNFa and
IL-lp stimulate glucocorticoid secretion by enhancing expression of both CRH and
ACTH (Turnbull & Rivier 1999), and by promoting production of ACTH
secretagogues such as noradrenaline, pituitary adenylate cyclase-activating
polypeptide, vasopressin and other cytokines (Chesnokova & Melmed 2002). Within
specific tissues, intracellular glucocorticoid availability may also be enhanced as a
result of the effects of inflammatory cytokines on the 11 P-hydroxysteroid
dehydrogenases (as discussed in depth in Section 1.2.7). In a classical endocrine
negative feedback loop, glucocorticoids then act to interrupt the pro-inflammatory
cytokine-mediated signalling pathways and alter immune cell function thereby aiding
the resolution of inflammation.
The major mechanism by which glucocorticoids inhibit cytokine-mediated signalling
cascades is through reducing expression (transrepression) of inflammatory genes
such as adhesion factors, cytokines and chemokines. Glucocorticoids attenuate the
ability of pro-inflammatory transcription factors such as NF-kB and AP-1 to induce
gene expression (transactivation). The antagonistic effects of glucocorticoids on
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inflammatory gene transactivation by these transcription factors have largely been
attributed to direct protein-protein interactions between activated GR and subunits of
NF-kB (p65) (Ray & Prefontaine 1994; McKay & Cidlowski 1998) and AP-1 (c-Jun
and c-Fos) (Pfahl 1993), although GR is also able to repress AP-1 by interfering with
c-Jun N-terminal kinase activity (Bruna et al. 2003). Additionally, glucocorticoids
promote the expression of IkBcx, the cytoplasmic inhibitor of NF-kB, thereby
reducing the amount of NF-kB available to translocate to the nucleus (Auphan et al.
1995; Scheinman et al. 1995). Alternative mechanisms by which glucocorticoids
antagonise the effects of pro-inflammatory transcription factors include inhibition of
histone acetylation (which results in tighter coiling of DNA and reduced access of
transcription factors to their binding sites) (Ito et al. 2000; Adcock et al. 2004) and
competition for transcriptional co-activators (such as cAMP response element
binding protein (CREB)-binding protein (CBP))(Smoak & Cidlowski 2004).
Glucocorticoids are also able to directly activate transcription of a number of anti¬
inflammatory proteins (including lipocortin-1, interleukin 10 and IL-1 receptor
antagonist) by classical binding of GR to GREs on DNA (Barnes 1998) and, through
transcriptional induction of MAPK phosphatase-1 (MPK-1), may regulate
inflammatory signalling cascades by inhibiting phosphorylation/activation of a
number of essential kinases (De Bosscher et al. 2003).
There is clearly considerable cross-talk between the multiple inflammatory signalling
pathways and glucocorticoid receptor activation (Adcock & Caramori 2001), which
is unsurprising considering the direct physical interactions between transcription
factors, GR and other transcriptional coactivators. Both NF-kB (McKay & Cidlowski
1998) and AP-1 (Periyasamy & Sanchez 2002) are able to directly antagonise GR-
mediated gene transcription, and, as mentioned earlier, this mutual antagonism may
be due to competition for cofactors such as CBP (Smoak & Cidlowski 2004). The
activity of the glucocorticoid receptor, and hence its ability to transactivate GR-
dependent genes, also depends upon its phosphorylation state. Kinases involved in
the cytokine signalling pathways (such as c-jun N-terminal kinases) can alter the
phosphorylation of GR and in doing so inhibit GR-dependent gene transcription
(Rogatsky et al. 1998).
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In addition to their effects on cytokine-mediated signalling pathways, glucocorticoids
also modulate the function of the cellular component of the immune system. They
alter the peripheral leukocyte differential by increasing circulating granulocytes and
reducing circulating monocytes, lymphocytes and eosinophils. Glucocorticoids also
have direct actions on both T and B lymphocytes, including inhibition of
immunoglobulin synthesis and induction of lymphocyte apoptosis. Synthetic
glucocorticoids also contribute to the resolution of inflammation by accelerating the
acquisition of phagocytic capacity for apoptotic leukocytes in maturing monocytes
and increasing the capacity of individual macrophages to ingest multiple apoptotic
cells (Liu et al. 1999; Giles el al. 2001).
1.1.3.3 Effects on the cardiovascular system
Glucocorticoids exert their influences on cardiovascular physiology and
pathophysiology through both systemic and local mechanisms. A comprehensive
discussion of the direct vascular effects of glucocorticoids is provided in Section 1.3.
Glucocorticoids play a key role in the regulation of blood pressure. As discussed
earlier in Section 1.1.3, glucocorticoid deficiency and excess are associated with
hypotension and hypertension, respectively. The mechanisms by which
glucocorticoids influence blood pressure are undoubtedly complex, and not fully
characterised. Glucocorticoids enhance sensitivity to vasopressors such as
norepinephrine and angiotensin II (Sato et al. 1994) and impair nitric oxide-mediated
endothelial vasodilatation (Mangos et al. 2000). Glucocorticoids influence renal
electrolyte and water homeostasis via effects on glomerular filtration rate, proximal
tubular epithelial sodium transport and free water clearance (Marver 1984). The
regulation of intra-vascular volume is also affected by glucocorticoid-dependent
release of hepatic angiotensinogen (Saruta et al. 1986), hypothalamic AVP (Raff et
al. 1987) and atrial natriuretic peptide (ANP) from cardiac myocytes. Finally, there
may be central nervous system effects of steroids which contribute to the
development of hypertension (Scoggins et al. 1989).
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In addition to their effects on blood pressure, glucocorticoid excess is associated with
atherosclerosis. It is now widely recognised that atherosclerosis is an inflammatory
disease process (Ross 1999; Libby et al. 2002); chronic low-grade inflammation is
thought to contribute to the progression of atherosclerotic lesions and inflammatory
markers predict those patients at risk of future cardiovascular events (Albert et al.
2003; Schwartz et al. 2003). The potential therapeutic applications of
glucocorticoids, as inhibitors of both inflammation and proliferation, in the treatment
of atherosclerosis have been explored. Glucocorticoids inhibit macrophage and lipid
accumulation into atherosclerotic lesions (Asai et al. 1993; Naito et al. 1992), and
dexamethasone treatment inhibits neointimal proliferation in some (Villa et al. 1994;
Guzman et al. 1996; Petrik et al. 1998; Van Put et al. 1995), but not all (Karim et al.
1997; Lincoff et al. 1997), animal models of vessel injury. Local and systemic
glucocorticoid administration also reduces the development of stenoses following
vascular stent placement in animals (Strecker et al. 1998; Pires et al. 2005) and in
humans (Versaci et al. 2002; Patti et al. 2005), although this is in conjunction with
adverse vascular morphological changes (Pires et al. 2005).
Overall, however, the benefits of glucocorticoids have been disappointing, and may
have been offset by their systemic side effects. Moreover, despite their potent anti¬
inflammatory properties, systemic endogenous or exogenous glucocorticoid excess
actually contributes to many of the risk factors for ischaemic heart disease including
obesity, hypertension, insulin resistance and dyslipidaemia (Etxabe & Vazquez
1994). In healthy subjects, enhanced Cortisol production rates are associated with
higher blood pressure, obesity, insulin resistance and impaired glucose tolerance
(Walker et al. 1998). Furthermore, there is an increased risk of cardiovascular events
in patients exposed to exogenous glucocorticoid therapy (Wei et al. 2004; Souverein
et al. 2004). Additionally, there is evidence that glucocorticoids modulate factors
involved in coagulation (Brotman et al. 2005) and endogenous fibrinolysis (thrombus
dissolution) (Udden et al. 2002) to produce a pro-thrombotic state. These adverse
consequences of systemic glucocorticoid administration have prevented their
therapeutic application in the management of atherosclerosis and its sequelae.
14
However, it is increasingly recognised that local availability of glucocorticoids at the
tissue level, rather than circulating concentrations, may determine glucocorticoid
action. This concept will be discussed in depth in the following sections.
1 1.2 11 p-Hydroxysteroid dehydrogenases
This section describes the enzymology, physiology and significance of the lip-






The 11P-hydroxysteroid dehydrogenases (11 PHSDs) interconvert active
glucocorticoids (Cortisol in man, corticosterone in rodents) with their inert 11-keto
metabolites (cortisone and 11-dehydrocorticosterone, respectively). Tissues which
express 11 pHSDs can therefore regulate local exposure to active glucocorticoids.
Whilst circulating glucocorticoid concentrations are under the control of the
I hypothalamic-pituitary-adrenal axis (see Section 1.1.1), it is now recognised that the
11P-hydroxysteroid dehydrogenases are key determinants of tissue-specific
glucocorticoid hormone action.
1.2.2 History of 11 p-hydroxysteroid dehydrogenase
The inter-conversion of glucocorticoids with their inert 11-keto metabolites was first
described in 1953 (Amelung et al. 1953). Evidence for the importance of this inter-
conversion first emerged with the use of cortisone as a potent anti-inflammatory
therapy in patients with rheumatoid arthritis (Ward et al. 1951). It was not known at
the time, but cortisone was in fact the inactive hormone, and 11 pHSD activity in the
liver was responsible for generation of the active glucocorticoid, Cortisol. Studies
soon followed which identified lipHSD activity in placenta (Osinski 1960), liver
(Jenkins 1966), and kidney (Bush 1969), though the equilibrium "set point" varied
with tissue type - predominantly oxidative (and producing inactive 11-keto
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metabolites) in kidney and placenta, and reductive (regenerating active
glucocorticoids) in liver. Subsequent isotopic studies (Hellman et al. 1971), and
studies in patients with renal disease (Srivastava et al. 1973; Whitworth et al. 1989)
revealed that the kidney was a key site for glucocorticoid inactivation by 11(3HSD.
Glucocorticoid reactivation, by contrast, was found to occur in the liver, as suggested
by high cortisolrcortisone ratios in hepatic venous blood (Walker et al. 1992a). The
opposing enzyme directionalities in liver and kidney have since been attributed to the
existence of two distinct isoforms of lipHSD: a predominantly reductive NADP-
dependent type 1 isozyme (lipHSDl) and an NAD-dependent oxidative type 2
isozyme (11PHSD2).
The clinical importance of the 11 pHSDs came to light with the identification of the
"syndrome of mineralocorticoid excess" (SAME) (Ulick et al. 1979; Stewart et al.
1988). Patients, predominantly children, presented with signs of mineralocorticoid
excess with severe hypertension, sodium retention, hypokalaemia and suppressed
renin levels despite low plasma aldosterone concentrations. A similar clinical picture
of primary hyperaldosteronism had been noted some time previously in patients
receiving carbenoxolone for peptic ulcer disease, or following excessive
consumption of liquorice (Epstein et al. 1911): carbenoxolone is the hemi-succinate
derivative of glycyrrhetinic acid, the active ingredient of liquorice. These conditions
were ameliorated by treatment with dexamethasone or the mineralocorticoid
antagonist spironolactone (Hoefnagels & Kloppenborg 1983; Shackleton et al. 1980;
Doll et al. 1968) and exacerbated by physiological doses of Cortisol (Oberfield et al.
1983), suggesting that the pathophysiology was attributable to an ACTH-dependent
MR agonist. Patients with SAME, and healthy volunteers treated with glycyrrhetinic
acid were also noted to have abnormalities of glucocorticoid metabolism, with
elevated urinary free Cortisol levels, higher ratios of Cortisol:cortisone metabolites
and impaired elimination of [3H]-cortisol (Stewart et al. 1988; MacKenzie et al.
1990). The discovery that liquorice inhibited 11 (SHSD (Stewart et al. 1987;
MacKenzie et al. 1990; Stewart et al. 1990; Monder et al. 1989), together with
evidence that glucocorticoids co-localised with MR in the kidney following
administration of liquorice derivatives (Edwards et al. 1988) and were able to
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activate the receptor (Souness & Morris 1989), led to the description of the
pathology underlying SAME, and explained the paradox of mineralocorticoid
receptor selectivity for mineralocorticoids in the presence of glucocorticoids. Unlike
the ubiquitously expressed glucocorticoid receptor, the mineralocorticoid receptor,
which binds aldosterone and glucocorticoids with equal affinity (Krozowski &
Funder 1983; Arriza et al. 1987), is localised to aldosterone-target tissues such as the
distal nephron and colon (Lombes et al. 1990). In these tissues, despite far higher
circulating concentrations of glucocorticoids (Sheppard & Funder 1987a), only
aldosterone binds MR, due to inactivation of glucocorticoids by 11(3HSD2. Hence,
inactivation of 11 (3HSD2 by mutation, as in patients with congenital SAME (Stewart
et al. 1996), or by inhibition by liquorice (or its derivatives) (Edwards et al. 1988;
Funder et al. 1988) allows illicit activation of MR by glucocorticoids with the
resultant syndrome of apparent mineralocorticoid excess. This "apparent
mineralocorticoid excess" phenotype is also evident in mice with genetic inactivation
of 11|3HSD2 which show hypertension associated with hypokalaemia,
hypochloraemia, and supressed plasma aldosterone and renin activity (Kotelevtsev et
al. 1999; Holmes et al. 2001). 11(3HSD2 was thus identified as the "guardian" of
MR, preventing illicit activation by glucocorticoids to permit aldosterone-driven
activation (as illustrated in Figure 1.4).
1.2.3 Two isozymes of 1ip-hydroxysteroid dehydrogenase
Evidence for the existence of more than one isozyme of 11PHSD came from a
number of sources. Studies in the rat kidney showed that 11PHSD did not always co-
localise with the mineralocorticoid receptor (Edwards et al. 1988; Castello et al.
1989; Rundle et al. 1989), suggesting that there was an isozyme of lipHSD which
was distinct from that "guarding" MR. Kinetic studies using 11 PHSD isolated from
liver also suggested that the enzyme would be unlikely to compete with MR for
glucocorticoid binding as the Km for 11 PHSD was in the pM range (Lakshmi &
Monder 1985) whilst the Kd for MR is subnanomolar (Arriza et al. 1987).
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Figure 1.4 Pre-receptor metabolism of glucocorticoids by 11PHSD2
Active glucocorticoids (Cortisol in man, corticosterone in rodents) are inactivated by
the type 2 isozyme of 113-hydroxysteroid dehydrogenase. In this manner, illicit
occupation of the mineralocorticoid receptor (MR) by glucocorticoids is prevented,
thus conferring aldosterone specificity on the receptor.
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Clinical evidence for distinct isozymes came from the observation that patients with
11 pHSD deficiency had residual 11 P-reductase activity and were able to convert oral
cortisone to Cortisol (Ulick et al. 1979; Stewart et al. 1988). Furthermore, whilst the
lipHSD inhibitor carbenoxolone inhibited both 11 P-reductase and dehydrogenase
activity (Stewart et al. 1987; Stewart et al. 1988), glycyrrhetinic acid only inhibited
11 p-dehydrogenase activity (Stewart et al. 1990). The conclusive proof of the
existence of two isozymes has come with the the cloning of genes for 11 PHSD types
I and 2. 11 PHSD type 1 (lipHSDl) was cloned from rat liver in 1989 (Agarwal et
al. 1989) and the confirmation of a second isoform came with the cloning of
II PHSD type 2 (11PHSD2) from sheep and human kidney (Agarwal et al. 1994;
Albiston et al. 1994) and from human placenta (Brown et al. 1996) in the mid 1990s.
1.2.4 11 (3-Hydroxysteroid dehydrogenase type 2
11PHSD2 is a high affinity exclusive dehydrogenase, catalysing the conversion of
glucocorticoids (corticosterone, Cortisol) to their inactive 11-keto metabolites (11-
dehydrocorticosterone and cortisone, respectively). The gene for 11PHSD2, located
on chromosome 16 in humans and chromosome 8 in mice, has 77% sequence
homology between species and is therefore highly conserved (Krozowski et al.
1999). 11PHSD2 is a microsomal membrane-bound enzyme (Naray & Fejes-Toth
1996), which uses nicotinamide adenine dinucleotide (NAD) as its cofactor and has a
Km in the nanomolar range (Brown et al. 1993). The primary role of 11PHSD2 is to
prevent illicit occupation of MR by glucocorticoids in aldosterone-target tissues such
as the distal nephron, sweat glands, salivary glands and colon (Stewart & Krozowski
1999). This concept is supported by the syndrome (SAME) which results from
pharmacological inhibition (Monder et al. 1989), genetic inactivation (Kotelevtsev et
al. 1999) or congenital deficiency (Ulick et al. 1979; Stewart et al. 1988; Mune et al.
1995; Wilson et al. 1995) of 1 ipHSD2.
11PHSD2 is also highly expressed in the placenta (Stewart et al. 1995; Waddell et al.
1998) where it protects the foetus from exposure to excessive maternal
glucocorticoids (Brown et al. 1996). This is of great importance, as 11PHSD2
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inhibition, or maternal dexamethasone administration (dexamethasone is a poor
substrate for 11 pHSD2), results in low birth weight offspring (Benediktsson et al.
1993; Lindsay et al. 1996) which may "programme" individuals to a propensity for
hypertension, insulin resistance and hypercortisolaemia in adult life (Nyirenda et al.
1998; Nyirenda & Seckl 1998).
Our understanding of the physiological importance of the 11 (3HSDs has been vastly
aided by transgenic mouse studies (Paterson et al. 2005; Kershaw et al. 2005;
Kotelevtsev et al. 1999; Kotelevtsev et al. 1997; Masuzaki et al. 2001; Morton et al.
2004a). Mice with adipose specific over-expression of human 11PHSD2 (under the
control of the murine aP2 promotor; aP2-hl lpHSD2) (Kershaw et al. 2005) resist
weight gain on high-fat diet and have improved glucose tolerance and insulin
sensitivity. aP2-hlipHSD2 mice have a favourable adipocytokine profile, with
decreased expression of leptin and resistin and increased expression of adiponectin.
These data suggest that inactivation of glucocorticoids exclusively in adipose tissue
is an important determinant of a favourable metabolic phenotype. By contrast,
genetic inactivation of 11PHSD2 is associated with reduced viability and a severe
hypertensive phenotype (Kotelevtsev et al. 1999), although this phenotype is milder
on a C57B6J background than the original MF1 strain. The role of 11PHSD2 in the
control of vascular function and blood pressure will be discussed in detail in section
1.3.2.
1.2.5 11 P-Hydroxysteroid dehydrogenase type 1
In contrast to 11PHSD2, lipHSDl is a low affinity NADP-dependent enzyme
expressed in many glucocorticoid target tissues; particularly those which are
metabolically active such as adipose and liver (Stewart & Krozowski 1999). The
gene for lipHSDl is located on chromosome 1 in both humans and mice, and is
highly conserved between species, with 85% sequence homology (Krozowski et al.
1999). Initially, it was thought that lipHSDl played a similar role to that of
11PHSD2 as it acts as a dehydrogenase, inactivating glucocorticoids, in tissue
homogenates and microsomes (Lakshmi & Monder 1988). However, it is now
20
generally accepted that lipHSD acts as a predominant reductase in vivo,
regenerating active glucocorticoids. The reductase activity of lipHSDl has a Km of
~lpM in vitro (Agarwal et al. 1990) (Pu & Yang 2000; Shafqat et al. 2003),
significantly higher than endogenous concentrations of its substrates, 11-
dehydrocorticosterone and cortisone, which circulate in the low nanomolar range
(Harris et al. 2001). However, 1 lpHSDl is now known to occur as a dimeric enzyme
(Zhang et al. 2005a) which exhibits co-operative kinetics for 11-oxoreduction (Maser
et al. 2002), permitting dynamic adaptation in response to wide fluctuations in
endogenous glucocorticoid levels.
A novel insight into the bi-directional capability of lipHSDl has come from the
discovery that lipHSDl co-localises with hexose-6-phosphate dehydrogenase
(H6PDH) within the lumen of the endoplasmic reticulum (ER) (Atanasov et al.
2004). H6PDH catalyses the first two steps of the pentose phosphate pathway in
which glucose-6-phosphate is utilised to generate nicotinamide adenine dinucleotide
phosphate (NADP), the requisite co-factor for lipHSDl reductase activity. Co-
expression of H6PDH and lipHSDl in intact cells results in up-regulation of lip-
reductase activity and down-regulation of 11 p-dehydrogenase activity (Atanasov et
al. 2004; Bujalska et al. 2005). Conversely, lip-dehydrogenation becomes the
predominant reaction direction when H6PDH silencing RNA is transfected into cells
already expressing lipHSDl (Bujalska et al. 2005). Furthermore, there is a positive
correlation between H6PDH mRNA levels and lipHSDl activity, but not mRNA, in
human omental preadipocytes (Bujalska et al. 2005). These data suggest that H6PDH
activity may directly determine the reaction direction of 1 lpHSDl. Evidence of an
interconnection between the 1 lpHSDl and H6PDH enzyme systems also comes
from findings that glucose-6-phosphate stimulates lipHSDl reductase activity in
intact microsomes, whilst substrates for lipHSDl reductase (11-
dehydrocorticosterone or cortisone) or dehydrogenase (corticosterone) activity either
enhance or inhibit pentose flux, respectively (McCormick et al. 2005; Banhegyi et al.
2004). Therefore, the predominant 11 P-reduction of steroids by 1 lpHSDl in vivo has
been attributed to its physical proximity to the H6PDH co-factor generating system,
and the observation of dehydrogenase activity in tissues in vitro (Jellinck et al. 1999;
21
Brem et al. 1995) may reflect a change in directionality of 11(3HSD1 upon liberation
of the enzyme from its intracellular environment (where physical separation of the
enzyme from H6PDH favours 11 P-dehydrogenation) (Hewitt et al. 2005).
Interestingly, congenital lipHSDl deficiency, apparent cortisone reductase
deficiency (ACRD), first described in 1984 (Taylor et al. 1984) and reported in only
11 cases, is associated with few symptoms or signs relating to altered local
glucocorticoid metabolism, although there is evidence of increased metabolic
clearance of Cortisol. The predominant clinical consequences of this deficiency
(hirsutism, oligomenorrhoea and acne) relate to impaired negative feedback of
Cortisol on the HPA axis, resulting in increased ACTH secretion and consequent
adrenal androgen excess. The genetic explanation for ACRD is under debate: whilst
common polymorphisms in both the lipHSDl and the hexose-6-phosphate
dehydrogenase (H6PDH) genes have been found together in ACRD patients (Draper
et al. 2003), these polymorphisms are common (7%) in the general population, and
are not associated with features of ACRD (White 2005).
lipHSDl is thought to be important as an amplifier of glucocorticoid action in
glucocorticoid target tissues, and is widely expressed, most notably in liver, adipose
tissue, vasculature and the central nervous system. The physiological role of
11PHSD1 in different tissues is discussed in the following sections.
1.2.5.1 11PHSD1 in liver and adipose tissue
lipHSDl is expressed in both liver (Ricketts et al. 1998b), and adipose tissue
(Lindsay et al. 2003) and its physiological importance in the regulation of
metabolism has been elucidated through a series of transgenic studies (Paterson et al.
2005; Kotelevtsev et al. 1997; Morton et al. 2004a; Masuzaki et al. 2001). Mice with
genetic inactivation of 11(3HSD1 appear to have a "cardioprotective" phenotype;
they are protected from obesity (Morton et al. 2004a), resist stress- and obesity-
induced hyperglycaemia (Kotelevtsev et al. 1997), have lower serum triglycerides
and have a favourable adipocytokine profile, with reduced intra-adipose TNFa and
22
resistin and increased adiponectin levels. Systemic administration of a novel
pharmacological inhibitor of 11 (3HSD1 to diet-induced obese mice produces a
similar improvement in metabolic parameters (Hermanowski-Vosatka el al. 2005).
Furthermore, lipHSDl inhibition in humans results in improved hepatic insulin
sensitivity (Walker et al. 1995a) and lowers cholesterol (Andrews et al. 2003).
Murine adipose over-expression of 1 lpHSDl under the tissue-specific promoter aP2
results in a phenotype which mimics that of the metabolic syndrome with obesity,
insulin resistance, glucose intolerance, elevated circulating free fatty acids and
triglycerides and hypertension despite normal circulating corticosterone levels
(Masuzaki et al. 2001; Masuzaki et al. 2003). Hepatic lipHSDl over-expression,
under the control of the ApoE promoter has a similar, if less severe, metabolic
phenotype but without the obesity and glucose intolerance (Paterson et al. 2004). In
human idiopathic obesity there is reduced hepatic lipHSDl activity (Stewart et al.
1999) whilst lipHSDl activity in subcutaneous adipose is increased (Rask et al.
2001; Rask et al. 2002).
1.2.5.2 11/3HSD1 in cells of the immune system
The local metabolism of glucocorticoids in tissues of the immune system was first
noted in 1960 (Dougherty et al. 1960). Subsequent studies have confirmed the
presence of lipHSDl activity in homogenised preparations of spleen and lymph
nodes (Hennebold et al. 1996). More recent studies have started to tease apart the
cell-specific distribution and role of 1 lpHSDl. 1 lpHSDl mRNA has been detected
in mouse (Zhang et al. 2005b) and human (Zhou et al. 1998) lymphocytes.
Interestingly, although 1 lpHSDl is not expressed in human monocytes, it is induced
upon differentiation to macrophages (Thieringer et al. 2001). 11 (3HSD1 clearly has
an important function in these cells, as mice with transgenic inactivation of
11PHSD1 show a delay in the acquisition of macrophage phagocytic capacity and
impaired clearance of apoptotic neutrophils (Gilmour JS et al., unpublished
observations).
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1.2.5.3 11(5HSD1 in the central nervous system
11PHSD1 is expressed in both human (Sandeep et al. 2004) and rat (Moisan et al.
1990; Lakshmi et al. 1991) cerebellum, hippocampus and cortex regions of the brain
where it may act to modulate the biological effects of glucocorticoids on neuronal
development and function. Indeed, 1 lpHSDl inhibition, in both man (Sandeep et al.
2004) and mouse (Yau et al. 2001), also improves cognitive function putatively
through lowering glucocorticoid levels in the CNS, where glucocorticoids cause
memory impairment.
1.2.5.4 11(3HSD1 in other tissues
11PHSD1 is also expressed in a number of other tissues including lung, kidney,
colon, fetoplacental, gonad, bone, eye and in malignant cells. A detailed discussion
of the function of lipHSDl in these tissues is beyond the scope of this thesis and is
comprehensively reviewed by Tomlinson et al. (2004).
The distribution and physiological importance of lipHSDl in vascular tissue is
discussed in detail in Section 1.3.2.
1.2.6 Regulation of 11 P-hydroxysteroid dehydrogenases
There is complex regulation of the 11 pHSDs, much of which has still to be
characterised, particularly as methodological difficulties in attributing enyzme
activity to each individual isozyme has hindered attempts to study their regulation.
As already discussed, tissue-specific activity of the 11 PHSDs is central to their role
in mediating local glucocorticoid action. Furthermore, studies of the ontogeny of the
11 PHSDs, in several tissues and from a number of species, suggests that there is an
increase in llpHSDl expression during gestation, with a further increase during the
pre-pubertal period (Hundertmark et al. 1994; Diaz et al. 1998; Moisan et al. 1992;
Maser et al. 1994; Yang et al. 1992). These data imply that the 11 PHSDs are
regulated rather than constitutive. Sexual dimorphism of the 11 PHSDs has also been
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observed, with higher 11PHSD activity in the male rat liver and kidney (Lax et al.
1978; Smith & Funder 1991), and in male mouse aorta (Christy 2003) compared with
females. There are also some data regarding the sexual dimorphism of 11 pHSDs in
humans, although the findings have been less consistent (Andrew et al. 1998;
Stewart et al. 1999; Finken et al. 1999; Fraser et al. 1999).
Increasingly, other factors are being identified which regulate 11 PHSD activity
and/or expression. These include cytokines, endogenous and synthetic
glucocorticoids, growth factors, insulin, sex steroids, thyroid hormones,
gonadotrophins, peroxisome proliferators-activated receptor (PPAR) agonists, CRH
and ACTH (and are comprehensively reviewed in Tomlinson et al. 2004).
Glucocorticoids up-regulate lipHSDl in vitro in rat vascular smooth muscle cells
(Takeda et al. 1994c), human fibroblasts (Sun & Myatt 2003; Hammami & Siiteri
1991) and rat hepatocytes (Jamieson et al. 1995; Liu et al. 1996). In vivo, 1 lpHSDl
in the rat liver is induced by glucocorticoids (Low et al. 1994) and inhibited by
adrenalectomy (Walker et al. 1994b). Metyrapone, an inhibitor of 11 P-hydroxylase
used as a treatment for systemic glucocorticoid excess (Nieman 2002), also inhibits
11 PHSD 1 in sheep liver microsomes (Sampath-Kumar et al. 1997). Peroxisome
proliferator-activated receptors (PPARs) are key regulators of glucose and lipid
homeostasis, and PPAR agonists are increasingly used for treatment of diabetes
mellitus (PPARy) and hyperlipidaemia (PPARa). It is therefore of interest that
11 PHSD 1 is down-regulated by PPARa (Hermanowski-Vosatka et al. 2000) and
PPARy (Berger et al. 2001; Laplante et al. 2003), whilst 11PHSD2 is suppressed by
PPAR6 (Julan et al. 2005).
llpHSDs are also altered in important pathophysiological conditions which are
themselves risk factors for cardiovascular disease. Obesity is associated with an
increase in adipose 11 PHSD 1 expression and activity (Livingstone et al. 2000a;
Masuzaki et al. 2001; Rask et al. 2001; Rask et al. 2002; Lindsay et al. 2003; Wake
et al. 2003;Westerbacka et al. 2003) and a reduction in hepatic 1 lpHSDl (Rask et al.
2002; Rask et al. 2001; Stewart et al. 1999). By contrast, in what is thought to
represent a protective metabolic adaptation to caloric excess, a high fat diet results in
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rapid down-regulation of adipose 11 pHSDl (Morton et al. 2004b). Furthermore,
given the severe hypertensive phenotype in 11PHSD2 deficiency states, it is
interesting, but perhaps unsurprising, to find that polymorphisms of 11 pHSD2
influence renal sodium handling and may, therefore, contribute to the pathogenesis of
essential hypertension (Lovati et al. 1999; Williams et al. 2005).
The mechanisms by which humoral factors and disease states regulate 11 piiSD
remain largely unclear. However, intriguing new data have found that methylation of
the 11PHSD2 gene is associated with a decrease in its expression (Alikhani-Koopaei
et al. 2004). As DNA methylation of many genes changes with age, disease states,
and environmental signals including diet, this epigenetic mechanism may provide
one explanation for the pathological changes in 11PHSD expression which are
evident under these conditions.
1.2.7 Regulation of 11 p-hydroxysteroid dehydrogenases by
inflammatory mediators
Inflammatory cytokines are perhaps the most extensively studied group of mediators
which regulate lipHSDs (see Table 1.1). Their effects on lipHSD activity are of
great interest and relevance considering that atherosclerosis and the predisposing risk
factors, obesity and the metabolic syndrome, are now widely recognised to be
inflammatory conditions (Ross 1999; Libby et al. 2002; Lee & Pratley 2005). The
majority of studies to date have reported changes in lipHSDs which favour an
increase in glucocorticoid availability during inflammation. TNFa and/or IL-ip
increase lipHSDl activity and/or expression in human aortic smooth muscle cells
(SMCs) (Cai et al. 2001), rat glomerular mesangial cells (Escher et al. 1997), human
adipocytes (Tomlinson et al. 2001; Handoko et al. 2000; Friedberg et al. 2003),
human osteoblasts (Cooper et al. 2001), and human ovarian epithelial cells (Yong et
al. 2002). In both osteoblasts (Cooper et al. 2001) and human aortic SMCs (Cai et al.
2001), an accompanying downregulation in 11PHSD2 is also observed. These
coordinated changes would be expected to increase local availability of active
glucocorticoids and contribute to feedback regulation of inflammation.
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However, the effects of cytokines on the 11 (3HSDs are not entirely consistent, as
TNFa has no effect on lip-reductase activity in cultured human hepatocytes
(Tomlinson et al. 2001). Furthermore, in circulating monocytes, lipHSDl
expression is not up-regulated by the pro-inflammatory cytokines TNFa or IL-1P but
is induced during differentiation into macrophages, and also following exposure to
the T-helper (Th2) lymphocyte-derived cytokines, IL-4 and IL-13 (Thieringer et al.
2001). Additionally, whilst IL-ip modestly increases lipHSDl expression (but not
activity) in cultured human amnion fibroblasts, no such effect is evident following
stimulation with TNFa, although both TNFa and IL-1P exert a synergistic effect on
the up-regulation of 11PHSD1 by dexamethasone (Sun & Myatt 2003).
Finally, recent studies have highlighted the potential importance of the state of
cellular proliferation and/or differentiation in modulating the regulation of 1 lpHSDs
by cytokines. Basal lipHSDl expression is lower, and 11PHSD2 expression higher,
in human cell lines derived from ovarian adenocarcinomas compared with human
ovarian surface epithelial (HOSE) cells obtained by primary culture (Gubbay et al.
2005). Moreover, treatment with the inflammatory cytokine IL-la selectively
enhances llpHSDl in HOSE cells but not in carcinoma cells, whilst 11PHSD2
expression is up-regulated in some carcinoma cell lines but not in HOSE cells.
Hence, changes in the regulation of 11PHSD may accompany, or even determine,
changes in cellular differentiation or proliferation (Rabbitt et al. 2003). Bearing this
last point in mind, it should be noted that all studies so far which have investigated
the regulation of lipHSDs by inflammatory mediators have utilised cell culture




























































































































































































The focus of this thesis is the regulation of vascular ll(3HSDs and, hence, local
glucocorticoid action, by inflammatory mediators. There is increasing evidence that,
as well as the systemic effects of glucocorticoids on the cardiovascular system
(discussed in Section 1.1.3.3), direct interaction of these steroids with cells of the
vessel wall may contribute to their associations with cardiovascular disease. As
inflammation also has direct effects on vascular function, the potential link between
these interactions is of great interest.
The previous section has described how local glucocorticoid action is determined by
tissue-specific pre-receptor metabolism by the 11 P-hydroxysteroid dehydrogenases.
Both isozymes of lipHSD are present in the vessel wall and their roles in the
regulation of the direct vascular effects of glucocorticoids are discussed in detail in
the following section.
1.3.1 Vascular glucocorticoid action
The presence of both mineralocorticoid and glucocorticoid receptors within cells of
the vascular wall (Ullian 1999; Christy et al. 2003) suggests that glucocorticoids can
interact directly with the vasculature to influence aspects of vascular function and
structure. This interaction may be site-specific as there is evidence that the cellular
distribution of these receptors is territory-dependent. For example, MR is present in
the endothelial and smooth muscle cells of rabbit aorta and pulmonary artery but not
in the arterioles and capillaries (Lombes et al. 1992), whilst in the rat mesenteric
microcirculation, both MR and GR are more abundant in the wall of the arterioles
and venules, as compared with the capillaries (DeLano & Schmid-Schonbein 2004).
Regulation of 11 pHSD activity within the vessel wall, for example by inflammatory
mediators, may play an important role in modulating direct glucocorticoid-mediated
changes in vascular function and structure.
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1.3.2 Vascular 11 p-hydroxysteroid dehydrogenases
Both lipHSDl and 11PHSD2 are present in the vessel wall (Hadoke et al. 2001;
Christy et al. 2003; Brem et al. 1998) (Figure 1.5). The cellular localisation of each
isozyme is debated, and may be both species and site-specific. Vascular endothelial
cells isolated from rats appear to express both lipHSDl and 11PHSD2 (Brem et al.
1998), although studies from this department have identified only the 11PHSD2
isoform in the endothelium of both rat and mouse aorta (Christy et al. 2003). The
expression of 1 lpHSD isozymes in vascular smooth muscle is also controversial.
Studies in the rat and mouse have suggested that vascular SMCs express only
lipHSDl (Brem et al. 1998; Christy et al. 2003), whereas both isozymes have been
identified in human aortic and coronary artery smooth muscle cells (Cai et al. 2001;
Hatakeyama et al. 1999). Whilst these differences may be attributable to species and
site specific differences in lipHSD expression, direct comparison between studies is
problematic due to the variety of investigative techniques employed (eg. intact
vessels vs cultured SMCs). There is data to suggest that there are territory-dependent
differences in lipHSD activity in the rat at least, as higher lipHSD activity is
present in mesenteric arteries compared with aorta (Walker et al. 1991).
As discussed previously in Section 1.2.5, lipHSDl is generally accepted to act
predominantly as a reductase in vivo, catalysing regeneration of active
glucocorticoids. However, there is some evidence that lipHSDl has bi-directional
capability in vascular tissue as significant 11 P-dehydrogenase activity has been
detected in endothelium-denuded aorta and smooth muscle cells apparently devoid of
11PHSD2 expression (Brem et al. 1995). Furthermore, lipHSDl antisense
oligonucleotides diminish conversion of glucocorticoids to their inert 11-keto
metabolites in rat aortic rings (Souness et al. 2002) suggesting the presence of
11PHSD1 dehydrogenase activity. Attempts to clarify the directionality of each
isozyme within vascular tissue using conventional activity assays in homogenised
tissue preparations (Christy 2003) haye been limited by a lack of co-factor specificity









Figure 1.5 Intra-vascular glucocorticoid metabolism by the UpHSDs
Interconversion of active glucocorticoids (corticosterone in rodents, Cortisol in man)
with their inert 11-keto metabolites (11-dehydrocorticosterone and cortisone,
respectively) occurs in vascular tissue through the actions of the type 1 and type 2
isozymes of 11 P-hydroxysteroid dehydrogenase.
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However, there is clearly a need to resolve the relative contributions of these
isozymes to lip-reductase and 11(3-dehydrogenase activities within vascular tissue
to understand the regulation of the 11 pHSDs.
1.3.3 Intra-vascular glucocorticoid effects
1.3.3.1 Effects ofglucocorticoids on vascular morphology
Angiogenesis, the formation of new blood vessels from the existing vascular
network, is a complex process which contributes to both physiological and
pathophysiological processes. Tightly regulated angiogenesis is essential for
embryonic development and during the reproductive cycle (Folkman 2001), whilst
uncontrolled angiogenesis is a component of disorders including neoplasia and
proliferative diabetic retinopathy, and can be stimulated by inflammation (Conway et
al. 2001).
Pharmacological doses of glucocorticoids inhibit angiogenesis both in vitro and in
vivo (Folkman et al. 1983; Maragoudakis et al. 1989; Nicosia & Ottinetti 1990;
Folkman & Ingber 1987; Hori et al. 1996), and they therefore have therapeutic
potential (Kinnaird et al. 2003; Siemann et al. 2004). However, once again, the
adverse effects of systemic glucocorticoid therapy have restricted their use in this
regard. Recent studies within this department have demonstrated that mice with
genetic inactivation of lipHSDl have enhanced angiogenesis in vitro and in vivo
within implanted sponges, wounds and infarcted myocardium (Small et al. 2005).
These exciting new data suggest that endogenous glucocorticoids, including those
generated locally by lipHSDl, exert tonic inhibition of angiogenesis. Thus,
inhibition of lipHSDl may provide a therapeutic approach to improve healing of
ischaemic or injured tissues.
In addition to their potent angiostatic properties, glucocorticoids also influence a
number of critical processes involved in the vascular response to injury.
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Glucocorticoids are known to inhibit vascular smooth muscle cell growth (Berk et al.
1988; Longenecker et al. 1982). However, they may also paradoxically promote cell
proliferation, as they attenuate the activity of nitric oxide (Walker et al. 1995b;
Mangos et al. 2000), a potent inhibitor of cell growth, and enhance production of
endothelin-1 (Morin et al. 1998) and angiotensin II (Fishel et al. 1995), which both
stimulate cell growth (Berk et al. 1989; Griffin et al. 1991). Thus there may be
complex interactions between glucocorticoids and the vasculature to regulate
vascular remodelling.
An important clinical consequence of the vascular response to injury is the process of
neointimal proliferation. Neointimal lesions develop in response to injury and/or
inflammation (for example in atherosclerosis or following metal stent deployment
during revascularisation) as a result of migration and proliferation of smooth muscle
cells on the luminal surface of the vessel wall (Wainwright et al. 2001).
Glucocorticoids, administered both locally and systemically in animal models, have
been shown to inhibit neointimal lesion development (Macdonald L, unpublished
observations; Villa et al. 1994; Guzman et al. 1996; Van Put et al. 1995; Petrik et al.
1998; Strecker et al. 1998; Pires et al. 2005). However, there is some evidence that
this inhibition of neointimal formation occurs in conjunction with adverse vascular
morphological changes pointing to a loss of vascular integrity (Pires et al. 2005).
Additionally, the inhibition of lesion development by glucocorticoids was not
universal (Karim et al. 1997; Lincoff et al. 1997) and, whilst one clinical study
suggested that systemic prednisolone reduced the incidence of in-stent restenosis
(Versaci et al. 2002), most clinical trials have been disappointing (Pepine et al. 1990;
Reimers et al. 1998; Rab et al. 1991). The potential for the 11 pHSDs to modulate
these morphological changes, through their effects on local vascular glucocorticoid
availability, is currently under investigation in this department. A recently published
study has demonstrated that systemic administration of a selective inhibitor of
lipHSDl dramatically slows plaque progression in a murine model of
atherosclerosis (Hermanowski-Vosatka et al. 2005). It is likely that the influence of
glucocorticoids on neointimal lesion development and atherosclerosis is mediated, at
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least in part, by their anti-inflammatory properties, since inhibition of inflammation
also reduces neointimal proliferation (Miller et al. 2001).
1.3.3.2 Effects ofglucocorticoids on inflammation
A critical component of the pathophysiology of vascular diseases such as
atherosclerosis or vessel injury is the inflammatory response to endothelial cell injury
(Ross 1999; Ross 1993; Ross 1986). In the initial stages of atheroma formation,
endothelial cell activation leads to expression of adhesion molecules, such as P-
selectin (Johnson et al. 1997) and vascular cell adhesion molecule-1 (Li et al. 1993),
and increased vascular permeability. In response to chemokines such as macrophage
chemoattractant protein-1, leukocytes adhere to the endothelium and migrate into the
sub-endothelial space (Gu et al. 1998). These leukocytes then become activated and
release inflammatory mediators such as interleukin-1 and tumour necrosis factor a,
causing further recruitment and activation of inflammatory cells and stimulation of
endothelial and vascular smooth muscle cells to take part in the inflammatory
response. Vascular SMC proliferation, driven by growth factors such as platelet-
derived growth factor (Ferns et al. 1991) and basic fibroblast growth factor (Lindner
& Reidy 1991), subsequently results in neointimal proliferation and lesion formation.
As described in Section 1.3.3.1, acute vessel injury can also result in an excessive
inflammatory response and subsequent neointimal proliferation.
Glucocorticoids exert an array of anti-inflammatory and anti-proliferative actions,
which have been discussed previously in Section 1.1.3.2. Many of these effects are
likely to be mediated by direct local interaction of glucocorticoids with blood
vessels, inflammatory cells within the vasculature and mediators of the inflammatory
response (Barnes & Adcock 1993). Glucocorticoids alter the recruitment of
neutrophils and macrophages to the site of vessel injury (Poon et al. 2001; Asai et al.
1993; Naito et al. 1992) by decreasing expression of cytokines, chemokines and
adhesion molecules (Poon et al. 1996). Glucocorticoids also inhibit leukocyte
activation and proliferation, promote phagocytosis of apoptotic neutrophils and
inhibit T cell synthesis and induce lymphocyte apoptosis. In a recent clinical trial,
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local vascular glucocorticoid therapy (administered via dexamethasone-eluting
stents) reduced systemic markers of inflammation, such as C-reactive protein, and
improved outcomes (Patti et al. 2005). As discussed in Section 1.3.3.1, it is likely
that the influence of glucocorticoids on the vascular response to injury is in part
explained by their immunomodulatory effects.
Whilst pharmacological doses of glucocorticoids are undoubtedly powerful
immunosupressants, the immunomodulatory effects of physiological glucocorticoids
in the vascular inflammatory process is less clear. Endogenous glucocorticoids are
thought to serve as a "brake" to the immune response, protecting tissues from the
adverse effects of an excessive inflammatory response (Munck et al. 1984), and are
an absolute requirement to survive endotoxin or cytokine challenge (Bertini et al.
1988). Furthermore, the activation of the HPA axis by numerous pro-inflammatory
cytokines (Turnbull & Rivier 1995; Tumbull et al. 2003) suggests that feedback
regulation of inflammation acts to limit an over-vigorous immune response. Thus,
the regulation of local vascular glucocorticoid levels by the lipHSDs, and the
influence of inflammation on this process is a pertinent topic. As discussed in
Section 1.2.7, there is evidence of regulation of 1 lpHSDs by inflammatory cytokines
in cultured vascular SMCs (Cai et al. 2001). If this process also occurs in intact
arteries, there may also be a process of feedback regulation of inflammation within
the vessel wall itself.
1.3.3.3 Effects ofglucocorticoids on vascular tone
The local regulation of vascular tone involves complex interactions between the cells
of the endothelium and vascular smooth muscle. The endothelium, in response to
stimulation (by factors such as acetylcholine, bradykinin, shear stress etc) produces a
wide number of vasoactive substances, including vasodilators such as nitric oxide,
prostaglandins and endothelium-derived hyperpolarising factor (EDHF), and
vasoconstrictors such as endothelin-1, angiotensin II and thromboxanes (Figure 1.6).
Nitric oxide, a key mediator of vascular tone, is synthesised from L-arginine by a











Figure 1.6 influence of the endothelium on vascular tone
The endothelium, in response to stimulation, releases a variety of vasodilators and
vasoconstrictors. NO = nitric oxide; PGI2 = Prostacyclin; EDHF = endothelium-
derived hyperpolarising factor; ET-1 = endothelin-1; All = angiotensin II, TXA2 =
thromboxane A2.
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Figure 1.7 Nitric oxide mediated vasodilatation
Upon stimulation of the endothelium by agents such as bradykinin (BK) or
acetylcholine (ACh), nitric oxide is synthesized by constitutive (endothelial and
neuronal) and inducible isoforms of nitric oxide synthase (eNOS, nNOS and iNOS,
respectively). The production of the essential cofactor for NOS, tetrahydrobiopterin,
BH4, is regulated by the activity of GTP cyclohydrolase-1. Nitric oxide acts on
smooth muscle cells to increase generation of cyclic guanosine monophosphate
(cGMP) from guanosine triphosphate (GTP) by soluble guanylyl cyclase (sGC),
resulting in vasorelaxation.
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The NOS isozymes require an essential cofactor, tehtrahydrobiopterin (BH4), whose
availability depends on the activity of the rate-limiting enzyme guanosine
triphosphate (GTP) cyclohydrolase I.
Unlike the constitutively expressed endothelial (eNOS) and neuronal NOS (nNOS)
isoforms, inducible nitric oxide synthase (iNOS) is activated in response to
inflammatory mediators and is capable of sustained production of large quantities of
nitric oxide (Moncada et al. 1991). Inflammation is associated with impaired
endothelium-dependent vasomotion (Chia et al. 2003b; Kofler et al. 2005), and
excessive generation of nitric oxide by iNOS may account for the vascular
dysfunction evident in a number of inflammatory conditions including sepsis and
endotoxaemia (Hallemeesch et al. 2003; Chauhan et al. 2003).Glucocorticoids have
been shown to inhibit iNOS (Korhonen et al. 2002) and GTP cyclohydrolase
(Mitchell et al. 2004) and improve sepsis-induced vascular dysfunction (Mansart et
al. 2003).
It is well recognised that glucocorticoids contribute to the maintenance of vascular
tone in vivo. As discussed in Section 1.1.3.3, glucocorticoid excess is associated with
hypertension, whilst deficiency results in hypotension. Although some of the
influences of glucocorticoids on systemic blood pressure are mediated through
effects on cardiac output and renal salt and water homeostasis, there is increasing
evidence that glucocorticoids interact directly with the vessel wall to influence
contractility. Glucocorticoids potentiate pressor-mediated vasoconstriction (Ullian
1999; Walker & Williams 1992) by modulating vascular smooth muscle cell
signalling mechanisms (Sato et al. 1994; Sato et al. 1992; Yasunari et al. 1990).
Furthermore, acetylcholine-mediated vasodilatation is attenuated by glucocorticoids
(Walker et al. 1995b; Mangos et al. 2000), which also reduce the activity of other
vasodilators (eg prostaglandins, nitric oxide) (Rosenbaum et al. 1986; Kelly et al.
1998; Wallerath et al. 1999; Simmons et al. 1996). It is likely that the mechanism of
impaired cholinergic dilatation following glucocorticoid therapy involves
abnormalities of the endothelial nitric oxide system (Hadoke et al. 2001; Mangos et
al. 2000). Despite the evidence that glucocorticoids directly influence mechanisms
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involved in the regulation of vascular tone, there are some important negative
findings which deserve attention. Although longer term treatment of healthy
volunteers with systemic glucocorticoids results in an increase in blood pressure and
impaired acetylcholine-mediated NO release (Mangos et al. 2000), short term
systemic or intra-arterial infusion of Cortisol does not appear to influence
physiological or biochemical markers of nitric oxide activity (Williamson et al.
2005; Mangos et al. 2000), supporting the concept that glucocorticoid-mediated
endothelial cell dysfunction may be secondary to effects of elevated blood pressure.
Early observations that either congenital deficiency or pharmacological inhibition
(by liquorice) of 11PHSD2 (Ulick et al. 1979; Stewart et al. 1988; Epstein et al.
1977) was associated with hypertension raised the possibility that 11 PHSD activity
played an important role in the regulation of vascular tone. Whilst the hypertension
related to 11PHSD2 deficiency was initially attributed to sodium retention as a result
of MR activation by glucocorticoids in the distal nephron (Stewart et al. 1988), there
is increasing evidence that the activity of 11 pHSDs within the vessel wall directly
influence vascular tone. This concept is supported by findings that 11PHSD activity
is altered in vessels from hypertensive rats (Takeda et al. 1994a; Takeda et al. 1994b;
Takeda et al. 1993). The relevance of the 11 PHSDs in modulating the effects of
glucocorticoids on vascular tone have been explored in more detail through a series
of studies using pharmacological inhibition or genetic inactivation of 11 PHSD.
However, the precise role for each isozyme in the regulation of vascular tone remains
incompletely understood.
In the rat, systemic inhibition of 11 PHSD by liquorice derivatives results in
hypertension which is associated with endothelial dysfunction (Quaschning et al.
2001; Ruschitzka et al. 2001). In man, pharmacological inhibition of 11 PHSD with
glycyrrhetinic acid enhances cortisol-mediated dermal vasoconstriction
(Teelucksingh et al. 1990). More recently, in vitro studies have demonstrated that
exposure to pharmacological inhibitors of 11PHSD such as glycyrrhetinic acid
(Walker et al. 1992c), carbenoxolone (Brem et al. 1997) or chenodeoxycholic acid (a
bile acid which is an endogenous inhibitor of 11 PHSD) (Morris et al. 2004) enhances
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glucocorticoid-potentiated vasoconstriction in isolated vessels, suggesting that these
effects may be due to direct changes in glucocorticoid availability within the vessel
wall itself. However, the lack of selectivity of inhibitors of 11 (3HSD has restricted the
conclusions that can be drawn from these studies. Additionally, direct adverse effects
of these pharmacological agents on vascular function have been noted (Walker et al.
1994a; Ullian et al. 1996), and thus the literature must be interpreted with caution.
Nevertheless, considering that these inhibitors consistently potentiate the vascular
effects of glucocorticoids, it is likely that their effects are mediated by inhibition of
inactivation rather than reactivation of steroids within the vessel wall.
Studies using mice with genetic inactivation of lipHSDl (Kotelevtsev et al. 1997;
Hadoke et al. 2001) or 11PHSD2 (Kotelevtsev et al. 1999; Hadoke et al. 2001)
support the conclusions that have been drawn from pharmacological studies. The
intra-vascular regeneration of glucocorticoids does not appear to be important for the
maintenance of vascular tone, as deficiency of lipHSDl has no effect on aortic
function or blood pressure (Kotelevtsev et al. 1997; Hadoke et al. 2001). By contrast,
mice with genetic inactivation of 11PHSD2 have a hypertensive phenotype
(Kotelevtsev et al. 1999), and exhibit enhanced vascular contractility as a result of
impaired endothelium-derived nitric oxide production (Hadoke et al. 2001).
Furthermore, incubation of rat aortic rings with 11PHSD2 antisense oligonucleotides
enhances glucocorticoid-potentiated vasoconstriction (Souness et al. 2002).
These findings have led to the proposal that 11PHSD2 plays a key role in vessels by
protecting the endothelium from the adverse effects of excessive glucocorticoid
exposure. However, attributing the endothelial cell dysfunction evident in 11PHSD2
deficiency/inhibition solely to direct effects within the vessel wall is likely to be an
over-simplification. Recent studies using mouse aortic rings have failed to show an
effect of glucocorticoids on endothelial cell function, even in vessels from mice with
genetic inactivation of llpHSD2 (Christy et al. 2003), suggesting that indirect
mechanisms (relating to sodium retention and/or hypertension) contribute to the
abnormal vascular phenotype which is evident. Nonetheless, the mechanisms of the
hypertension related to 11PHSD2 deficiency/inhibition are beginning to be
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unravelled: pharmacological inhibition of 11PHSD2 lowers eNOS protein and
activity levels and enhances levels of the vasopressor endothelin 1 in rat aorta; a
phenomenon ameliorated by either aldosterone receptor (Quaschning et al. 2001) or
endothelin receptor A antagonism (Ruschitzka et al. 2001). These data suggest that
there is undoubtedly a role for the 1 lflHSDs in modulating the effects of
glucocorticoids on vascular tone, although the precise mechanisms remain elusive.
1.3.3.4 Effects ofglucocorticoids on endogenous fibrinolysis
Endogenous fibrinolysis is a complex process whereby clot, produced by the action
of coagulation factors, is degraded by the hydrolytic cleavage of fibrin by plasmin.
Plasmin, a serine protease, is produced from its precursor plasminogen through the
co-ordinated action of a number of enzymes and inhibitors. An adequate fibrinolytic
response is essential to maintain arterial patency and to avoid intravascular fibrin
formation, vessel occlusion and tissue infarction. The fibrinolytic system, apart from
its role in maintaining blood flow, is also involved in macrophage migration (Saksela
& Rifkin 1988), tumour invasion (Dano et al. 1985), embryogenesis (Saksela &
Holthofer 1987) and ovulation (Strickland & Beers 1976).
Initiation of intravascular fibrinolysis (Figure 1.8) depends on the conversion of
plasminogen, produced in the liver (Raum et al. 1980), to plasmin through cleavage
of the Arg561-Val562 peptide bond by tissue plasminogen activator (t-PA) (Astedt
1979) (Kok 1979). The principle site of t-PA synthesis, storage and release is the
endothelium (Levin & del Zoppo 1994). There is a dynamic intracellular storage pool
of t-PA (Eijnden-Schrauwen et al. 1995) which is released in response to stimulation
by many physiological and pharmacological factors including cytokines, vasodilators
and environmental factors (smoking, alcohol) (Emeis 1992), without the need for de
novo protein synthesis (Tranquille & Emeis 1989). t-PA activity exhibits circadian
variation, with lowest activity in the early morning (as a consequence of high
plasminogen activator inhibitor-1 (PAI-1) concentrations) (Andreotti & Kluft 1991).
There is rapid hepatic clearance of t-PA, such that the plasma half life is only a few











Figure 1.8 The roles of tissue plasminogen activator (t-PA) and plasminogen
activator inhibitor 1 (PAI-1) in intra-vascular fibrinolysis
During intra-vascular fibrinolysis, fibrin clot is degraded by the enzyme plasmin into
fibrin degradation products (FDPs). Tissue plasminogen activator (t-PA) is released
by the endothelium to activate plasmin from plasminogen. The activity of t-PA is
inhibited by the protease inhibitor plasminogen activator inhibitor-1 (PAI-1).
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The action of t-PA is inhibited when it is bound to plasminogen activator inhibitor
type 1 (PAI-1). PAI-1 is produced predominantly by the endothelium and vascular
smooth muscle, but can also be synthesised from liver and platelets (Sprengers et al.
1986) (Simpson et al. 1991). Elevated PAI-1 levels and impaired t-PA activity are
associated with increased cardiovascular risk (Kohler & Grant 2000; Juhan-Vague et
al. 1999), so this dynamic aspect of endothelial cell function and fibrinolytic balance
may be directly relevant to the pathogenesis of atherothrombosis.
In vivo effects of glucocorticoids on fibrinolytic function have not been clearly
elucidated. A recent study found no effect on circulating PAI-1 levels in healthy
volunteers treated with dexamethasone for 5 days (Brotman et al. 2005). However,
patients with glucocorticoid excess, either endogenous or exogenous, have elevated
circulating PAI-1 levels and a hyper-coagulable state (Sartori et al. 2000; Fatti et al.
2000; Patrassi et al. 1985; Ikkala et al. 1985; Patrassi et al. 1992; Sartori et al. 1999).
Studies in vitro suggest that PAI-1 release is increased by glucocorticoids (Udden et
al. 2002; Fukumoto et al. 1992; Reinders et al. 1992; Halleux et al. 1999; Morange
et al. 1999), and there is also evidence that dexamethasone can augment cytokine
stimulated PAI-1 release (Yamamoto et al. 2004; He et al. 2000). Animal models
also suggest that in vivo glucocorticoid therapy increases PAI-1 levels, and decrease
t-PA release (van Giezen & Jansen 1992; van Giezen et al. 1994), a finding mirrored
in studies examining PAI-1 and t-PA expression in cultured hepatocytes (Uno et al.
1998). Whilst there is some suggestion that glucocorticoids may actually increase t-
PA release (Gelehrter et al. 1987), this is in conjunction with an even greater
increase in PAI-1, supporting the concept that glucocorticoids influence fibrinolysis
to favour a prothrombotic state.
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1.4 Hypothesis and aims
There is good evidence that glucocorticoids directly influence many aspects of
vascular function, and that these effects are modulated, at least in part, by the
isozymes of 11PHSD. Inflammation is a key component of many vascular disease
processes. The finding that inflammatory mediators influence local availability of
glucocorticoids in cultured cells through regulation of the 11 pHSDs suggests that
inflammation may influence local vascular glucocorticoid action.
1.4.1 Hypothesis
It was hypothesised that both 11 (31ISD1 and 11 pi ISD2 activities are present in the
intact vessel, where they act, as exclusive reductase and dehydrogenase respectively,
to regulate local availability of glucocorticoids. Further, it was proposed that
inflammatory cytokines selectively up-regulate 1 lpHSDl in intact vascular tissue to
enhance the local availability of active glucocorticoids, providing local feedback
regulation of inflammation. Finally, in addition to the adverse consequences of
enhanced glucocorticoid availability on endothelial cell vasomotor function, it is
proposed that there is an impairment of fibrinolysis, promoting a prothrombotic state.
1.4.2 Aims
1. To determine the presence, and specific directionalities, of llpHSDl and
11PHSD2 in the vessel wall in vitro and in vivo.
2. To investigate the influence of inflammatory mediators on 11PHSD activity in
intact vascular tissue in vitro and in vivo.
3. To assess the impact of variations in glucocorticoid availability on endothelial cell






Unless otherwise stated, all chemicals and reagents were purchased from Sigma, UK.
All radioactivity was purchased from Amersham, UK. HPLC grade solvents were
purchased from Rathburn Chemicals, UK. Drugs for clinical studies were purchased
from Merck Biosciences AG, Switzerland.
2.1.1 Buffers and solutions
C buffer: 63 g glycerol, 8.77 g NaCl, 186 mg EDTA and 3.03 g Tris made up to 500
ml with distilled water, pH 7.7, stored at 4°C.
EvansBlue: 25 mg Evans blue, in 5 ml distilled water (0.5% w/v).
Hanks' Balanced Salt Solution: 1.26 mM CaCl2, 0.49 mM MgCl2.6H20, 0.41 mM
MgS04.7H20, 5.3 mM KC1, 0.4 mM KH2P04, 137.9 mM NaCl, 4.2 mM NaHC03,
0.34 mM Na2HP04, 5.56 mM D-glucose, 0.03 mM Phenol Red.
Homogensiation buffer: 100 g glycerol, 300 mg Tris and 186 mg EDTA made up to
500 ml in distilled water, pH 7.5. Stored at 4°C and supplemented with 7.7 mg/50ml
dithiothreitol (DTT) immediately prior to use.
Krebs-Ringer buffer (KRB): NaCl 118 mM, KC1 3.8 mM, KH2P04 1.19 mM , CaCl2
2.54 mM, MgS04 1.19 mM, NaHC03 25 mM in distilled water, pH 7.4.
Modified Krebs'-Henseleit Buffer (KHB): NaCl 118.3 mM, KCL 4.7 mM,
MgS04.7H20 1.2 mM, KH2P04 1.2 mM, NaHC03 25 mM, EDTA 0.026 mM,
CaCl2.2H20 1.8 mM, Glucose 11.1 mMin distilled water, pH 7.4. Stored at 4°C and
supplemented with 2% bovine serum albumin immediately before use.
Nicotinamide Adenine Dinucleotide (NAD): 17.1 mg in 1 ml C buffer (final
concentration 25 mM).
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Nicotinamide Adenine Dinucleotide Phosphate (NADP): 7.65 mg in 1 ml KRB
buffer (final concentration 10 mM).
Phosphate buffered Saline (PBS): 0.1 M phosphate buffer with 137 mM NaCl, 2.7
mM KC1 in distilled water, pH 7.4, autoclaved before use.
Placental Homogenate: 2 Wistar rat placentas mechanically homogenised in 1ml
homogenisation buffer and stored in 300 pi aliquots at -80°C.
2.1.2 Drugs and radiolabeled steroids used in animal studies
Acetylcholine (ACh, chloride salt, FW 181.7): 54.51 mg ACh dissolved in 30 ml
distilled water (final concentration 102M). 500 pi aliquots stored at -20°C.
Bradykinin (BK, triacetate salt, FW 1240.36): 10 mg BK dissolved in 8.06 ml
distilled water (final concentration 10~3 M). 450 pi aliquots stored at -20°C.
[3H]-Corticosterone: Commercial stock solutions of [3H]-Corticosterone in ethanol
(with concentrations of 13.7 nmol/ml) were stored at -20°C.
Corticosterone: 6.93 mg corticosterone was made up in 1 ml of methanol (final
concentration 20 mM) and stored at -20°C.
11-Dehydrocorticosterone: 10 mg 11-dehydrocorticosterone was made up to 10 mis
ethanol (2.9 mM concentration) and this was further diluted ten-fold in ethanol to
give a 290 pM solution and again to give a 2.9 pM solution. These stock solutions
were stored at -20°C.
y o
[ H]-11-Dehydrocorticosterone: [ H]-ll-Dehydrocorticosterone was synthesised in-
house (see Section 2.6), resuspended in ethanol (to give concentrations of
approximately 10-15 nmol/ml) and stored at -20°C.
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Etanercept: 500 pi of a 25 mg/ml solution of etanercept (Enbrel® Amgen Inc, USA)
was added to 12 mis distilled water (final concentration 1 mg/ml), and stored at -
20°C. The stock solution was further diluted in water 1:100 to give a working
solution of 0.01 mg/ml. 500 pi aliquots stored at -20°C.
Interleukins 1(3 (IL-lp), 4 (IL-4), 13 (IL-13): 5 pg IL-lp, IL-4 or IL-13 (R&D
Systems, UK) dissolved in 5 mis PBS (Dako, UK) containing 0.1% w/v bovine
serum albumin (final concentration 1 ng/pl). 500 pi aliquots stored at -20°C.
Lipopolysaccharide (LPS): 10 mg LPS (derived from Escherichia coli serotype
0111:B4) solubilised in 5 ml sterile 0.9% NaCl and stored in 200 pi aliquots at -
20°C. Immediately prior to use, diluted further 1:4 in 0.9% NaCl to give a working
concentration of 0.5 mg/ml.
Norepinephrine (NE, Bitartrate salt, FW 319.3): 31.93 mg NE dissolved in 10 mis
distilled water (final concentration 10"2M). 500 pi aliquots stored at -20°C.
Tumour necrosis factor a (TNFa): 10 pg TNFa. (R&D Systems, UK) dissolved in
either 1 ml PBS (Dako, UK) containing 0.1% bovine serum albumin (final
concentration 10 ng/pl) or in 10 mis PBS (Dako, UK) containing 0.1% bovine serum
albumin (final concentration 1 ng/pl). Aliquots stored at -20°C.
2.1.3 Drugs used in clinical studies
Acetylcholine (ACh): 1 ml of 10 mg/ml pharmaceutical grade ACh (Cibavision
Ophthalmics, Southampton, UK) dissolved in 500 ml 0.9% NaCl immediately prior
to use and diluted further to give final concentrations of 5,10 and 20 pg/ml.
Bradykinin (BK, FW 1060.2): 52 pg pharmaceutical grade BK (Clinalfa,
Laufelfingen, Switzerland) dissolved in 50 ml 0.9% NaCl immediately prior to use
and diluted further to give final concentrations of 100, 300 and 1000 pmol/ml.
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Hydrocortisone: 100 mg pharmaceutical grade hydrocortisone (Solu-Cortef®;
Pharmacia and Upjohn, UK) dissolved in 100 ml 0.9% NaCl immediately prior to
use and diluted further to give final concentrations as described in the study protocol.
Metyrapone: 750 mg (3 x 250 mg capsules, Metopirone®; Alliance, UK)
administered orally according to study protocol.
Saline (NaCl): 0.9% w/v NaCl (Baxter, UK) containing 154 mM sodium and 154
mM chloride.
Sodium Nitroprusside (SNP): 50 mg pharmaceutical grade sodium nitroprusside
(David Bull Laboratories, Faulding, UK) dissolved in 500 ml 0.9% NaCl
immediately prior to use and diluted further to give final concentrations of 2, 4 and 8
pg/ml. Stored in light-protected syringes.
2.2 Animals
Male C57B6J mice were obtained from Charles River, Kent, UK. Leptin deficient
ob/ob mice on a C57B6J genetic background and Wistar rats were purchased from
Harlan Orlac, UK. ll^HSD 1 homozygous null (-/-) and llflHSD 2 homozygous
null (-/-) mice were bred in-house at the Biomedical Research Facility, Western
General Hospital, Edinburgh, UK. Genetic inactivation of 11 pHSDl and 11 (1HSD2
have been described previously in MF-1/129 mice (Kotelevtsev et al. 1997;
Kotelevtsev et al. 1999); for the current experiments mice were backcrossed over
more than 10 generations onto a C57B6J background (Morton et al. 2004a).
Animals were maintained under controlled conditions of light (on 0800 to 2000h)
and temperature (21°C) with free access to standard chow (Special Diet Services,
Witham, UK) and water. Animal experiments were carried out under Home Office
licence and conformed to standards defined in "The Principals of Animal Care" (NIH
publication no. 85-23, revised 1985). Mice were killed by either cervical dislocation
or decapitation; rats were killed by exposure to C02.
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2.3 Intact vessel preparation
Mice aged 8-16 weeks were killed by cervical dislocation. The thoraco-abdominal
aortae and proximal hindlimb vasculature were immediately removed into ice-cold
DMEM-F12 culture medium and cleaned of periadventitial fibroadipose tissue. Liver
and kidneys were also removed as intact organs into ice-cold DMEM-F12 culture
medium, and sliced into segments weighing approximately 25-50 mg for immediate
use as control tissues in enzyme activity assays. For homogenate assays, aortae were
snap frozen on dry ice and then stored at -80°C. For smooth muscle cell isolation,
aortas were kept whole and used immediately. For in vitro intact tissue assays, aortae
were divided into 2-3 mm rings and the proximal hindlimb vessels (external iliac and
femoral arteries) were divided into proximal and distal segments, and used
immediately.
2.4 Tissue homogenisation
Whole, frozen aortae were crushed in chilled tin foil under liquid nitrogen, using a
mortar and pestle, and then mechanically homogenised in 0.4 mis ice-cold Krebs-
Ringer buffer using an Ystral mechanical homogenizer (Scientific Instruments
Centre, UK). Homogenates were kept on ice for 10-15 min to allow any remaining
solid tissue to sink, and the supernatant was removed. A 40 pi aliquot from each
homogenate was removed for immediate protein assay. Remaining samples were
stored at -80°C prior to assay.
2.5 Protein assay
The protein concentration of aortic homogenates was determined using a
colorimetric Bio-Rad protein assay kit (Bio-Rad, Hertfordshire, UK). A range of
standards (0.02-0.3 mg/ml) was prepared in duplicate in distilled water from the
provided protein standard (bovine serum albumin). Protein assay dye reagent was
diluted 1:4 in distilled water and filtered through Whatman No. 1 filter paper prior to
use. Diluted protein assay dye reagent (1.96 ml) was added to 40 pi of protein
standard or appropriately diluted tissue homogenate in a borosillicate tube, vortexed
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to mix and left at room temperature for 15 min-1 hour to allow colour development.
Absorbance of samples at X595nm was measured using a Shimadzu UV/ visible
recording spectrophotometer and the concentration of protein in each sample was
estimated from the standard curve.
2.6 Synthesis of [3H]-11-dehydrocorticosterone
120 pi l,2,6,7-[3H]-corticosterone was dried down under nitrogen gas at 60°C and
reconstituted in 50 pi 100% ethanol. Reconstituted l,2,6,7-[3H].corticosterone was
incubated in a glass vial at 37°C with 300 pi placental homogenate and 200 pi NAD
cofactor (25 mM) in a final volume of 5 mis C buffer. After 4 hours, steroids were
extracted by serial additions of 8 mis ethyl acetate to a total of 10 volumes. After
each addition, the sample was vortexed and then centrifuged at 1700 g for 10 min at
4°C. The upper organic layer was transferred to a fresh tube, dried down under
nitrogen, reconstituted in 100 pi ethanol and stored at -20 until use. A 1 pi aliquot of
the l,2,6,7-[3H].corticosterone product was analysed by HPLC for assessment of
purity and concentration.
2.7 Smooth muscle cell culture
Murine aortic smooth muscle cells (MA-SMCs) were isolated and cultured by
modification of a method by Ray et al. ( 2001). Following aortic preparation as
described in Section 2.3, single aortas were incubated in modified Hanks' balanced
salt solution (HBSS, Invitrogen, containing 1% Penicillin/Streptomycin and 0.1%
Fungizone; Gibco) containing 175 U/ml Collagenase Type 2 (Worthington) for 3 to 5
minutes. The adventitia was separated from the aortae by dissection, the vessel was
opened longitudinally, and the endothelial cell layer removed by friction with blunt
forceps. Aortae were cut into 1-2 mm pieces and incubated overnight at 37°C in
oxygenated (95% 02.5% CO2) DMEM (Gibco) containing 10% Foetal Calf Serum
(FCS; Gibco). Aortae were then transferred to medium containing 420 U/ml
Collagenase type 2 and incubated for a further 3-4 hours. The cells were suspended
in culture medium (DMEM containing 20% FCS, 1% Penicillin/ Streptomycin and
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1% L-Glutamine 200mM; Gibco), centrifuged twice at 300 g for 5 mins and then
resuspended in culture medium in a humidified oxygenated (95% 02.5% CO2)
atmosphere.
The cells were confirmed as smooth muscle cells by staining with a-actin (Sigma),
using human umbilical vein endothelial cells (HUVECs) as a negative control. Cells
were counted on a haemocytometer, using a 1 in 10 dilution with Trypan Blue
(Sigma).
Cells were maintained in DMEM (containing 10% FCS, 1% Streptomycin, 1%
Penicillin and 1% L-Glutamine) in 75 cm2 flasks in a humidified oxygenated (95%
02.5% CO2) atmosphere. Cells were passaged once they reached confluence
(approximately once weekly). Cells at their 2nd passage were used for activity assays
unless otherwise stated.
2.8 Measurement of 11 pHSD activity in vitro
Although 11(3HSD1 is a predominant reductase in vivo (catalysing the conversion of
inactive 11-dehydrocorticosterone to active corticosterone (Jamieson et al. 2000)), in
homogenised cell preparations it is capable of bi-directional activity, with the
dehydrogenase direction predominating (Lakshmi & Monder 1988). Thus,
conventional in vitro assays have measured lipHSD l activity in the dehydrogenase
direction using homogenised tissue preparations. This technique is limited as it is not
possible to differentiate between activities attributable to the individual isozymes of
lipHSD. In the cell culture and intact tissue assays described below, therefore,
llflHSD activity is measured in both the reductase and dehydrogenase directions.
2.8.1 In cell culture
Murine aortic smooth muscle cells (MA-SMCs) were seeded onto 6 well plates at a
density of 1.75 x 105 cells per well, in 2 ml of assay medium. The following day, the
medium was changed to basal medium containing minimal (0.5%) FBS. After 48
hours, 10 pmol [3H]-ll-dehydrocorticosterone was added to the appropriate wells
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and cells were further incubated for 24 hours. After incubation, the overlying culture
medium was removed to a glass tube and stored at -20°C prior to Sep Pak steroid
extraction.
Enzyme activity was expressed as conversion per 105 cells after subtraction of
apparent conversion in negative control wells.
2.8.2 In homogenised aortae
lip-Dehydrogenase activity was measured in homogenates of aortae from ob/ob and
littermate control mice by a method adapted from Livingstone et al. (2000b).
Homogenised aortic tissue was prepared in duplicate in a total volume of 250 pi
Krebs-Ringer buffer containing 0.2% glucose, NADP (2 mM) and [3H]-
corticosterone (100 nM). Final protein concentration was 20 pg /ml. Samples
containing no cofactor served as negative controls, and tissue blanks were prepared
in duplicate in KRB buffer with NADP and [3H]-corticosterone in the absence of
tissue homogenate. Samples were incubated for 24 hours at 37°C. Following
incubation, the reaction was stopped by the addition of 10 volumes of ethyl acetate to
each tube, and tubes were vortexed. The upper organic phase (containing steroids)
was removed to a fresh tube and evaporated under oxygen free nitrogen at 60°C.
Enzyme activity was expressed as percentage conversion per 5 pg protein after
subtraction of apparent conversion in negative control samples.
2.8.3 In intact vascular preparations in vitro
11|3-reductase and -dehydrogenase activities were measured in aortic rings and
hindlimb vasculature from C57B6J, lipHSDl homozygous null (-/-) and 11PHSD2
homozygous null (-/-) mice by adaptation of a method by Souness et al. (2002).
Aortic rings were incubated for 24 hours at 37°C in 1 ml of DMEM-F12 medium
containing [3H]-steroid supplemented with streptomycin (100 pg/ml), penicillin (100
units/ml) and amphotericin (0.25 pg/ml). lip-Reductase activity was determined by
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adding 10 pmol [3H]-ll-dehydrocorticosterone. Murine liver slices incubated under
the same conditions served as a positive control. 11P-Dehydrogenase activity was
determined by adding 10 pmol [3H]-corticosterone. Murine kidney slices served as a
positive control in this case. As negative controls, [3H]-ll-dehydrocorticosterone or
[3H]-corticosterone was incubated in wells without tissue, and wells containing
medium alone served as blanks. Experiments were performed in duplicate (and
triplicate when possible). Following incubation, the overlying culture medium was
removed to a glass tube and stored at -20°C prior to Sep Pak extraction of steroids.
Tissue samples were blotted and weighed. It has previously been shown that aortic
ring tissue contains only 2-3% of the added radioactivity so that only the supernatant,
and not the vessels themselves, was included in the extraction (Souness et al. 2002).
Enzyme activity was expressed as percentage conversion per wet weight of aortic
tissue per 24 hours after subtraction of apparent conversion in negative control
samples.
2.9 Hindlimb perfusion model
2.9.1 Hindlimb set-up
The method used was an adaptation from that of Brandes et al. (2000). After
sacrifice by cervical dislocation, a laparotomy incision was performed and the aorta
and inferior vena cava (IVC) at the thoraco-abdominal transition was prepared by
blunt dissection. 6/0 Prolene sutures (Surgical Supplies Ltd, Cumbernauld, UK) were
threaded under the distal aorta and inferior vena cava (IVC), just proximal to the
aortic bifurcation, and under the proximal abdominal aorta and IVC, distal to the
renal and testicular arteries. A 24-gauge cannula (Neoflon, Ohmeda, Sweden) was
inserted into the aorta distal to the renal and testicular arteries and advanced to the
aortic bifurcation. An 18-gauge cannula (Venflon, BD, UK) was inserted into the
abdominal IVC, distal to the renal veins and advanced distally to a similar level of
the arterial cannula. Both cannulae were tied in with the distal suture to prevent
leakage and retrograde perfusion. The proximal suture was used to tie off both the
aorta and IVC distal to the renal and testicular vessels, to prevent retrograde
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perfusion of abdominal viscera, and then tied around both cannulae. A schematic
diagram of the hindquarter perfusion technique is shown in Figure 2.1
2.9.2 Perfusion technique
Modified Krebs-Henseleit buffer supplemented with 2% BSA was maintained in a
water bath at 40°C, whilst constantly bubbled with carbogen (95% 02:5% CO2). A
peristaltic pump was used to constantly perfuse the hindquarters with warmed
oxygenated buffer at a rate of between 0.8 and 1.2 ml/min. Hindquarters were
perfused with oxygenated buffer within 30 minutes of sacrifice, and perfusion studies
lasted up to 60 minutes.
2.9.3 11 pHSD activity
Following a ten minute equilibration period, [3H]-ll-dehydrocorticosterone (for
determination of reductase activity) or [3H]-corticosterone (for determination of
dehydrogenase activity) was added to the perfusion buffer at a concentration of 5
nM. Aliquots of effluent were collected at intervals throughout the perfusion and
stored at -20°C until analysis.
Steroids were purified from the effluent samples by Sep Pak extraction and analysed
by HPLC (as described in Section 2.10). Buffer containing [3H]-11-
dehydrocorticosterone or [3H]-corticosterone served as a positive control, and buffer
containing no radioactivity served as a negative control.
2.9.4 Effect of systemic inflammation on 11 ^-reductase activity
To observe the effects of inflammation on 11PHSD activity in the perfused hindlimb,
lipopolysachharide (LPS, 10 mg/kg in a volume of 20 ml/kg) or 0.9% saline vehicle
was administered to C57B6J mice by intraperitoneal injection at 0800 h. 6 hours
later, mice were sacrificed by cervical dislocation and underwent a hindlimb
perfusion protocol as described above. On each occasion, an LPS-treated and
vehicle-treated mouse were studied on the same day.
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IVC Aorta
Figure 2.1 Schematic diagram of murine hindquarter perfusion technique
Following laparotomy, 24-gauge and 18-gauge cannulae were inserted into the
aorta and inferior vena cava (IVC), respectively. The aortic cannula was inserted
distal to the renal and testicular arteries and advanced to the aortic bifurcation. The
IVC, cannula was inserted distal to the renal veins and advanced distally to a similar
level of the arterial cannula. To prevent retrograde flow, sutures were tied around
both vessels (i) below the level of the testicular arteries, and (ii) proximal to the
aortic bifurcation as shown. Buffer was perfused into the aortic cannula, and effluent
collected from the inferior vena cava cannula, as described in detail in the Methods
Section 2.9.2.
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2.9.5 Systemic effects of lipopolysaccharide
In a further set of studies to characterise the systemic response to LPS, C57B6J mice
underwent LPS or vehicle administration as described in Section 2.9.4. Mice were
weighed prior to injection and prior to sacrifice. 6 hours following drug
administration, mice were killed by decapitation and aortae were removed into ice-
cold DMEM in preparation for in vitro activity assays. The spleens were weighed,
snap frozen and stored at -80°C.
2.10 Steroid analysis
2.10.1 Sep Pak extraction and purification
In order to extract a clean preparation of steroids from culture medium or buffer,
samples were run through C]8 Sep Pak columns (Waters Millipore, Watford, UK)
under gravity. The columns were prepared for use with 5 mis HPLC grade methanol,
to separate the C]8 chains, and then washed with 5 mis HPLC grade H2O. The sample
was then run onto the column, washed once with 5 mis HPLC grade H2O and eluted
into glass tubes using 2 mis HPLC grade methanol. Steroid-containing methanol
samples were then dried down at 60°C under nitrogen gas.
2.10.2 High Performance Liquid Chromatography
The high-performance liquid chromatography (HPLC) system comprised an auto-
sampler and mobile phase pump (Waters, UK), a symmetry shield RP]8 5 pm column
(Waters, UK) and a radioactivity monitor linked to a scintillation fluid pump
(Berthold, UK). The system was controlled by the Window computer programme
(JMBS Developments, France). Steroid samples extracted by either ethyl acetate (in
the case of tissue homogenates or cell culture) or Sep Pak extraction (in the case of
intact vascular tissue experiments) were re-suspended in 1 ml mobile phase (60%
water, 15% acetonitrile, 25% methanol) and 180 pi of each sample was injected into
the HPLC system. The flow rate of the mobile phase was 1 ml/ min and the flow rate
of the scintillant (Quicksafe Flow 2; Zinsser, UK) was 2 ml/ min to achieve optimal
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mixing and counting efficiency. The column temperature was 35 °C to improve peak
shape and maintain stability of retention times. Radioactive standards were injected
at the start of each batch of samples to confirm peak identity. The approximate
retention times for [3H]-corticosterone and [3H]-ll-dehydrocorticosterone were 12-
14 min and 16-19 min respectively (variations in retention times in some assays were
due to intentional changes in mobile phase composition and column condition), with
greater than 1 minute between the two peaks. Peaks were less than lmin 30s wide
and peak height was at least 50-fold higher than background. An additional peak
(retention time 9-10 min, always less than 6% of total radioactivity) was present in a
proportion of samples, particularly those from assays involving a long incubation
duration or in samples from assays using llflHSDl -/- mice. By exclusion of other
possible metabolites, it was determined that this peak may be the 20(1-
dihydrocorticosterone metabolite of corticosterone. However, standards of this
steroid metabolite are unavailable to allow confirmation of this. A representative
chromatogram obtained from a typical assay is shown in Figure 2.2. Following
chromatography, the area under each peak was integrated using the Winflow
software and used to quantify the percentage conversion of [3H]-corticosterone to
[3H]-ll-dehydrocorticosterone (11 (1-dehydrogenase activity) or [3H]-11-
dehydrocorticosterone to [3H]-ll-corticosterone (ll(3-reductase activity). The
percentage conversion in each tissue sample was corrected for the "apparent
conversion" occurring in tissue blanks included in each experiment, which was
always <2%.
2.11 TNFa bioactivity assay
To confirm bioactivity of the murine TNFa, isolated human neutrophils (5xl06 cells
per well) were incubated in a volume of 150 pi containing 12.5 ng/ml TNFa for 2-6
hours (Murray et al. 1997). 100 pi of the cells were plated onto glass slides and
stained with Diff Quick (Baxter Healthcare, UK). Cells were examined under oil
immersion light microscopy, and the proportion of apoptotic neutrophils (defined as
those containing darkly stained pyknotic nuclei (Savill et al. 1989)) was estimated.
The results are shown in figure 2.3.
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Retention Time (mins)
Figure 2.2 Representative HPLC chromatogram
A representative chromatogram from high performance liquid chromatography of a
sample from an 11p-reductase assay. Retention times for [3H]-11-

















Figure 2.3 Neutrophil apoptosis assay to demonstrate TNFa bioactivity
A human neutrophil apoptosis assay was used to determine the bioactivity of murine
TNFa. Human neutrophils (5x106 cells per well) were incubated with TNFa (12.5
ng/ml) for 2-6 hours, after which, apoptotic cells were determined by morphological
analysis. Results are mean ± standard error, n=3, * p<0.05.
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2.12 Measurement of endothelial cell function in vivo in
humans
2.12.1 Subjects
Please refer to Chapter 5, Section 5.2.1
2.12.2 Study design
Please refer to Chapter 5, Section 5.2.2
2.12.3 Drugs
Please refer to Chapter 5, Section 5.2.3
2.12.4 Haemodynamic measurements
Please refer to Chapter 5, Section 5.2.4
2.12.5 Venous sampling
Please refer to Chapter 5, Section 5.2.5
2.12.6 Sample analysis
Please refer to Chapter 5, Section 5.2.6
2.12.7 Data analysis and statistics
Please refer to Chapter 5, Section 5.2.7
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2.12 Statistics
Values are expressed as mean ± standard error. Numbers (n) refer to either individual
animals or human subjects unless otherwise stated. Data were analysed by Student's
t-tests, Analysis of Variance (ANOVA) or ANOVA with repeated measures followed




vascular tissue in vitro
3.1 Introduction
Modulation of lipHSD activity may provide a mechanism for local feedback
regulation of inflammation in vascular smooth muscle cells. Pro-inflammatory
cytokines (e.g tumour necrosis factor-a (TNFa)) up-regulate 11 PHSD1 activity and
expression and down-regulate 11(3HSD2 expression in cultured human aortic smooth
muscle cells (Cai et al. 2001). These coordinated changes favour an increase in the
availability of active glucocorticoid within vascular smooth muscle and would be
expected to inhibit inflammation. This is significant, given the importance of
inflammation in the vascular response to injury (Wainwright et al. 2001). However,
whilst cytokine-mediated changes in lipHSD activity have been demonstrated in
cultured vascular cells (Cai et al. 2001), adipocytes (Tomlinson et al. 2001),
macrophages (Thieringer et al. 2001), fibroblasts (Sun & Myatt 2003), ovarian
epithelial cells (Yong et al. 2002; Rae et al. 2004), osteoblasts (Cooper et al. 2001),
and glomerular mesangial cells (Escher et al. 1997), the influence of cytokines on
intact blood vessels has not been established. Furthermore, it has not been
demonstrated whether acute or chronic systemic inflammation (for example in
endotoxaemia or obesity respectively) leads to an up-regulation of lipHSDl activity
in vascular tissue.
In order to determine whether cytokine exposure selectively up-regulates llflHSDl
in the vascular wall it is necessary to measure activity of both lipHSDl and
11PHSD2 isozymes. This is important for two reasons: first, both isozymes are
expressed in the vessel wall (although lipHSDl may be localised to the smooth
muscle (Brem et al. 1998) (Christy et al. 2003) and 11PHSD2 to the endothelium
(Brem et al. 1998; Christy et al. 2003)) and, second, lipHSDl may act in a bi¬
directional manner (as both a reductase and a dehydrogenase (Brem et al. 1995;
Souness et al. 2002)). In the absence of suitable selective inhibitors for lipHSD
isozymes, mice with genetic inactivation of either lipHSDl (Kotelevtsev et al.
1997; Morton et al. 2004a) or 11PHSD2 (Kotelevtsev et al. 1999) provide an
invaluable tool for assessing the activities of the individual isozymes. However,
whilst these animals have been used to show that both isozymes are active in mouse
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aortic homogenates (Hadoke et al. 2001; Christy et al. 2003) the directionality of
11PHSD1 and 11PHSD2 has not been addressed in intact arteries. The choice of
methodology is significant as llpHSD activity is traditionally measured in the
dehydrogenase direction in homogenates (Livingstone et al. 2000a; Hadoke et al.
2001). However, due to the lack of co-factor specificity between isozymes of
lipHSD in mice (Walker et al. 1992b), measurement of both reductase and
dehydrogenase activities requires the use of intact tissues (Souness et al. 2002).
The work described in this chapter explores the hypothesis that inflammatory
mediators selectively up-regulate lipHSDl reductase activity in intact blood vessels
in vitro. The specific aims were (1) to determine the reaction directionality of the
11PHSD isozymes in intact murine arteries in vitro, and (2) to investigate the
influence of inflammation on lipHSD activity within cultured mouse aortic smooth
muscle cells and in intact murine arteries. These studies required the application of
existing techniques and the development of novel methodology to determine 11 p-
reductase and -dehydrogenase activities in cultured murine aortic smooth muscle
cells and in intact murine arteries in vitro.
3.2 Methods
3.2.1 Mice
Unless otherwise specified, all arteries were obtained from male C57B6J mice aged
8-16 weeks. Vessels and control tissues were prepared as described in Methods
Section 2.3.
3.2.2 Effects of cytokines on 11PHSD activity in cultured murine aortic
smooth muscle cells
In order to assess the effects of IL-lp on 11 P-reductase activity, cultured murine
aortic smooth muscle cells (MA-SMCs, at passage 2; see Section 2.7) were incubated
for 48 hours (37°C in 95% 02.5% CO2) in 2 ml of basal medium with IL-ip (20
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ng/ml) or vehicle. A 48 hour incubation period was chosen as previous studies
demonstrated a clear up-regulation of 11P-reductase activity in cultured vascular
smooth muscle cells over this period (Cai et al. 2001). llp-Reductase activity was
then determined by incubation for a further 24 hours with [3H]-11-
dehydrocorticosterone as described in Section 2.8.1. Conversion of [3H]-11-
dehydrocorticosterone to [3H]-corticosterone was determined by HPLC (as described
in Section 2.10).
Replication of these studies required the use of cells at later passage stages (4th - 6th
passage), and as preliminary experiments suggested that there was considerable
variability in basal 11 P-reductase in these cells, a reduced cell density (0.5x 105 cells
per well) was used in later experiments.
To investigate whether the effects of IL-ip on 11 P-reductase activity were influenced
by corticosterone, 11 P-reductase activity was determined in MA-SMCs following
prior incubation (48 hours) with IL-ip, corticosterone (100 pM) or both.
To confirm lipHSDl as the sole reductase in MA-SMCs, attempts were made to
culture MA-SMCs from lipHSDl-/- mice using the method described in Section
2.7.
3.2.3 11f3HSD activity in intact vascular tissue in vitro
3.2.3.1 Establishing directionality and enzyme activities in intact tissue
In order to develop a murine in vitro model with which to determine the effects of
cytokines on vascular lipHSD activity, extensive development of existing
methodology in rat tissue (Souness et al. 2002) was undertaken. It was necessary to
vary culture conditions, tissue quantities and/or duration of incubations in order to
optimise conditions for more detailed investigations.
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3.2.3.2 11^-Reductase activity in intact arteries
11(3-Reductase activity was determined (as described in Section 2.8.3) in single
intact aortic rings and iliofemoral arteries from male C57B6J mice (n=6) using
murine liver and kidney as positive control tissues. HPLC analysis (as described in
Section 2.10) determined the percentage conversion of [3H]-11-
dehydrocorticosterone to [3H]-corticosterone.
In order to confirm that the standard conditions (as described in Section 2.8.3) were
appropriate to measure 11 P-reductase enzyme velocity within the linear range,
enzyme kinetics were established by repeating the assay using increasing numbers
(1-9) of aortic rings per well.
3.2.3.3 11^-Dehydrogenase activity in intact arteries
11|3-Dehydrogenase activity was determined in aortic rings and iliofemoral vessels
from C57B6J (n=6) mice using murine liver and kidney as a positive control tissues
(as described in Section 2.8.3). HPLC analysis (as described in Section 2.10)
determined the percentage conversion of [3H]-corticosterone to [3H]- 11-
dehydrocorticosterone.
In order to determine the time course of dehydrogenase activity, aortic rings were
incubated for 32 hours in medium containing 100 nM [3H]-corticosterone, and 100 pi
aliquots of medium were removed at serial time points (n=4).
3.2.4 Effects of selective genetic inactivation of 11PHSD isozymes on
11 P-reductase and -dehydrogenase activities
To establish whether 1 lpHSDl is the sole reductase in vascular tissue, 11P-reductase
activity was determined in single intact aortic rings and iliofemoral arteries from
male C57B6J and homozygous null llpHSDl (-/-) mice, using liver and kidney
slices as control tissues (as described in Section 2.8.3; n=6).
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To determine whether lipHSDl exhibits dehydrogenase activity in intact vascular
tissue, 11p-dehydrogenase activity was determined in aortic rings, and kidney slices
from male C57B6J and homozygous null 11PHSD2 (-/-) mice (as described in
Section 2.8.3; n=4).
3.2.5 Influence of cytokines on 11 (3HSD activity in intact arteries in vitro
To examine the effects of pro-inflammatory cytokines on lipHSD activity, lip-
reductase and -dehydrogenase activities were determined (as described in Section
2.8.3) in aortic rings from C57B6J mice following incubation for 16 hours (37°C,
95%:5% 02:C02) with IL-ip (10 ng/ml), TNFa (100 ng/ml) or vehicle (n=4-10). In
a previous study of cultured aortic SMCs, TNFa exerted maximal effect on lip-
reductase activity after 16 hours (Cai et al. 2001), hence this incubation period was
chosen. To establish whether there was a dose-response to these inflammatory
cytokines, further studies were performed using a range of concentrations of IL-
ip (1-100 ng/ml) and TNFa (10-1000 ng/ml).
Other cytokines which have been reported to influence 1 lpHSDl activity include the
T-lymphocyte derived interleukins, IL-4 and IL-13 (Thieringer et al. 2001). To
investigate whether these cytokines influence lipHSDl activity in intact vessels,
11 P-reductase activity was determined in aortic rings following incubation (16 hours)
with either IL-4 (50 ng/ml) or IL-13 (50 ng/ml).
In order to examine whether endogenous inflammation was contributing to
regulation of basal 11PHSD activity within the intact aortic ring, 11 p-reductase
assays were performed in aortic rings following incubation (16 hours) with
etanercept (a fusion protein that antagonises human and murine TNFa (Xing, L,
Personal communication), and which ameliorates the cardiovascular effects of
murine TNFa (Vallejo et al. 2005); 0.1-10 p-g/ml; n=4).
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3.2.6 Influence of systemic lipopolysaccharide in vivo
In order to investigate the influence of in vivo inflammation on lipHSD activity,
llp-reductase and -dehydrogenase activities were determined (as described in
Section 2.8.3) in aortic rings from C57B6J mice which had received intraperitoneal
lipopolysaccharide (LPS, 10 mg/kg) or saline 6 hours previously (as described in
Section 2.9.5; n=3-6).
3.2.7 11PHSD activity in aortic homogenates from obese ob/ob mice
Obesity is characterised by systemic inflammation (Rajala & Scherer 2003) and up-
regulation of adipose 11 (1HSD type 1 activity in both humans (Sandeep et al. 2005)
and rodents (Livingstone et al. 2000a). The possibility that obesity, as a chronic
inflammatory state, might alter lipHSD activity within vascular tissue was explored
in aorta from obese ob/ob mice. Total lipHSD activity was determined by
measurement of dehydrogenase activity in homogenised preparations of aorta (as
described in Section 2.8.2) from obese ob/ob and lean littermate control mice (n=8-
11). HPLC analysis (as described in Section 2.10) determined the percentage
conversion of [3H]-corticosterone to [3H]-ll-dehydrocorticosterone by aortic
homogenates with known protein concentrations.
3.2.8 Statistics
Data are expressed as mean ± standard error and were analysed by Student's t-test or
ANOVA and post-hoc tests where appropriate.
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3.3 Results
3.3.1 Effects of cytokines on 11PHSD activity in cultured murine aortic
smooth muscle cells
Stimulation with IL-ip significantly increased 11 (3-reductase activity (87±2%
conversion compared with 62±3% in controls, p<0.05, n=6; Figure 3.1) in cultured
MA-SMCs (n=6). Replication of these studies, however, showed the basal activity to
be highly variable (data not shown). Furthermore, the up-regulation of 11 [3-reductase
activity by IL-1(3 was difficult to reproduce (Figure 3.2). On further investigation,
two variables had a marked influence on reductase activity: passage stage and the
presence of corticosterone. Basal lip-reductase activity in MA-SMCs was lower in
cells at higher passage stage (n=6, Figure 3.2). Also, in experiments in which 11(3-
reductase activity in MA-SMCs was either unchanged or only modestly up-regulated
upon stimulation with IL-1(3, co-incubation with exogenous corticosterone (100 pM)
resulted in a more marked (80%) increase in ll(3-reductase activity in response to the
addition of IL-ip (Figure 3.3).
Despite several attempts to culture murine aortic smooth muscle cells from 11PHSD
type 1 homozygous (-/-) null mice using the same conditions as for C57B6J MA-
SMCs, there was no evidence of cell growth.
3.3.2 11 PHSD activity in intact arteries in vitro
3.3.2.1 11^-Reductase activity
lip-Reductase activity was present in intact aortic rings, hindlimb arteries and liver
and kidney slices from wild type C57B6J mice, as indicated by conversion of [3H]-
11-dehydrocorticosterone to [3H]-corticosterone (Figure 3.4). In wild type tissues,
lip-Reductase activity was higher in aorta as compared with hindlimb arteries (n=6,
p<0.005), and both vascular tissues had higher reductase activity when compared
with the control tissues (n=6, p<0.005).
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Figure 3.1 Effect of IL-1 p on 11[3-reductase activity in cultured MA-SMCs
11(3HSD activity is expressed as the percentage conversion of [3H]-11-
dehydrocorticosterone to [3H]-corticosterone by 1.75 x 105 cells (passage 2) from
C57B6J mice. UpHSD activity was measured after 24 hour incubation. 48 Hour
stimulation with IL-1 (3 significantly increased 1 ip-reductase activity (87±2%
conversion compared with 62±3% in controls, * p<0.05 when compared by unpaired
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Figure 3.2 Effect of passage on 11 p-reductase activity in cultured MA-SMCs
11PHSD activity is expressed as the percentage conversion of [3H]-11 -
dehydrocorticosterone to [3H]-corticosterone by 0.5 x 105 cells from C57B6J mice.
11(3HSD activity was measured at 8 and 24 hours, with (solid bars) or without (open
bars) prior incubation (48 hours) wittv !L-1p (20 ng/ml). Results are mean ± standard
error, n=6 (where n refers to the number of wells).
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Figure 3.3 Influence of IL-ip and corticosterone on 11 p-reductase activity in
cultured MA-SMCs
11PHSD activity is expressed as the percentage conversion of [3H]-11-
dehydrocorticosterone to [3H]-corticosterone by 0. 5 x 105 cells from C57B6J mice.
11pHSD activity was measured at 24 hours, following prior incubation (48 hours)
with IL-1(3 (20 ng/ml), corticosterone (100 p,M) or both. 11P-Reductase activity was
significantly increased, compared with control, following corticosterone incubation
(#p<0.05). Combined incubation with IL-ip and corticosterone resulted in
significantly higher 11 P-reductase activity compared with control, IL-1 p alone and
corticosterone alone, when analysed by ANOVA and post-hoc analysis (**p<0.001).
Graph shows combined data using cells at passage 1 (n=3 wells) and 2 (n=6 wells).
Results are mean ± standard error.
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Reductase activity within liver and kidney slices were not significantly different
under these assay conditions (n=6, p=0.18). A linear relationship between wet tissue
weight and reductase activity in aortic tissue was demonstrated, confirming that, by
using single aortic rings in subsequent assays, any increase in activity should be
readily detectable (Figure 3.5).
3.3.2.2 11^-Dehydrogenase activity
lip-Dehydrogenase activity was present in intact aortic rings, hindlimb arteries and
liver and kidney slices from C57B6J mice, as indicated by conversion of [3H]-
corticosterone to [3H]- 11-dehydrocorticosterone (Figure 3.6). llfl-Dehydrogenase
activity was similar in aortic rings and hindlimb arteries (n=6, p=0.48). Although the
reductase (Figure 3.4) and dehydrogenase (Figure 3.6) assays were not performed
contemporaneously, it is worthwhile noting that the absolute levels of reductase
activity in vascular tissue were higher than the dehydrogenase activity, suggesting
that the predominant direction of llflHSD activity within vascular tissue is in the
reductase direction.
The generation of product over time by dehydrogenase activity in aortic rings and
kidney and liver slices is shown in Figure 3.7. In all three tissues, a plateau of
activity was reached by 32 hours. In aortic rings and kidney slices, there was an
initial linear phase of product generation which persisted beyond 24 hours (Figure
3.7A and 3.7B respectively). However, there was a biphasic activity in liver slices
(Figure 3.7C) with a rapid initial rate, which fell again before a more gradual rise to a
plateau.
As dehydrogenase activity is much lower than reductase activity in aortic tissue,
optimal assay conditions were chosen for subsequent investigations (2-5 aortic rings
per well, incubated for 24 hours) to ensure that it would be possible to detect both
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Figure 3.4 Effect of 11PHSD type 1 deletion on 11 (3-reductase activity in
murine tissues
11(3-Reductase activity is expressed as the amount of [3H]-corticosterone formed
from [3H]-11-dehydrocorticosterone, per milligram (wet weight) over 24 hours, in
liver slices, kidney slices, aortic rings and hindlimb artery segments from C57B6J
(open bars) and 11pHSD type 1 homozygous null (-/-; solid bars) mice. 11 (3-
Reductase activity in the control tissues from C57B6J mice was similar (p=0.18
when compared by unpaired Student's t-test). Reductase activity was higher in the
wild type aortic tissue compared with the femoral tissue (**p<0.005) and both
vascular tissues demonstrated higher activity than control tissues (**p<0.005).
Reductase activity was effectively abolished in tissues from 1ipHSD type 1 -/- mice
(activity less than 0.1 pmol/mg/24hrs). Results are mean ± standard error, n=6.
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Figure 3.5 11|3-Reductase activity in aortic rings: a comparison of activity by
wet weight of tissue
11(3-Reductase activity in aortic rings from C57B6J mice is expressed as the
percentage of [3H]-corticosterone formed from [3H]-11-dehydrocorticosterone over
24 hours. The trendline shown has the equation y = 35.655x + 1.8934, with an R2
value of 0.9313. Results are for single wells containing 1, 3 or 6 rings each.
Representative graph from an experiment repeated twice, using aorta from 6 mice.
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Figure 3.6 11 p-Dehydrogenase activity in tissues from C57B6J mice
11 p-Dehydrogenase activity is expressed as the amount of [3H]-11-
dehydrocorticosterone formed from [3H]-corticosterone, per milligram (wet weight)
over 24 hours, in liver slices, kidney slices, aortic rings and hindlimb vascular
segments from C57B6J mice. 11 p-Dehydrogenase activity did not differ significantly
between vascular tissues (p=0.48 when compared by unpaired Student's t-test).






Figure 3.7 1ip-Dehydrogenase activity as a function of time
11p-Dehydrogenase activity is expressed as the amount of [3H]-11 -
dehydrocorticosterone formed from [3H]-corticosterone per milligram tissue, over
time, in (A) aortic rings, (B) kidney slices and (C) liver slices from C57B6J mice.




Figure 3.8 1ip-Dehydrogenase activity in tissues from 11PHSD type 2
homozygous null (-/-) mice
1 ip-Dehydrogenase activity is expressed as the amount of [3H]-11-
dehydrocorticosterone formed from [3H]-corticosterone, per milligram (wet weight)
over 24 hours, in kidney slices and aortic rings from C57B6J and 11pHSD type 2
homozygous null (-/-) mice (n=4). 1 ip-Dehydrogenase activity was significantly
reduced in kidney (*p<0.005) but not in aorta (p=0.28) from 11PHSD 2 -/- mice
compared with controls. Results are mean ± standard error, and were compared by
unpaired Student's t-test.
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3.3.3 Effects of selective genetic inactivation of 11pHSD isozymes on
11 P-reductase and dehydrogenase activities
Genetic inactivation of lipHSDl effectively abolished 11P-reductase activity in all
tissues studied, with all activity less than 0.1 pmol/mg/24hrs (n=6, Figure 3.4). By
contrast, genetic inactivation of 11PHSD2 resulted in a marked reduction, but not
abolition, of 11 (l-dehydrogenase activity in kidney (n=4, p<0.005), and did not
significantly reduce 11 (1-dehydrogenase activity in aortic rings (p=0.28, n=4, Figure
3.8).
3.3.4 Influence of cytokines on 11PHSD activity in intact arteries in vitro
Pre-incubation of aortic rings with the pro-inflammatory cytokines IL-1 (3 and TNFa
did not alter 11 p-reductase activity (n=4-10, Figure 3.9). Similarly, there was no
effect of the Th2 cytokines, IL-4 or IL-13, or of etanercept on reductase activity
(n=4, Figure 3.9). Incubation with IL-ip or TNFa had no effect on dehydrogenase
activity (n=4, p=0.25, Figure 3.10).
3.3.5 Influence of systemic lipopolysaccharide in vivo
Systemic LPS administration produced a small increase in 11p-reductase activity in
aortic rings (n=6, p=0.045, Figure 3.11). 11 P-Dehydrogenase activity in mouse aortic
rings was unaltered by systemic LPS administration (n=3, p=0.16, Figure 3.11).
3.3.6 11pHSD activity in aortic homogenates from obese ob/ob mice
NADP-dependent lip-dehydrogenase activity was detected in the homogenates of
aortae from both ob/ob and lean littermate control mice. There was no significant
difference in activity between the two groups (Figure 3.12; n=8-ll; p=0.62)
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Figure 3.9 Influences of cytokines on 11 P-reductase activity in the mouse
aorta
Aortic rings were incubated for 48 hours with TNFa, IL-ip, IL-4, IL-13, etanercept or
vehicle (V), and then for a further 24 hours in the presence of [3H]-11-
dehydrocorticosterone. 11 P-Reductase activity is expressed as [3H]-corticosterone
formed relative to activity in control incubations without cytokine manipulation.
Results are mean ± standard error; there were no differences between groups when




Figure 3.10 Influences of TNFa and IL-ip on 11 ^-dehydrogenase activity in
mouse aorta
1 ip-Dehydrogenase activity is expressed as the amount of [3H]-11-
dehydrocorticosterone formed from [3H]-corticosterone, per milligram (wet weight)
over 24 hours in aortic rings from C57B6J mice following incubation with TNFa (100
ng/ml), IL-1 (3 (10 ng/ml) or vehicle control. 1 ip-Dehydrogenase activity was similar
in all groups (p=0.25). Results are mean ± standard error, n=4, and were compared




Figure 3.11 Effects of systemic LPS on 11PHSD activity in mouse aorta
1 ip-Reductase and -dehydrogenase activities are expressed as the amount of [3H]-
corticosterone or [3H]-11-dehydrocorticosterone formed, respectively, per milligram
(wet weight) over 24 hours in aortic rings from C57B6J mice 6 hours following
intraperitoneal administration of lipolysaccharide (10 mg/kg) or vehicle control. 1 ip-
Reductase activity was significantly increased following LPS injection (*p=0.045,
n=6) 1ip-Dehydrogenase activity was similar in both groups (p=0.16, n=3). Results
are mean ± standard error, and were compared by unpaired Student's t-test.
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Figure 3.12 11PHSD activity in aortic homogenates from ob/ob mice
11(3HSD activity is expressed as the percentage conversion of [3H]-corticosterone to
[3H]-11-dehydrocorticosterone (per 5 ng protein) in aortic homogenates from lean
and obese mice. 11(3-HSD activity was measured after 24 hour incubation in the
presence of NAD. 11(3HSD activity was not significantly different in the two groups




The intention of these studies was to determine the reaction directionality of the
llpHSD isozymes in intact murine arteries and to investigate the influence of
inflammatory mediators on the activity of these enzymes. The results demonstrate
the predominant regeneration of glucocorticoids within the vessel wall by 11J3HSD1,
the sole reductase, and confirm that 11PHSD2 is an exclusive dehydrogenase. In
contrast to findings in cell culture, regulation of 1 lpHSDl activity by inflammatory
mediators does not occur in healthy murine arteries in vitro.
11/^-Reductase activity in cultured murine aortic SMCs
Initial experiments with cultured murine aortic SMCs confirmed that, consistent with
previous studies using human aortic SMCs (Cai et al. 2001), 11 P-reductase activity
was enhanced following stimulation with the inflammatory cytokine IL-ip.
However, the effect of IL-ip on 11P-reductase activity was less marked in murine
aortic SMCs (40% increase in activity) than the five-fold enhancement shown
previously in human SMCs (Cai et al. 2001). Moreover, in repeat experiments, both
basal 11 p-reductase activity within murine SMCs and the response to IL-ip was
found to be highly variable, with as much as 100% increase in basal activity and
often no measurable up-regulation of this activity following IL-1P stimulation. It is,
therefore, possible that cytokine-mediated regulation of lipHSDl activity in
cultured smooth muscle cells differs between species. The decline in basal 11P-
reductase activity with increasing passage raises the possibility that 11PHSD activity
may also depend on the degree of cellular proliferation and/or differentiation. This
hypothesis is supported by studies which have demonstrated differences in both basal
and stimulated lipHSDl activity in human ovarian carcinoma cell lines compared
with primary cultures of ovarian surface epithelial cells (Gubbay et al. 2005).
Preliminary studies showed that whilst 11 P-reductase activity in MA-SMCs was
either unchanged or only modestly up-regulated upon stimulation with IL-ip, co-
incubation with pharmacological doses of exogenous corticosterone resulted in a
more marked increase in 11P-reductase activity. Although these enzyme activity
assays were performed using cells which had been sustained for at least 16 hours in
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serum-free conditions, the maintenance cell culture medium contained 10% foetal
calf serum (FCS). It is therefore possible that exposure to inconstant amounts of
serum-derived glucocorticoid explains the variability in both basal and stimulated
11 P-reductase activity which was evident. The synergistic effect of glucocorticoids
on cytokine-mediated up-regulation of 11 pHSD activity noted in these studies is in
keeping with some (Sun & Myatt 2003), but not all (Cooper et al. 2001), published
data, and raises the possibility that physiological or pathological variations in
glucocorticoid availability within vascular tissue may also influence the
inflammatory regulation of lipHSD activity. It should be noted that the dose of
corticosterone used in the present study (lOOpM) was far in excess of physiological
circulating glucocorticoid levels. This was due to experimental error, and the dose
was intended to be lOOnM; however, the positive effect of such a high dose on
11 PHSD activity (which would be expected to result in feedback inhibition of
reductase activity) suggests that physiological variations in glucocorticoid levels may
play an important role in the inflammatory regulation of 11 PHSD 1 in conditions
where the HPA axis might be activated, and future work should seek to address this
possibility. The potential influences of these factors on the inflammatory regulation
of 11 PHSD 1 highlight the importance of extending these investigations into intact
arteries.
Smooth muscle cells from 1 lpHSDl homozygous null (-/-) mice did not grow well
in culture. This methodological difficulty is relevant, as abnormal proliferation of
vascular smooth muscle cells is an important mechanism in vascular remodelling.
Moreover, glucocorticoids play a key role in vascular growth, as exogenous
glucocorticoid excess reduces rodent smooth muscle cell proliferation (Reil et al.
1999) and inhibits angiogenesis (Small et al. 2005). Additionally, we have shown an
angiostatic effect of endogenous glucocorticoids, mediated by lipHSDl, which is of
pathological importance as 1 lpHSDl null mice exhibit greater angiogenic responses
in wounds and in infarcted myocardium (Small et al. 2005). However, the effects of
alterations in 11 PHSD activity, and hence endogenous glucocorticoid availability, on
smooth muscle cell proliferation have yet to be explored. It is of interest, then, that
contrasting effects of exogenous and endogenous oestrogens on vascular SMC
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proliferation have been demonstrated: exogenous oestrogens inhibit human vascular
smooth muscle cell proliferation (Morey et al. 1997; Somjen et al. 1998), whilst in
the aromatase knockout (ArKO) mouse model, endogenous oestrogen deficiency
reduces vascular smooth muscle cell proliferation and enhances cytokine-mediated
apoptosis (Ling et al. 2004). There may, therefore, be interesting analogies between
oestrogens and glucocorticoids with respect to their effects on vascular smooth
muscle cell proliferation.
/ IfiHSD activity and directionality in intact mouse arteries
The studies presented here have demonstrated, for the first time, both 11P-reductase
and -dehydrogenase activities in intact murine aorta and hindlimb arteries in vitro.
Conventional activity assays in homogenised tissue preparations have been limited
by lack of co-factor specificity, and have failed to resolve the relative contributions
of 11 P-reductase and lip-dehydrogenase activities to the overall control of local
glucocorticoid availability. Thus the findings here are important, given the presence
of both isozymes in the mouse aorta (Christy et al. 2003), and the potential for
lipHSDl to act in a bi-directional fashion, as both reductase and dehydrogenase
(Brem et al. 1995; Souness et al. 2002). Whilst dehydrogenase activity was similar in
the vessels examined, there appear to be regional differences in basal 11P-reductase
activity, a finding that has been noted previously (Walker et al. 1991), with higher
activity in aorta than in the iliofemoral arteries. Interestingly, under these assay
conditions, 11 P-reductase activity in vascular tissues exceeded that in liver.
However, these data should be interpreted with caution as the in vitro assay was
established to assess 11PHSD activity in viable vascular tissue, and the viability of
other tissues over time under these conditions has not been verified. Indeed, the
biphasic dehydrogenase activity observed in the liver time course experiment may
represent initial lipHSDl dehydrogenase activity as a result of liberation of enzyme
from the cut surfaces of the liver slice, and then after a few hours, cell death within
the rest of the liver slice resulting in further cellular leakage of lipHSDl and
renewed dehydrogenase activity at later time points.
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Experiments using vascular tissue from lipHSDl-/- mice have confirmed that, in
keeping with previous reports, lipHSDl acts as the sole reductase (Kotelevtsev et
al. 1997), and that 11PHSD2 is an exclusive dehydrogenase (Agarwal et al. 1994).
The persistence of dehydrogenase activity in intact aorta from llpHSD2 -/- mice in
vitro is evidence that lipHSDl may be acting as both reductase and dehydrogenase
under these assay conditions. The question of whether lipHSDl has the potential to
act in a bi-directional fashion, as both reductase and dehydrogenase, in vivo is
controversial (Seckl & Walker 2004; Tomlinson et al. 2004; Brem et al. 1995). The
findings from the in vitro studies presented here do not provide absolute
confirmation of bi-directional activity of lipHSDl in intact vascular tissue as the
persistent dehydrogenase activity seen in vessels from 11PHSD2-/- mice may be a
function of the assay, simply reflecting a change in directionality of lipHSDl upon
liberation of the enzyme from its intracellular environment, such as occurs in
homogenised tissue preparations (Lakshmi & Monder 1988). The novel hypothesis
that hexose-6-phosphate dehydrogenase confers reductase activity upon 1 lpHSDl in
intact cells is intriguing (Hewitt et al. 2005). However, although H6PDH expression
has been noted in many rat tissues, including the heart (Mandula et al. 1970), it has
not yet been identified in cells of vascular origin. In any case, despite the potential
contribution to total dehydrogenase activity from lipHSDl, a comparison of the
absolute reductase and dehydrogenase activities in intact vascular tissue from wild
type mice demonstrates that the reductase direction predominates by approximately
10:1 in vitro.
Regulation of llfiHSD activity in intact murine arteries by inflammatory mediators
Extensive examination of the influence of cytokines on lipHSD activity in intact
aortic rings was undertaken. In contrast to the findings in cell culture, there was no
evidence of up-regulation of vascular lipHSDl reductase activity by cytokines in
intact tissue in vitro. The pro-inflammatory cytokines IL-ip and TNFa had no effect
on lip-reductase activity, and no counter-regulatory effect on lip-dehydrogenase
activity. Bioactivity of TNFa was confirmed by neutrophil apoptosis assay (Section
2, Figure 2.3) and IL-ip by a positive effect on lip-reductase activity in cultured
cells (Figure 3.1). Furthermore, the anti-inflammatory Th2 cytokines, IL-4 and IL13,
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at doses which up-regulate 11(3HSD1 activity in human peripheral blood monocytes
(Thieringer et al. 2001), were also ineffective at regulating lipHSDl. To investigate
the possibility that the presence of endogenous inflammation, and increased TNFa
production, within the intact aortic ring was resulting in maximal stimulation of basal
11 P-reductase activity, the influence of the TNFa antagonist, etanercept, was
examined. The lack of effect of etanercept on 11 P-reductase activity suggests that
endogenous activation of lipHSDl by TNFa does not account for the inability of
exogenous TNFa to enhance 11 P-reductase activity.
There are a number of studies reporting effects of inflammatory cytokines on
lipHSDl activity in a variety of different cell types (see Table 1.1). The majority of
these demonstrate a selective increase in 11P-reductase activity and/or expression
upon stimulation with pro-inflammatory cytokines (Cai et al. 2001; Sun & Myatt
2003; Tomlinson et al. 2001; Rae et al. 2004; Yong et al. 2002; Cooper et al. 2001;
Escher et al. 1997; Tetsuka et al. 1999). However, this effect is not universal, as
TNFa has no effect on 11P-reductase activity in cultured human hepatocytes
(Tomlinson et al. 2001). Furthermore, in circulating monocytes, lipHSDl
expression is not up-regulated by the pro-inflammatory cytokines TNFa or IL-
lp, but is induced during differentiation into macrophages, and also following
exposure to the Th2 cytokines IL-4 and IL-13 (Thieringer et al. 2001). All studies
reported to date have utilised cell culture systems, which undoubtedly alter the
natural cell phenotype. The discrepancy between the ability of cytokines to up-
regulate lipHSDl activity in cell culture but not in intact tissue preparations
suggests that the regulation of lipHSDl by inflammatory stimuli may be tissue
specific and may also depend on the degree of cell proliferation and/or
differentiation.
In contrast to the in vitro findings, there was a small (18%) selective increase in 11(3-
reductase activity in aortic rings of mice which had received in vivo LPS. Thus,
although individual cytokines appear ineffective at enhancing lipHSDl activity in
intact tissue, the result of in vivo LPS may be to produce an altered inflammatory
"milieu" which favours a modest increase in 11P-reductase activity. It is open to
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conjecture as to whether the resultant change in glucocorticoid availability following
these modest effects could have physiologically relevant consequences.
Finally, total aortic llpHSD activity in obese ob/ob mice, a condition associated
with systemic inflammation (Hotamisligil et al. 1993), was unaltered compared with
lean littermates, supporting the concept that inflammatory regulation of 11 pHSDs in
tissue or homogenate preparations does not mirror that found in cell culture. It is
noteworthy that although alterations in lipHSDl have been demonstrated in this
murine model of obesity (and also in rats and humans, reviewed by Wake & Walker
(2004)) these appear to be tissue-specific, with an increase in 1 lpHSDl in liver (Liu
et al. 2003), and a decrease in adipose (Masuzaki et al. 2001; Alberts et al. 2003).
That there may be discordant changes in 1 lpHSDl in different tissues in response to
the same systemic disease only serves to highlight the complexity of lipHSDl
regulation.
Conclusions
In summary, these data confirm the presence, and describe the directionality, of both
lipHSDl and llpHSD2 activity in intact murine vascular tissue in vitro. Although
there was evidence of inflammatory regulation of 1 lpHSDl in cultured MA-SMCs,
which may depend on cellular phenotype, a similar effect was not evident in healthy
intact vascular tissue in vitro. In contrast, systemic inflammation in vivo produced a
modest up-regulation of 11 P-reductase activity in intact vascular tissue, suggesting
that there may be factors present in vivo but not in vitro which are required for the
inflammatory regulation of lipHSDl to be manifest. Although these data do not
consistently support the idea that there is inflammatory regulation of 11 pHSDs, it
should not be inferred that lipHSDl does not play a role in modulating
glucocorticoid signalling since the current studies demonstrate the predominant
regeneration of glucocorticoids within the vessel wall. To explore the inflammatory
regulation of vascular 11PHSD activity further, under more physiological conditions,
it was felt pertinent to develop a model to allow determination of 11 PHSD activity in




the murine perfused hindquarter
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4.1 Introduction
The importance of the 11 P-hydroxysteroid dehydrogenases (lipHSDs) in the
regulation of local vascular glucocorticoid concentrations, and the contributions of
each isozyme to overall 11 P-reductase and dehydrogenase activities, have been
underlined by the in vitro studies described in Chapter 3. Selective regulation of
isozyme activity by inflammatory mediators (Cai et al. 2001), which was
demonstrated in cultured smooth muscle cells, may have a significant influence on
glucocorticoid-mediated modulation of vascular function. However, the lack of effect
of cytokines on 11PHSD activity within intact vascular tissue in vitro (despite up-
regulation of lipHSDl in response to inflammation in vivo) has challenged the
notion that these findings can be extrapolated to the in vivo environment. Thus, it
was deemed important to extend the studies into a more physiologically relevant
model of vascular inflammation.
The method for perfusion of the rodent hindquarter (Brandes et al. 2000) provides an
attractive model for determination of lipHSD activity and endothelial cell function
within a perfused vascular bed. It is a physiological model and has been used to
explore both metabolism (Ye & Colquhoun 1998a; Ohshima et al. 1989) and
vascular function (Emeis 1983; Brandes et al. 2000; Tranquille & Emeis 1990; Ceiler
et al. 1999; McAllister 2003; Bohlooly et al. 2001) in an intact vascular territory. It
was selected in preference to other methods (for example, the perfused mesenteric
bed) as it allows both perfusion of large and small vessels and measurement of
biochemical signals within a physiological environment. Although metabolism
within the perfused hindquarter has been studied in detail (Ye & Colquhoun 1998a;
Ohshima et al. 1989), glucocorticoid metabolism by the lipHSDs has not been
investigated previously.
The studies presented in this chapter explore the hypothesis that systemic
inflammation up-regulates lipHSDl reductase activity in the perfused mouse
hindquarter. The specific aims of the investigations were (1) to develop a murine
hindquarter perfusion model, (2) to characterise the activity and reaction
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directionality of the lipHSDs within this regional perfused territory, and (3) to
assess the influence of systemic inflammation on lipHSDl activity. The studies
required the application of existing techniques of hindquarter perfusion and of
systemic inflammation. It was also necessary to develop a novel method with which




Unless otherwise specified, all hindquarter perfusions were performed using male
C57B6J mice aged 8-16 weeks. Mice were killed by cervical dislocation prior to
commencement of perfusion studies, as anaesthetic agents are known to have effects
on mediators of vascular tone (Toda et al. 1992; Zuo et al. 1996).
4.2.2 Method Development
A model of mouse hindlimb perfusion was required which would allow infusion of
radiolabeled steroids, collection of perfusate for analysis and determination of
perfusion pressure. This would provide a relatively physiological model in which to
determine the significance of glucocorticoid metabolism by 11 pHSDs. Therefore, a
method was developed (see Chapter 2, Section 2.9) based on studies by Brandes et
al. (2000) to allow selective perfusion of the hindquarters, with physiological buffer
containing steroids, via a cannula sited in the distal aorta. lipHSD activity was
determined in this model by collecting aliquots of venous effluent, over the course of
the perfusion study, from a cannula sited in the distal inferior vena cava. Analysis of
the proportion of radiolabelled 11-dehydrocorticosterone and corticosterone within
each aliquot by HPLC (as described in Methods Section 2.10) allowed determination
of enzyme activity. Conditions were optimised during pilot studies using a variety of
flow rates, buffer compositions, temperatures and surgical techniques, and these are
detailed in the following sections. Attempts to study vascular function within this
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hindquarter model proved difficult. Few publications have reported the use of a
mouse hindlimb model for functional studies (Brandes et al. 2000; Bohlooly et al.
2001), and some of these have clearly been hampered by methodological difficulties
(Bohlooly et al. 2001). Moreover, the purposes of these particular functional studies
in the context of this thesis were superseded by findings in parallel human studies,
detailed in Chapter 5.
4.2.2.1 Perfusion Set Up
The aim of the surgical set up described in Chapter 2 (Section 2.9.1 and Figure 2.1)
was to allow selective perfusion of both hindlimbs, without retrograde (or otherwise)
perfusion of metabolically active abdominal or pelvic viscera. The perfused region
was confirmed in preliminary perfusion studies using C57B6J mice (n=3) in which
KH buffer containing Evans Blue dye (0.5% w/v) was used to evaluate the perfused
regions (Hamza & Kaufman 2004).
4.2.2.2 Perfusion Conditions
Initial perfusion experiments used modified Krebs-Henseleit (KH) buffer, based on
studies by Brandes et al. (2000). However perfusion of hindquarters with this buffer
resulted in significant tissue oedema, which could be prevented with the addition of
2% bovine serum albumin (Ye & Colquhoun 1998b; Bohlooly et al. 2001). Thus, all
perfusion studies described in this chapter have utilised a modified KH buffer
containing 2% bovine serum albumin.
Animals were kept on a warmed dish at 37°C and perfused with buffer at the same
temperature (Bohlooly et al. 2001). To achieve a buffer temperature of 37°C at the
abdominal aorta, preliminary studies indicated that the buffer required to be
maintained in a water bath at 40°C.
A constant-flow approach, using a peristaltic pump, was used to perfuse the
hindquarters. Flow rates of 0.8-1.2 ml/min were chosen to approximate physiological
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perfusion pressures (-40 mmHg) within the maximally-dilated hindlimb and to avoid
tissue oedema. Inflow was determined by timed collection of venous effluent, and
perfusion pressure was monitored during initial flow vs. pressure perfusion studies
using a transducer connected to a side port of the perfusion system (data not shown).
The pressure transducer was immediately proximal to the aortic cannula and at the
same level as the animal, and was connected to a Powerlab analogue-to-digital
converter.
Standard conditions for the perfusion studies utilised buffer containing [ H]-
corticosterone or [3H]-ll-dehydrocorticosterone at concentrations of 5 nM. These
concentrations were chosen to be sufficient for detection by HPLC and were close to
physiological levels (circulating corticosterone and 11-dehydrocorticosterone
concentrations in the mouse vary diurnally within the ranges 25-150 nM and 0-10
nM, respectively (Harris et al. 2001)).
4.2.2.3 Steroid Recovery
In all perfusion studies, 20 pi aliquots of effluent samples and perfusate (stock buffer
which had not been perfused through the hindquarter) were added to 3 mis Zinsser
Aquasafe 300 plus scintillation fluid and analysed by scintillation counting (Packard
Tri-carb 2100TR) to estimate steroid content. The proportion of steroid recovered in
the effluent was then calculated from the counts per minute (c.p.m.) in each aliquot
as:
% Recovery = (c.p.m. recovered in effluent / c.p.m. recovered in perfusate) x 100
4.2.3 Glucocorticoid metabolism in the perfused hindquarter
4.2.3.1 11^-Reductase activity
llp-Reductase activity was determined in perfused hindquarters of wild type mice
(n=3) using standard conditions (as described in Section 2.9), over a 55 minute
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period. Buffer contained 5 nM [3H]-ll-dehydrocorticosterone and aliquots of
effluent were collected over 5 minute intervals throughout the perfusion.
In further studies, reductase enzyme kinetics were established by perfusing
hindquarters over 60 minutes under similar conditions, except with varying
concentrations of [3H]-ll-dehydrocorticosterone (5, 7.5, 15, 30 and 500 nM; n=3
animals at each concentration). Aliquots of effluent were collected over 90 seconds
at intervals throughout the study.
4.2.3.2 11^-Reductase activity in 11(3HSD1 -/- mice
11 (3-Reductase activity was determined in the perfused hindquarters of 11(3HSD1-/-
and age-matched C57B6J mice (n=3) as described above (Section 4.2.3.1).
4.2.3.3 11 fl-Dehydrogenase activity
11 (3-Dehydrogenase activity was determined (as described in Section 2.9) in the
perfused hindquarters of wild type mice (n=4) over a 55 minute time period. Buffer
contained 5 nM [3H]-corticosterone and aliquots of effluent were collected over 5
minute intervals throughout the perfusion.
4.2.3.4 11^-Dehydrogenase activity in 11fSHSD2 -/- mice
1 ^-Dehydrogenase activity was determined in the perfused hindquarters of male
11(3HSD2-/- and age-matched C57B6J mice (n=3-4) over a 55 minute time period as
described above (Section 4.2.3.3).
4.2.4 11(3-Reductase activity in hindlimb tissues in vitro
In order to establish which tissues within the hindlimb were contributing to the
observed 11 p-reductase activity, iliofemoral arteries, pieces of quadriceps muscle,
and skin and subcutaneous adipose tissue were dissected from C57B6J mice and
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assayed for 11 P-reductase activity in vitro using the method described for arteries in
Section 2.8.3 (n=4).
4.2.5 Effect of LPS on 11 P-reductase activity
To observe the effects of systemic inflammation on 11 P-reductase activity in the
perfused hindquarter, perfusion studies were performed on mice which had received
intraperitoneal LPS (10 mg/kg) or vehicle 6 hours previously (as described in Section
2.9.4). Perfusions lasted 60 minutes, and aliquots were collected over 90 second
intervals throughout the study.
4.2.6 Statistics




4.3.1.1 Perfusion Set Up
Use of Evans blue dye confirmed that there was no retrograde perfusion of
abdominal viscera or of the testes, epidiymis or epididymal adipose tissue. Evans
Blue staining was seen in the hindlimbs, the tail, the inferior peritoneal lining and the
glandula vesicularis, suggesting that the perfused territory was not confined to the
hindlimbs alone, but rather encompassed perfusion of bilateral hindquarters.
4.3.1.2 Steroid Recovery
During perfusion of C57B6J hindquarters with [3H]-11-dehydrocorticosterone (5-500
nM, n=15), the recovery of perfused steroid increased linearly to reach a steady state
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within approximately 15 minutes. Once this equilibrium was reached, approximately
90% of radiolabeled steroid was recovered (Figure 4.1). Similar recoveries were
calculated for studies infusing [3H]-corticosterone, and also in studies with
11PHSD1-/- or 11PHSD2-/- mice (data not shown).
4.3.2 Glucocorticoid Metabolism in the Perfused Hindlimb
4.3.2.1 11P-Reductase Activity
11(1-Reductase activity was detected in the perfused hindquarters of C57B6J mice, as
indicated by conversion of [3H]-ll-dehydrocorticosterone to [3H]-corticosterone
(Figure 4.2). 11 P-reductase activity increased throughout the study to reach a
maximum of approximately 80% conversion (equivalent to a velocity of 3.2 pmol
[3H]-corticosterone / minute).
4.3.2.2 11^-Reductase Kinetics
11 P-Reductase activity increased in proportion to substrate concentration (Figure
4.3). Kinetic constants for 11 P-reductase were calculated from the Lineweaver-Burke
linear transformation of the Michaelis-Menten equation (Lineweaver & Burk 1934),
using the mean data (n=3) of enzyme activity at the 11 minute time point (which is
midway along the linear initial phase of product generation, and thus approximates to
initial reaction velocity, Figure 4.4). These data gave an apparent Km of 1.064 pM
and a maximum velocity 313 pmol/min.
4.3.2.3 11^-Reductase in 11($HSD1 -/- Mice
In contrast to studies using wild type mice, no 11P-reductase activity was detected in
hindquarters of 11PHSD1-/- mice (Figure 4.2).
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Figure 4.1 Steroid recovery following hindquarter perfusion of C57B6J mice
Percentage of total [3H]-steroid recovered from effluent during perfusion of C57B6J
hindquarters with 5-500 nM [3H]-11-dehydrocorticosterone. [3H]-steroid content was
estimated by scintillation counting of 20 \i\ aliquots of perfusate (stock buffer which
had not been perfused through hindquarters) and effluent samples. % Recovery was
calculated as (c.p.m. recovered in effluent / c.p.m. recovered in perfusate) x 100.
Results are mean ± standard error; n=15.
99
Figure 4.2 11 P-Reductase activity in perfused hindquarters of C57B6J and
110HSD1-/- mice
11P-Reductase activity in perfused hindquarters of C57B6J (closed squares) and
11PHSD1-/- (open circles) mice. Enzyme activity is expressed as the percentage of
[3H]-corticosterone formed from [3H]-11-dehydrocorticosterone. 11P-Reductase
activity was abolished in 11PHSD1-/- mice. Results are mean ± standard error; n=3,
**p<0.005, compared with controls.
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Figure 4.3 Effect of substrate concentration on 11 (3-reductase activity in the
perfused hindquarter
Effect of increasing substrate concentration (5-500 nM 11-dehydrocorticosterone) on
enzyme activity in the perfused hindquarter. C57B6J mice underwent 60 minute
hindquarter perfusions. Results are mean ± standard error, n=3 at each
concentration.
101
Figure 4.4 11 p-Reductase kinetics in the perfused hindquarter
Lineweaver-Burke plot showing kinetics of 11 (3-reductase activity in perfused
hindquarters of C57B6J mice. Using a time point of 11 minutes following the
commencement of the perfusion, Km was calculated as 1.064 pM and maximum
velocity (Vmax) 313 pmol/min. Results are mean ± standard error, n=3 at each
concentration. A = 11-dehydrocorticosterone.
102
4.3.2.4 11 ^-Dehydrogenase Activity
lip-Dehydrogenase activity, albeit at a very low level, was detected in the perfused
hindquarters of C57B6J mice, as indicated by conversion of [3H]-corticosterone to
[3H]-ll-dehydrocorticosterone (Figure 4.5). In keeping with previous in vitro
findings, dehydrogenase activity in hindquarters of wild type mice (approximately
6% conversion, or 0.24 pmol [3H]-ll-dehydrocorticosterone/minute) was
approximately 10-fold lower than reductase activity (80% conversion, or 3.2 pmol
[3H] -corticosterone/minute).
4.3.2.5 11^-Dehydrogenase activity in 11PHSD2 -/- Mice
In contrast with the findings in vitro (Chapter 3), dehydrogenase activity was below
the limit of detection by HPLC (2% conversion) in hindquarters of mice with genetic
inactivation of 11PHSD2 (Figure 4.5).
4.3.3 1ip-Reductase activity in hindlimb tissues ex vivo
Ex vivo activity assays of tissues from the hindlimb confirmed the presence of
reductase activity in the hindlimb vasculature (11.4±31.4 pmol/mg/24hrs), skeletal
muscle (0.14±0.02 pmol/mg/24hrs) and skin and subcutaneous adipose tissues
(0.27±0.05 pmol/mg/24hrs). Weight for weight, reductase activity in the vasculature
far exceeded that in the skeletal muscle or skin/subcutaneous adipose (p<0.0001,
n=4, Figure 4.6).
4.3.4 Effects of LPS on 11 p-reductase activity in the perfused
hindquarter
Lipopolysaccharide administration resulted in significant weight loss (p<0.05, n=6)
and splenomegaly (p<0.05, n=6) compared with vehicle injection (Figure 4.7). The
proportion of steroid recovered in effluent from perfused hindquarters was not
influenced by LPS treatment (p>0.05, n=6, Figure 4.8).
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Figure 4.5 11 P-Dehydrogenase activity in perfused hindquarters of wild type
and 11(3HSD2-/- mice
11 (3-Dehydrogenase activity in perfused hindquarters of C57B6J (closed squares)
and 11(BHSD2-/- (open circles) mice. Enzyme activity is expressed as the
percentage of [3H]-11-dehydrocorticosterone formed from [3H]-corticosterone. 11(3-
Dehydrogenase activity in 11(3HSD2-/- mice was below the limit of detection by
HPLC (conversion all less than 2%). Results are mean ± standard error; n=3-4,
*p<0.05, compared with controls. Note difference in Y-axis range when making
comparison with Figure 4.2.
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Figure 4.6 11 p-Reductase activity in hindlimb tissues
11(3-Reductase activity is expressed as the amount of [3H]-corticosterone formed
from [3H]-11-dehydrocorticosterone, per milligram (wet weight) over 24 hours, in
intact iliofemoral vessels, chunks of quadriceps muscle and skin and subcutaneous
adipose tissue from C57B6J mice (n=4). 1 ip-Reductase activity in ileofemoral
vessels far exceeded that in the skeletal muscle and skin and subcutaneous
adipose (***p<0.0001). Results are mean ± standard error, n=4.
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Figure 4.7 Effects of LPS on body weights and spleen weights
Changes in (A) total body weight and (B) spleen weights of C57B6J mice, 6 hours
following intraperitoneal LPS (10 mg/kg, solid bars) or saline vehicle (open bars).
LPS administration resulted in significant weight loss (*p<0.05) and splenomegaly





Figure 4.8 Effects of LPS on total steroid recovery
Percentage of total [3H]-steroid recovered from the effluent of C57B6J hindquarters
perfused with 5nM [3H]-11-dehydrocorticosterone. Mice had received either LPS (10
mg/kg, closed circles) or saline (20 ml/kg, open circles) intraperitoneally 6 hours
previously. [3H]-steroid content was estimated by scintillation counting of 20 ^il
aliquots of perfusate (stock buffer which had not been perfused through an animal)
and effluent samples. % Recovery was calculated as (c.p.m. recovered in effluent /




Figure 4.9 Effects of LPS on 11{3-reductase activity in the perfused hindquarter
11 (3-Reductase activity in perfused hindquarters of C57B6J mice 6 hours following
in vivo intraperitoneal administration of lipolysaccharide (LPS, 10 mg/kg, closed
circles) or vehicle (open squares). 11 (3-Reductase activity is expressed as the
amount of [3H]-corticosterone formed. Results are mean ± standard error; there
were no differences between groups (d=0.12 by repeated measures ANOVA, n=6).
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11 P-Reductase activity in the perfused hindquarter was similar in animals treated
with LPS compared with vehicle controls, although a trend to a modest increase in
activity following LPS treatment was noted (p=0.12, n=6, Figure 4.9).
4.4 Discussion
The intention of these studies was to determine the activity and reaction
directionality of the lipHSD isozymes in the perfused mouse hindquarter, and to
investigate the influence of systemic inflammation on the activity of these enzymes.
The results demonstrate the presence of both 11 P-reductase and -dehydrogenase
activities in the perfused hindquarter, with lip-reduction being the predominant
reaction direction, consistent with the in vitro findings from Chapter 3. Again in
keeping with results in Chapter 3, 11PHSD2 was confirmed as an exclusive
dehydrogenase. However, whereas lipHSDl may have bidirectional activity in
arteries in vitro, it appeared to act solely as a reductase in the perfused hindquarter in
situ. Whilst systemic LPS had a modest effect on 11 P-reductase activity in aortic
rings ex vivo, this effect was not evident in perfused hindquarters suggesting that up-
regulation of lipHSDl reductase by inflammatory stimuli is unlikely to be an
important accompaniment of vascular inflammation in vivo.
11/3HSD activity and directionality in theperfused hindquarter
These are the first studies to determine the presence of 11PHSD activity in a regional
vascular bed in situ. The data from the studies described in this chapter suggest that
the hindquarter model is a robust, reproducible technique with which alterations in
11 PHSD activity can be investigated. Both 11 p-reductase and 11 P-dehydrogenase
activities were detected. In keeping with the in vitro vascular studies described in the
previous chapter, the reductase direction predominated by ~10-fold, illustrating again
the predominant regeneration of glucocorticoids within a vascular territory.
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Reductase activity within the hindlimb appears substantial, particularly in relation to
the lower dehydrogenase activity, with around 65% of 11-dehydrocorticosterone
being converted to corticosterone after just 30 minutes. However, the absolute
magnitude of this enzyme activity represents a reaction velocity of approximately 3
pmol of corticosterone produced per minute. This level of activity is significantly
lower (by around 20-fold) than that found in rat livers perfused under similar
conditions, where the enzyme activity is of the order of 70 pmol of corticosterone
generated per minute (Jamieson et al. 2000). Considering 11 [1HSD1 is highly
expressed in the liver, a key site for glucocorticoid regeneration, it is perhaps not
surprising to find much lower levels of 11 P-reductase activity in the hindlimb.
Interestingly, in contrast to the results from the murine studies presented here,
investigations using the deuterated Cortisol tracer method (Andrew et al. 2002) to
measure 11PHSD activities in humans in vivo failed to detect generation of active
glucocorticoid within the leg (Basu et al. 2004). These apparent differences between
enzyme activities in human leg and murine hindlimb may highlight species-specific
variations in llpHSDl (Ricketts et al. 1998a), or may simply reflect differences
between the investigative methods employed.
More detailed kinetic studies of 11 P-reductase activity revealed an apparent Km of ~1
pM in the perfused hindlimb, consistent with values reported for 11 P-reduction by
11PHSD1 in vitro (Agarwal el al. 1990) (Pu & Yang 2000; Shafqat et al. 2003), and
is evidence that the reductase activity present in the hindlimb can be attributed to the
11PHSD1 isozyme. This Km value suggests that the affinity of lipHSDl for
corticosterone within the hindquarter is similar to that found in vitro. There is an
enigma in this, however, since endogenous concentrations of 11-
dehydrocorticosterone, the substrate for lipHSDl reduction, are in the low
nanomolar range (Harris et al. 2001). It is of interest, then, that llpHSDl is now
known to occur as a dimeric enzyme (Zhang et al. 2005a) which appears to obey
Michaelis-Menten kinetics for 11 P-dehydrogenation but exhibits cooperative kinetics
for 11-oxoreduction (Maser et al. 2002). This positive cooperativity, in addition to
the upregulation of 1 lpHSDl by glucocorticoids (Takeda et al. 1994c) (Sun & Myatt
2003; Hammami & Siiteri 1991; Jamieson et al. 1995; Liu et al. 1996), might
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provide a flexible system whereby dynamic adaptation in response to wide
fluctuations in endogenous glucocorticoid levels is possible.
Perfusion studies using lipHSDl-/- mice, in keeping with results from in vitro
studies, confirmed that llpHSDl is the sole reductase (Kotelevtsev et al. 1997), and
that 11PHSD2 is an exclusive dehydrogenase (Agarwal et al. 1994). Further
experiments, with perfused hindquarters of llpHSD2 -/- mice demonstrated virtual
abolition of 11 p-dehydrogenase activity which suggests that, although 1 lpHSDl has
capacity to act as both reductase and dehydrogenase in arteries in vitro, this is likely
to be an artefact of the assay (as discussed in Section 3.4) as 1 ip-reduction is the
predominant reaction direction in vivo.
The high level of lipHSDl reductase activity demonstrated in these perfusion
studies raised the question of where, within the hindlimb, lip-reduction of 11-
dehydrocorticosterone was occurring. lipHSDl activity has been demonstrated in
several cells/tissues which comprise the hindlimb, including subcutaneous adipose
(Bujalska et al. 1997; Sandeep et al. 2005), skeletal myoblasts (Whorwood et al.
2001) and, of course, vascular tissue (Christy et al. 2003; Brem et al. 1998; Brem et
al. 1995). Ex vivo studies described in this chapter demonstrated that hindlimb
arteries, skeletal muscle and skin and subcutaneous adipose all have 11 P-reductase
capacity. Whilst vascular tissue was found to have much higher lipHSDl activity
than skeletal muscle or skin and subcutaneous adipose tissue weight for weight, the
proportional contribution of each tissue to overall glucocorticoid regulation within
the hindlimb has not been evaluated. It is therefore likely that all of these tissues
make a contribution to the reductase activity determined during perfusion studies.
Whilst it could be argued that the hindquarter model is not a "clean" vascular
preparation, it may in fact be a more physiologically relevant model of in vivo
glucocorticoid metabolism, as there may be vascular consequences of altered
glucocorticoid levels within adjacent tissues which may be overlooked in isolated
vascular preparations.
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Effects ofLPS on 11J3HSD activity the perfused hindquarter
LPS had no significant effect on 1 lpHSDl activity in the perfused hindquarter. This
is in contrast to in vitro findings in which there was a modest increase in lip-
reductase activity in aortic rings of mice which had received in vivo LPS. Although
the regulatory effect of LPS on 1 lpHSDl was not evident in perfused hindlimbs as it
was in aortic rings, there was a similar trend towards an increase in lip-reductase
activity, raising the possibility that there is a small effect of LPS on hindlimb
vascular llpHSDl activity which may be masked by the contributions from other
tissue types within the regional perfused territory. Additionally, it is worth
considering that regional differences in the inflammatory regulation of vascular
llpHSDl activity may account for the differing effects of LPS in the hindquarter and
the aorta.
Systemic lipopolysaccharide, a well validated model of inflammation, was selected
for use in these studies as it is associated with activation of the innate immune
system (Parrillo 1993) and release of the pro-inflammatory cytokines TNFa and IL-
ip (Corbacho et al. 2004; Saito et al. 2003). Circulating levels of these cytokines
peak within 2-6 hours following LPS injection (Corbacho et al. 2004; Saito et al.
2003; Sallenave et al. 2003). When administered at a dose of lOmg/kg, animals
exhibited significant weight loss (in keeping with previous studies (Simon et al.
2004)) and splenomegaly, indicative of systemic illness and activation of the immune
system. Indeed, mortality studies suggest that this dose produces profound
endotoxaemia with mortality rates of 75% at 48 hours (Hirschfield et al. 2003).
There is no doubt, therefore, that this model of inflammation produces a severe
inflammatory phenotype with a rapid onset, and could be predicted to result in up-
regulation of vascular llpHSDl. Although no effect of LPS on hindlimb llpHSDl
activity was seen, it is possible that there is a positive effect of LPS on 1 lpHSDl
which is simply not apparent at 6 hours. However, the modest up-regulation of aortic
11PHSD1 activity ex vivo, following just such an insult (Chapter 3), suggests that the
hindlimb findings are reliable, rather than artefactual, and imply that inflammatory
regulation of 1 lpHSDl in healthy vessels is absent in vivo.
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Conclusions
In summary, these data confirm the presence, and describe the directionality, of both
11 (3HSD1 and 11J3HSD2 activity in the perfused mouse hindquarter in situ. Whilst
systemic inflammation in vivo produced a modest up-regulation of 11 (3-reductase
activity in intact vascular tissue (Chapter 3), a similar effect was not seen in the
perfused hindquarter suggesting that up-regulation of llpHSDl reductase is unlikely
to be a significant accompaniment of vascular inflammation in healthy arteries in
vivo. However, it remains possible that lipHSDl may be up-regulated in
pathological conditions associated with intense cell proliferation, such as vessel
injury or atheroma, or in the context of augmented glucocorticoid availability (e.g.,
stress, acute illness). It is exciting to speculate further, therefore, that up-regulation
of 11 P-reductase activity by inflammatory mediators may not be relevant under
physiological conditions but may become important during pathophysiological
disease processes. To address the hypothesis that 1 lpHSDl activity may be regulated
by inflammatory mediators under pathological conditions, further studies are
required to establish the role of lipHSDl in the context of vascular disease states.
The hindquarter model described in this chapter will now provide an extremely
useful tool for the investigation of lipHSDl activity under pathological conditions
such as femoral artery injury.
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Chapter Five
Effects of acute variations in
glucocorticoid availability on
endothelial cell function in vivo
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5.1 Introduction
Systemic glucocorticoid excess is associated with an increased incidence of adverse
cardiovascular events (Wei et al. 2004; Souverein et al. 2004). Indeed, even
variations in endogenous glucocorticoid levels within the normal physiological range
correlate with long-term cardiovascular risk factors such as hypertension and insulin
resistance (Walker et al. 1998; Fraser et al. 1999; Walker et al. 2000). The link
between elevated glucocorticoid concentrations and cardiovascular risk may be due,
at least in part, to direct changes in vascular reactivity. Glucocorticoids potentiate
vasoconstrictor responses to noradrenaline and angiotensin II (Ullian 1999; Walker
& Williams 1992), and impair endothelium-dependent vasodilatation (Walker et al.
1995b; Mangos et al. 2000; Iuchi et al. 2003). The mechanism of impaired
cholinergic dilatation following glucocorticoid therapy is likely to involve
abnormalities of the endothelial nitric oxide system (Hadoke et al. 2001; Mangos et
al. 2000). Glucocorticoid excess, either endogenous or exogenous, is also associated
with elevated plasma concentrations of plasminogen activator inhibitor type 1 (PAI-
1), and a hypercoagulable state (Sartori et al. 2000; Fatti et al. 2000; Patrassi et al.
1985; Ikkala et al. 1985; Patrassi et al. 1992; Sartori et al. 1999). Within the vessel
wall, it is likely that there is a balance between the adverse (inhibition of endothelial
nitric oxide generation, altered fibrinolytic and coagulation factors) and beneficial
(inhibition of inflammation, attenuation of thrombin-induced mitogenesis) effects of
glucocorticoids. Studies described in this thesis have addressed the possibility that
inflammation alters 11 (1HSD activity and hence local glucocorticoid action within
vascular tissue. However, it is not known whether acute variations in endogenous
glucocorticoid levels, such as those which might occur following alterations in
11 pHSD activity, are influential in the balance of these local glucocorticoid effects.
In order to determine whether acute alterations in glucocorticoid availability impair
endothelial cell function, it was desirable to use a technique which would allow
measurement of endothelial cell function within a physiologically relevant system.
Vasodilatation and fibrinolytic capacity are markers of endothelial function, and it is
possible to measure these variables in vivo in man. The measurement of bilateral
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forearm blood flow, by venous occlusion plethysmography, coupled with unilateral
brachial artery infusion of vasoactive drugs at sub-systemic, locally active doses,
provides a powerful and reproducible method of directly assessing vascular
responses in man in vivo (Benjamin et al. 1995; Webb 1995). Combined with
bilateral forearm venous sampling, this technique also permits the assessment of
local release of tissue and endothelium-derived factors (Plumpton et al. 1995),
including t-PA and PAI-1 (Newby et al. 1997; Newby et al. 1998; Jern et al. 1994b;
Jem et al. 1994a; Jern et al. 1997). The use of this method in healthy volunteers, in
conjunction with manipulation of circulating glucocorticoid levels, should allow
comparison of the endothelial effects of basal 'physiological' and moderately
'stressed' levels of glucocorticoids with glucocorticoid deficiency.
The study described in this chapter explores the hypothesis that acute variations in
circulating glucocorticoid levels (within the physiological range) impair endothelial
cell vasomotor and fibrinolytic function. The specific aims of the study were to
examine the effects of altered circulating glucocorticoid levels (1) on endothelium-
dependent vasodilatation and (2) on basal and stimulated release of t-PA and PAI-1.
5.2 Methods
5.2.1 Subjects
Twelve healthy non-smoking men aged between 18 and 60 years were enrolled in the
study which was undertaken with the approval of the Lothian Research Ethics
Committee and the written informed consent of each subject. Subjects were excluded
if they had biochemical evidence of elevated fasting glucose, or significant hepatic,
renal or thyroid dysfunction at an initial screening visit.
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5.2.2 Study design
This study compared basal 'physiological' and moderately 'stressed' levels of
glucocorticoids with glucocorticoid depletion. Subjects attended on three occasions
and treatment phases were separated by a washout period of at least a week. Subjects
were permitted a light breakfast prior to the commencement of each study, but were
requested to refrain from all medications for 7 days, alcohol for 24 hours and
caffeine for at least 4 hours prior to the start of the study. All subjects received 750
mg of the lip-hydroxylase inhibitor, metyrapone, at midnight and 8 am on each
occasion. Subjects attended the Wellcome Trust Clinical Research Facility for each
study visit at 8 am, and rested recumbent throughout the study. A 17-G cannula was
inserted into the antecubital vein of each arm as described previously (Plumpton et
al. 1995), to allow blood sampling, and a dorsal foot vein was cannulated with a 23-
G cannula for intravenous drug administration. At 8.30 am, subjects received either
(i) intravenous saline placebo bolus and continuous infusion (absence of endogenous
glucocorticoids), (ii) intravenous hydrocortisone 2.8 mg priming bolus and 1.8 mg/hr
infusion (calculated to produce plasma Cortisol -300 nM, equivalent to physiological
endogenous plasma glucocorticoid concentrations), or (iii) intravenous
hydrocortisone 9.4 mg priming bolus and 6.1 mg/hr infusion (calculated to produce
plasma Cortisol concentrations -1000 nM, ie supraphysiological glucocorticoid
concentrations) in a randomised, double blind, placebo-controlled cross-over design.
Two and a half hours after the commencement of the intravenous infusion of
hydrocortisone or placebo, the brachial artery of the non-dominant arm was
cannulated with a 27-G steel needle (Cooper's Needle Works Ltd, Birmingham, UK)
under 1% lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley, UK)
local anaesthesia. The cannula was attached to a 16-gauge epidural catheter (Portex
Ltd, Hythe, UK) and patency maintained by infusion of saline (0.9%: Baxter
Healthcare Ltd, Thetford, UK) via an IVAC PI000 syringe pump (IVAC Ltd,
Basingstoke, UK). The total rate of intra-arterial infusions was maintained constant
throughout all studies at 1 ml/min.
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Forearm studies were timed such that the basal forearm blood flow measurement was
taken precisely 3 hours following the commencement of the intravenous
hydrocortisone/placebo (i.e at approximately 11.30 am). Following a 30 minute
equilibration period (during which intra-arterial saline was administered) subjects
received intra-arterial infusions of bradykinin at 100, 300 and 1000 pmol/min (BK,
an endothelium-dependent vasodilator which releases t-PA (Labinjoh et al. 2000;
Labinjoh et al. 2001)), acetylcholine at 5, 10 and 20 pg/min (ACh, an endothelium-
dependent vasodilator which does not release t-PA (Stein et al. 1998; Brown et al.
1999)) and sodium nitroprusside at 2, 4 and 8 pg/min (SNP, an endothelium-
independent vasodilator which does not release t-PA (Jern et al. 1994b; Newby et al.
1997; Stein et al. 1998; Brown et al. 1999)) for 6-10 minutes at each dose. Forearm
blood flow was measured three minutes after the start of each drug dose, and every
6-10 minutes throughout the washout periods. The three intra-arterial drug infusions
were separated by 20 minute saline infusions and were administered in a random
order, although this was kept constant for each individual subject. The study protocol
is illustrated in Figure 5.1.
5.2.3 Drugs
Pharmaceutical grade bradykinin (BK; Merck Biosciences AG, Laufelfingen,
Switzerland), acetylcholine (ACh, Novartis UK Ltd) and sodium nitroprusside (SNP,
David Bull Laboratories, UK) were dissolved in physiological saline (0.9% sodium
chloride: Baxter Healthcare Ltd, Thetford, UK) on the day of the study. Oral
metyrapone (Metopirone®, Alliance Pharmaceuticals, UK) and intravenous
hydrocortisone (dissolved in physiological saline; Solu-Cortef®, Pfizer UK) were
administered according to the study protocol (Section 5.2.2, Figure 5.1).
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Figure 5.1 Study protocol
Subjects attended on three occasions and received intravenous placebo (0.9%
saline), low dose hydrocortisone (2.8 mg bolus followed by 1.8 mg/hr) or high dose
hydrocortisone (9.4 mg bolus followed by 6.1 mg/hr). The first intra-arterial drug
infusion was commenced three hours after the start of the intravenous treatment.
Venous sampling and venous occlusion plethysmography was performed as
indicated. All subjects received 750 mg oral metyrapone at midnight and 8 am
before each study. ACh = Acetylcholine, BK = bradykinin, SNP = sodium
nitroprusside, NaCI = sodium chloride.
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5.2.4 Haemodynamic measurements
Blood pressure and pulse were monitored in the non-infused arm at intervals
throughout each study using a semi-automated non-invasive oscillometric
sphygmomanometer (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan)(Wiinberg
et al. 1988).
The underlying principle of venous occlusion plethysmography is that if venous
return from the forearm is occluded without impedance of arterial inflow, the
forearm will swell in proportion to the rate of arterial inflow (Benjamin et al. 1995).
This method measures forearm blood flow through skeletal muscle (50-70% of total)
and skin. The hands must be excluded from the circulation as blood flow here is
predominantly through arteriovenous shunts within the skin and this has different
physiology from that of the forearm (Benjamin et al. 1995). Mercury-in-silastic
strain gauges applied to the widest part of the forearm were used to measure changes
in forearm circumference (Webb 1995). During measurement periods, the hands
were excluded from the circulation by rapid inflation of the wrist cuffs to a pressure
of 200 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson Inc, Washington,
USA). Upper arm cuffs were inflated intermittently to 40 mmHg pressure for 8 s in
every 11 s to achieve venous occlusion and obtain plethysmographic recordings.
Analogue voltage output from an EC-4 strain gauge plethysmograph (D.E.
Hokanson) was processed by a PowerLab® analogue-to-digital converter and Chart™
v4.1.2 for Windows software (AD Instruments Ltd, Castle Hill, Australia) and
recorded onto a portable computer (Figure 5.2). Calibration was achieved using the
internal standard of the plethysmograph.
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Figure 5.2 Representative plethysmography tracing
Representative trace (Chart™ v4.1.2 for Windows) from mercury-in-silastic strain
gauges (converted to mV by analogue-to-digital converter) during intra-arterial
bradykinin infusion. The slope from each cuff inflation period is used to calculate
forearm blood inflow over the time period.
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5.2.5 Venous sampling
Venous blood (8 ml) was withdrawn simultaneously from each arm at intervals
throughout the study and collected into tubes containing potassium ethylene diamine
tetraacetic acid (EDTA; Monovette®, Sarstedt, Niimbrecht, Germany), lithium
heparin (Monovette®, Sarstedt, Niimbrecht, Germany), acidified buffered citrate
(Biopool® Stabilyte™, UmeS, Sweden) and trisodium citrate (Monovette®, Sarstedt,
Niimbrecht, Germany) for estimation of haematocrit, Cortisol, t-PA, and PAI-1,
respectively. Lithium heparin tubes were spun within 10 minutes at 2380 rpm for 10
minutes at 4°C. Citrate and stabilyte tubes were kept on ice before being centrifuged
at 2,000 g for 30 minutes at 4°C. Platelet free plasma was decanted and stored at -
80°C (Kluft et al. 1988).
5.2.6 Sample analysis
Biochemical screening assays were undertaken on venous samples obtained at
screening visits by the hospital Clinical Laboratory facility (data not shown).
Haematocrit was also determined by the hospital Clinical Laboratory facility using
an automated Coulter counter (Beckman-Coulter ACt.8, High Wycombe, UK).
Plasma PAI-1 and t-PA antigen concentrations were determined using enzyme-linked
immunosorbent assays (Elitest® for PAI-1 (Declerck & Collen 1990) and
Zymutest® for t-PA (Booth et al. 1987), previously known as Coaliza®; Hyphen-
Biomed, France). Intra-assay coefficients of variation were 7.0% and 5.5% for t-PA
and PAI-1 antigen respectively. The sensitivities of the assays were 1 ng/ml and 11
ng/ml, respectively.
Plasma Cortisol concentrations were determined using an enzyme-linked
immunosorbent assay (DRG Instruments GmbH, Germany) with <2% cross-
reactivity for 11-deoxycortisol.
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5.2.7 Data analysis and statistics
Plethysmographic data were extracted from the Chart™ data files and forearm blood
flows were calculated for individual venous occlusion cuff inflations. Forearm blood
flow, expressed as millilitres per 100 ml forearm per minute, was calculated from the
rate of increase in forearm circumference, using the internal calibration of the
plethysmograph to convert the voltage changes resulting from changes in strain
gauge length (mV) into circumference changes (mm) (Whitney 1953; Roddie &
Wallace 1979). Recordings from the first 60 seconds after wrist cuff inflation were
not used because of the variability in blood flow that this incurs (Kerslake DMcK
1949; Webb 1995). Usually, the last five flow recordings in each three minute
measurement period were calculated and averaged for each arm.
To reduce the variability of blood flow data, the ratio of flows in the two arms was
also calculated for each time point: in effect using the non-infused arm as a
contemporaneous control for the infused arm (Benjamin et al. 1995; Webb 1995).
Percentage changes in the infused forearm blood flow were calculated (Benjamin et
al. 1995; Webb 1995) as follows:
% Change in blood flow = 100 x (It/NIt - h/Nh) / h/Nh
where lb and Nib are the infused and non-infused forearm blood flows at baseline
(time 0) respectively, and It and NIt are the infused and non-infused forearm blood
flows at a given time point (t), respectively.
For the forearm studies, estimated net release of t-PA antigen was defined as the
product of the infused forearm plasma flow (based on the haematocrit, Hct and the
infused forearm blood flow, FBF) and the concentration difference between the
infused ([t-PA]inf) and non-infused arms ([t-PA]Non-inf):
Estimated net forearm t-PA release = FBF x (1-Hct) x ([t-PA]/nf - [t-PA]Non.inf)
Values are expressed as mean ± standard error. Data were analysed using Student's t-
tests, analysis of variance (ANOVA) or ANOVA with repeated measures followed
by post-hoc tests, as appropriate. Statistical significance was taken at the 5% level.
5.3 Results
Oral, intravenous and intra-arterial drugs were well tolerated with no serious adverse
events.
5.3.1 Plasma Cortisol levels
An increase in plasma Cortisol was evident following both low dose and high dose
intravenous Cortisol compared with placebo (p<0.0001; Figure 5.3).
5.3.2 Haemodynamic variables
Baseline (prior to intravenous drug administration) mean arterial pressure (MAP) and
heart rate were similar on all three visits (Table 5.1). There was no change in pulse
over the course of the study, although a significant rise in mean arterial pressure
during the study days was noted in all three treatment groups (Figure 5.4; p<0.001).
Baseline forearm blood flows (at commencement of intra-arterial drug
administration) were similar in infused and non-infused arms (Table 5.1). Although
baseline blood flows did not differ significantly between placebo and hydrocortisone
treatments, there was a trend towards a difference between groups (p=0.08 for non-
infused arm).
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Figure 5.3 Changes in plasma Cortisol
Plasma Cortisol levels over the course of the study in subjects (n=12) treated with
intravenous saline (closed circles), low dose hydrocortisone (closed squares) and
high dose hydrocortisone (closed triangles). Time is recorded from commencement
of intravenous infusion. Significant differences in plasma Cortisol were observed
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Figure 5.4 Haemodynamic variables
Pulse (beats per minute, bpm; A) and mean arterial pressure (MAP, mmHg; B) in
subjects (n=12) treated with intravenous saline (closed circles), low dose
hydrocortisone (closed squares) and high dose hydrocortisone (closed triangles).
Time is recorded from commencement of intravenous infusion. There was no
change in pulse during the study (p=0.10, by repeated measures ANOVA). A
significant increase in MAP was observed in all three groups over the course of the
study (*p<0.001, by repeated measures ANOVA). Shaded area represents forearm
plethysmography study.
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Table 5.1 Baseline haemodynamic characteristics
Measurement Placebo Low dose High dose P value
Heart rate (/min) 67±3 63±3 68±4 0.30
Mean Arterial
Pressure (mmHg)








1.8±0.2 2.8±0.4 2.3±0.3 0.08
Haematocrit values at baseline (prior to intravenous drug administration) were
similar on all three visits (p=0.85, Table 5.2). There was a significant fall in
haematocrit over the course of the study (p<0.05) although the absolute fall in
haematocrit following intravenous hydrocortisone (reduction of 0.03±0.01 with
either dose) did not differ significantly from placebo (reduction of 0.04±0.01,
p=0.86).
Table 5.2 Haematocrit values
. . . _. . Low dose High dose n .Haematocrit Placebo .. . .. .. . 3 . P value
Hydrocortisone Hydrocortisone
Baseline 0.45±0.01 0.45±0.01 0.44±0.01 0.85
End of study 0.41±0.01 0.42±0.01 0.41 ±0.004 0.38
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5.3.3 Intra-arterial drug administration
Bradykinin (Figure 5.5), acetylcholine (Figure 5.6) and sodium nitroprusside (Figure
5.7) all caused dose-dependent increases in forearm blood flow. There were no
significant changes in non-infused forearm blood flows.
Compared with placebo, administration of intravenous hydrocortisone caused no
significant difference in the infused forearm blood flow during intra-arterial
acetylcholine (Figure 5.6) or sodium nitroprusside (Figure 5.7). The percentage
increase in forearm blood flow during intra-arterial bradykinin appeared blunted by
hydrocortisone, at both low and high dose, although this did not reach statistical
significance (p=0.08; Figure 5.5B).
5.3.4 Plasma fibrinolytic variables
Baseline plasma t-PA antigen concentrations were unchanged by systemic
hydrocortisone infusion (Figure 5.8, Table 5.3). Bradykinin caused dose-dependent
increases in infused arm t-PA concentrations which did not differ between treatment
groups when comparing either actual t-PA release (p=0.74 for area under curve;
Table 5.3) or estimated net t-PA release (p=0.88, Figure 5.8).
There was a trend towards an increase in infused arm baseline plasma PAI-1
concentrations with increasing intravenous hydrocortisone dose which did not reach
statistical significance (p=0.10). However, in the non-infused arm, there was no
difference between the groups (p=0.37; Table 5.3). There was no significant change
in plasma PAI-1 concentrations throughout the study in either the infused (p=0.45) or
non-infused (p=0.71) arm.
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Figure 5.5 Forearm blood flow responses to bradykinin
Absolute (A) and percentage change (B) in infused (closed symbols) and non-
infused (open symbols) forearm blood flows in response to increasing doses of
bradykinin in subjects (n=12) treated with intravenous saline (circles), low dose
hydrocortisone (squares) and high dose hydrocortisone (triangles). Intra-arterial
bradykinin caused dose-dependent increases in forearm blood flow. There were no
significant changes in non-infused forearm blood flows. The percentage increase in
forearm blood flow during intra-arterial bradykinin appeared blunted by
hydrocortisone, at both low and high dose, although this did not reach statistical
significance (p=0.08).
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Figure 5.6 Forearm blood flow responses to acetylcholine
Absolute (A) and percentage change (B) in infused (closed symbols) and non-
infused (open symbols) forearm blood flows in response to increasing doses of
acetylcholine in subjects (n=12) treated with intravenous saline (circles), low dose
hydrocortisone (squares) and high dose hydrocortisone (triangles). Intra-arterial
acetylcholine caused dose-dependent increases in forearm blood flow. There were
no significant changes in non-infused forearm blood flows. Compared with placebo,
administration of intravenous hydrocortisone caused no significant difference in the





Figure 5.7 Forearm blood flow responses to sodium nitroprusside
Absolute (A) and percentage change (B) in infused (closed symbols) and non-
infused (open symbols) forearm blood flows in response to increasing doses of
sodium nitroprusside in subjects (n=12) treated with intravenous saline (circles), low
dose hydrocortisone (squares) and high dose hydrocortisone (triangles). Intra¬
arterial sodium nitroprusside caused dose-dependent increases in forearm blood
flow. There were no significant changes in non-infused forearm blood flows.
Compared with placebo, administration of intravenous hydrocortisone caused no
significant difference in the infused forearm blood flow response to intra-arterial
sodium nitroprusside (p=0.19).
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Figure 5.8 Estimated net t-PA release during intra-brachial bradykinin infusion
Net release of t-PA antigen during intra-brachial bradykinin infusion in subjects
treated with intravenous saline (circles), low dose hydrocortisone (squares) and high
dose hydrocortisone (triangles). Intra-arterial bradykinin caused dose-dependent
increases in endothelial t-PA release which was not affected by intravenous
hydrocortisone infusion when competed with saline placebo (n=12, p=0.88).
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Table 5.3 Plasma t-PA and PAI-1 concentrations at baseline and during
bradykinin administration, following intravenous placebo or hydrocortisone
Bradykinin, pmol/min 0 100 300 1000
Placebo
Plasma t-PA antigen, ng/ml
Infused arm
Non-infused arm




Plasma t-PA antigen, ng/ml
Infused arm
Non-infused arm




Plasma t-PA antigen, ng/ml
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Non-infused arm









































The intention of these studies was to determine the effects of acute variations in
glucocorticoid availability on endothelial cell function. The results demonstrate that,
in contrast to prolonged administration of pharmacological doses of glucocorticoids
(Mangos et al. 2000), short-term variations in circulating glucocorticoid levels,
within the physiological range, do not alter endothelial cell vasomotor or fibrinolytic
function in vivo in man.
Effects ofCortisol on endothelium-dependent vasodilatation
Previous studies have shown that prolonged administration (5 days) of
hydrocortisone results in hypertension and impairment of endothelium-dependent
vasodilatation (Mangos et al. 2000). The effects of glucocorticoids on vascular
responsiveness have been attributed to impairment of nitric oxide bioavailability
(Mangos et al. 2000; Whitworth et al. 2002; Iuchi et al. 2003), although the exact
mechanisms remain elusive. The findings that Cortisol can induce hypertension
within 24 hours (Whitworth et al. 2002; Williamson et al. 1996; Tarn et al. 1997),
and that ACTH infusion produces an elevation in blood pressure within 2-8 hours
(Jackson et al. 2001) suggest that cortisol-mediated effects on vascular tone may
occur through rapid non-genomic mechanisms. Thus it might be predicted that short-
term variations in glucocorticoid availability would influence endothelial cell
vasomotor function. However, the present study has demonstrated that this appears
not to be the case, as no effect of variations in circulating Cortisol levels on
vasomotor function was evident. These results are consistent with a recently
published study which found that systemic administration of hydrocortisone (at doses
far in excess of those used in the present study: 200mg, infused over three hours) had
no effect on plasma nitrate/nitrite activity or forearm vascular responsiveness to
acetylcholine (Williamson et al. 2005). Additionally, a single dose of oral
prednisolone (50mg) has been shown to have no effect on endothelium-dependent
vasodilatation within 6 hours (Farquharson and Struthers 2002). Taken together with
evidence that direct intra-arterial short-term Cortisol infusion does not alter vascular
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resistance in the human forearm (Williamson et al. 2005; van Uum et al. 2002a) or
renal (van Uum et al. 2002b) vascular beds, these data collectively suggest that
Cortisol does not acutely alter basal vascular tone, nitric oxide generation or
vasodilator responses.
Hydrocortisone infusion had no effect on either acetylcholine- or sodium
nitroprusside-mediated vasodilatation. Absolute infused forearm blood flows during
intra-arterial bradykinin (expressed as area under curve) were also similar in all three
groups. However, upon "normalising" the forearm blood flow data, by calculating
the percentage change in the ratios of the infused and non-infused flows,
hydrocortisone infusion (at both low and high dose) appeared to impair bradykinin-
mediated vasodilatation, although this did not reach statistical significance (p=0.08,
Figure 5.5B). This result is difficult to interpret, however, as there were non¬
significant differences in basal forearm blood flow between the groups immediately
prior to bradykinin administration (infused arm flows of 2.4±0.3, 3.6±0.6 and
3.3±0.5ml/100ml/min following placebo, low dose hydrocortisone and high dose
hydrocortisone, respectively; p=0.06). When basal blood flows differ, the
concentration of drug reaching the tissues vary and direct comparisons of vasodilator
responses may not be valid (Benjamin et al. 1995; Pedrinelli et al. 1991).
Furthermore, although the mean difference in percentage change in forearm blood
flow during bradykinin infusion (1000 pmol/min) was 467% (for low dose
hydrocortisone compared with placebo), the confidence intervals are wide and
encompass zero (95% confidence intervals -148 to +1082%). For the study to have
had an 80% power of detecting this magnitude of difference, it would have been
necessary to increase the sample size to 42 subjects, which was not practicable. On
balance therefore, considering the lack of effect of hydrocortisone on both
acetylcholine- and bradykinin-mediated changes in absolute forearm blood flow, it is
likely that acute variations in circulating glucocorticoids do not alter endothelium-
dependent vasodilatation in the forearm.
As mentioned earlier, there was a trend towards an effect of hydrocortisone infusion
on basal vascular tone with higher baseline forearm blood flows in the low dose
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hydrocortisone group than either the placebo or high dose hydrocortisone group
(Table 5.1). Whilst the magnitude of the difference in basal flows between low dose
Cortisol and placebo is of potential physiological relevance (1.0 ml/100 ml/min; 95%
confidence intervals -2.4 to +3.4), the wide confidence intervals suggest significant
variability in this response.
There are a number of possible explanations for the lack of effect of short term
hydrocortisone infusion on endothelium-dependent vasodilatation. It may be that
there are no direct effects of glucocorticoids on endothelial cell function in man. This
conclusion is supported by previous studies which have shown that in vitro
incubation of human subcutaneous resistance arteries with Cortisol (30 uM for 3
hours) had no effect on endothelium-dependent vasoreactivity (Hadoke P et al.,
unpublished observations). However, if glucocorticoid effects on nitric oxide
bioavailability or other facets of vascular reactivity are mediated through de novo
gene transcription, these may take many hours to become evident and might not have
been detected by a study of this nature. For example, the excessive generation of
reactive oxygen species and reduced nitric oxide availability which occur in human
umbilical vein endothelial cells following incubation with dexamethasone are evident
only after 6 hours (Iuchi et al. 2003). In contrast, however, other studies have
demonstrated acute in vivo effects of glucocorticoids on the generation of reactive
oxygen species by mononuclear cells (Dandona et al. 1998) and on muscle
sympathetic nerve activity (Dodt et al. 2000) which are evident within 3 hours.
Another possible explanation for the lack of effect of variations in circulating
glucocorticoids (within the physiological range) on vasomotor function is that
11PHSD activity within the vasculature may be sufficient to compensate for
physiological variations in circulating concentrations of glucocorticoids achieved,
resulting in "damping" of the vascular response to the fluctuations in circulating
glucocorticoid levels achieved in this study. This tissue-specific regulation of
glucocorticoid action is the central premise on which this thesis is based. However,
this hypothesis is not supported by previous work which has shown that in vivo
administration of the non-selective lipHSD inhibitor carbenoxolone has no effect on
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endothelium-dependent vasoreactivity in man (Hadoke P et ah, unpublished
observations). Furthermore, the data presented in Chapters 3 & 4 indicate the
predominant regeneration of glucocorticoids by the 11 (3HSDs within murine vascular
tissue. If 11 P-reduction is also the predominant reaction direction within human
vasculature, then the 11 pHSDs would be expected to amplify, rather than dampen,
intracellular glucocorticoid action in the vasculature. This debate highlights the
challenges that are faced when undertaking translational research. Studies using
transgenic 11PHSD2-/- mice have allowed investigation of glucocorticoid effects in
vitro in a situation when absolute vascular glucocorticoid levels can be predicted as
there is no inactivation of glucocorticoids (Christy et al. 2003). However, the present
study was conducted in an attempt to extend these studies to examine these
glucocorticoid effects in humans in vivo. There are as yet no selective inhibitors of
the isozymes of 11PHSD available for use in man and, therefore, it is not possible to
examine the influences of glucocorticoids in man in vivo without the need to consider
tissue-specific variations in glucocorticoid availability as a result of 11 PHSD
activity. Nevertheless, if the negative findings here are explained by "damping" of
physiological variations in glucocorticoids by 11 PHSD activity, then this is an
important in vivo component of the question as to whether endogenous variations in
glucocorticoids influence endothelial cell function.
It is worth considering that metyrapone was administered to all subjects in each
treatment phase. Whilst it is possible that this drug had an effect on endothelial
function which confounded the effects of glucocorticoids, for example due to altered
levels of the precursor mineralocorticoid 11-deoxycortisol between groups (due to
differing feedback inhibition of ACTH by Cortisol in the three groups), this is
unlikely as previous studies have shown no effect of this drug on either basal forearm
blood flow in vivo or endothelial nitric oxide release in vitro (Broadley et al. 2005) .
Effects ofhydrocortisone on endothelial cell fibrinolytic function
Although glucocorticoid excess has been associated with elevated circulating PAI-1
concentrations and also with a hypercoagulable state (Sartori et al. 2000; Fatti et al.
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2000; Patrassi et al. 1985; Ikkala et al. 1985; Patrassi et al. 1992; Sartori et al. 1999),
there have been no previous studies which have investigated whether physiological
variations in glucocorticoid concentrations influence the local fibrinolytic capacity of
the endothelium.
The present study has demonstrated that short term systemic administration of
hydrocortisone has no effect on acute fibrinolytic capacity. Variations in circulating
glucocorticoid levels had no effect on plasma PAI-1 concentrations and no effect on
basal or bradykinin-stimulated release of t-PA from the endothelium. Taken together
with the lack of clear effect of acute hydrocortisone administration on endothelium-
dependent vasodilatation, these results support the conclusion that short term changes
in plasma glucocorticoid concentrations, within the physiological range, do not
impair endothelial cell function. The mechanisms regulating acute t-PA release and
plasma PAI-1 concentrations remain to be established but are likely to involve the
nitric oxide pathway (Newby et al. 1998). Augmentation of t-PA release is seen
following local and systemic inflammation (Chia et al. 2003b; Chia et al. 2003a),
and impairment of t-PA release, evident in smokers (Newby et al. 2001), is
predictive of increased cardiovascular risk (Meade et al. 1993). Whilst the present
study has shown that there is no effect of short term glucocorticoid administration on
bradykinin-stimulated endothelial cell t-PA release, acute t-PA release can also be
stimulated by other agonists such as substance P and methacholine through different
mechanisms, thus it remains possible that glucocorticoids influence alternative
pathways of t-PA release. However, the vaosomotor and fibrinolytic results are
concordant, with a lack of effect of hydrocortisone on both vasodilatation and acute
t-PA release, making it likely that this negative finding is robust.
In addition to the lack of effect of hydrocortisone on acute t-PA release, the present
study also demonstrated that there was no significant change in plasma PAI-1
concentrations following short term hydrocortisone administration. These results
parallel those from a recent study which showed no change in plasma PAI-1
concentrations in healthy volunteers treated with dexamethasone (6 mg) daily for 5
days (Brotman et al. 2005). However, elevations in plasma PAI-1 concentrations
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have been previously demonstrated in patients with endogenous glucocorticoid
excess (Fatti et al. 2000) and in those receiving long term glucocorticoid therapy
following heart (Sartori et al. 1999) and renal transplantation (Patrassi et al. 1985;
Patrassi et al. 1992). These elevations in PAI-1 improve upon surgical cure (Fatti et
al. 2000) or steroid withdrawal (Sartori et al. 2000). Furthermore, studies in vitro
(Gelehrter et al. 1987; Udden et al. 2002; Fukumoto et al. 1992; Reinders et al.
1992; Halleux et al. 1999; Morange et al. 1999; Uno et al. 1998), and in animal
models in vivo (van Giezen & Jansen 1992; van Giezen et al. 1994) have also
demonstrated an augmentation of PAI-1 release following glucocorticoid treatment.
The lack of effect of short term hydrocortisone on plasma PAI-1 concentrations in
this study suggests that, in contrast to studies of chronic steroid excess, or studies in
vitro, PAI-1 is not released in response to hydrocortisone over the time course and at
the physiological doses used in the present study.
Conclusions
In summary, these data suggest that short-term variations in plasma glucocorticoid
concentrations within the physiological range do not alter endothelial cell fibrinolytic
or vasomotor function. It may be that there are either no direct effects of
glucocorticoids on endothelial cell function in vivo, or that they require a longer
duration to become manifest. Alternatively, within the range of glucocorticoid
concentrations studied here, the vascular 11 PHSDs may provide a "damping"
mechanism which regulates exposure of the endothelium to glucocorticoids.
However, the negative results from this study should not be over-interpreted. A key
hypothesis of this thesis was that inflammation alters 11 piISD activity to favour
increased glucocorticoid availability. It remains a possibility that whilst up-
regulation of 11 p-reductase activity by inflammatory mediators may not be relevant
under physiological conditions, it may become important during pathophysiological
disease processes. The present study aimed to determine whether changes in
glucocorticoid availability (that might result from inflammation-mediated changes in
11 PHSDs) would impair endothelial cell function in man in vivo. However, the
technique of systemic manipulation of glucocorticoids to address this is limited in
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part by the fact that intracellular glucocorticoid levels may be modulated by the
activity of the 11 fSHSDs. Therefore, it remains a possibility that pathological insults
which alter vascular 11 (3HSD activity may have consequences for endothelial cell
function. The emergence of pharmaceutical preparations of selective inhibitors of the
isozymes of lipHSD will allow more detailed exploration of the influences of





It is known that glucocorticoids directly influence many aspects of vascular function,
and that these effects are mediated, at least in part, by the isozymes of lipHSD.
Inflammation, a key component of many vascular disease processes, up-regulates
11PHSD1 in cultured human smooth muscle cells, but whether this process occurs in
intact arteries had not been explored previously. The research presented in this thesis
aimed to determine whether inflammatory mediators influence local metabolism of
glucocorticoids in intact vascular tissue, and whether the resultant changes in
glucocorticoid availability impair endothelial cell function.
The activity, expression and localisation of the lipHSD isozymes in vascular tissue
have been extensively investigated. However, the relative contributions of
dehydrogenase and reductase activities, and the directionality of each isozyme within
intact vascular tissue had not been clearly elucidated. The first hypothesis contained
in this thesis was that both 11PHSD1 and 11PHSD2 activities are present in the intact
vessel, where they act, as exclusive reductase and dehydrogenase, respectively, to
regulate local availability of glucocorticoids. To address this question, novel in vitro
and in vivo assays were developed to measure 11 P-reductase and dehydrogenase
activities independently. In Chapter 3, an in vitro intact artery assay was used to
demonstrate that both 11 p-reductase and dehydrogenase activities are present in both
aorta and iliofemoral arteries from wild type mice, and that the reductase direction
predominates by approximately 10-fold. Moreover, regional differences in 11P-
reductase activity were noted, with higher activity in the aorta than the iliofemoral
vessels. Use of mice with genetic inactivation of either lipHSDl or 11PHSD2 made
it possible to determine the reaction direction for each isozyme. 11PHSD2 was
shown to act as an exclusive dehydrogenase whilst llpHSDl appeared to have bi¬
directional activity in vitro. As there has been much debate as to whether 1 lpHSDl
acts as both reductase and dehydrogenase in vivo, it was necessary clarify this
contentious issue by extending the studies of isozyme directionality into an in vivo
model. Studies presented in Chapter 4 used a hindquarter perfusion model to assess
11PHSD activity in vivo in a regional perfused bed. As with the in vitro studies, lip-
reduction was the predominant reaction direction. However, in contrast to the in vitro
studies, no 11 P-dehydrogenase activity was evident in the perfused hindquarter of
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11PHSD2-/- mice. Thus it is likely that 1 lpHSDl acts as a predominant reductase in
intact vascular tissue. The dehydrogenase activity attributed to 11|3HSD1 in vitro is
likely to be due to liberation of this isozyme from cells damaged during preparation
and sectioning of the artery.
Inflammatory cytokines up-regulate lipHSDl activity and expression in cultured
human aortic smooth muscle cells, but their influence on 11 pHSDs in intact vessels
had not been previously evaluated. Studies described in Chapter 3 addressed the
question of whether inflammatory mediators up-regulate lipHSDl activity in intact
arteries in vitro. Although it was possible to demonstrate that cytokines up-regulate
11PHSD1 in cultured murine aortic smooth muscle cells, there was no such effect of
individual cytokines on lipHSDl or llpHSD2 activity in intact aortic rings in vitro.
However, a modest increase in 11 P-reductase activity in aortic rings from mice who
had received in vivo LPS suggested that there may be factors present in vivo, but not
in vitro, which are required for the inflammatory regulation of 1 lpHSDl to become
manifest. To explore this further, under more physiological conditions, studies in
Chapter 4 were performed using the hindquarter perfusion model. Consistent with
the data from Chapter 3, there was no effect of LPS on lipHSDl activity in the
perfused hindquarter suggesting that up-regulation of 11p-reductase activity is
unlikely to be a significant accompaniment of vascular inflammation in healthy
arteries in vivo. However, it remains possible that 1 lpHSDl may be up-regulated in
pathological conditions associated with intense cell proliferation, such as vessel
injury or atheroma, or in the context of augmented glucocorticoid availability (e.g.,
stress, acute illness). Thus, although up-regulation of 11 P-reductase activity by
inflammatory mediators may not be relevant under physiological conditions it may
become important during pathophysiological disease processes.
Regulation of glucocorticoid activity within the arterial wall has the potential to
influence many aspects of vascular structure and function. Elevations in circulating
glucocorticoid concentrations, and even variations in the normal range in healthy
individuals, are associated with increased cardiovascular risk. This association may
be linked to the ability of glucocorticoids to directly impair endothelial cell function.
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However, the effects of acute changes in glucocorticoid availability on endothelium-
dependent vasodilatation and fibrinolytic function in man have not been explored
previously. The final hypothesis in this thesis was that acute variations in
glucocorticoid availability would mediate impaired endothelial function, an early
marker of vascular disease. The study described in Chapter 5 used the forearm
venous occlusion plethysmography technique to investigate whether short-term
changes in circulating glucocorticoid levels altered endothelium-dependent
vasodilatation or the fibrinolytic capacity of the endothelium. The results from this
study suggest that, in contrast to previously demonstrated effects of prolonged
glucocorticoid administration, acute changes in systemic glucocorticoid levels do not
alter endothelial cell function. This suggests that the effects of glucocorticoids on
endothelial cell function either take longer than 3 hours to become manifest, or are
indirect. A speculative explanation for this negative finding may lie in the exquisite
11(3HSD system, central to this thesis, whereby, despite fluctuations in circulating
glucocorticoid concentrations, vascular intracellular glucocorticoids levels are tightly
regulated.
To summarise, the studies presented in this thesis demonstrate that both lipHSDl
and 11PHSD2 activities are present in intact arteries where they act, as reductase and
dehydrogenase respectively, to modulate local glucocorticoid concentrations.
Although inflammatory up-regulation of lipHSDl is not evident in healthy intact
vascular tissue, it should not be inferred that the enzyme does not play a role in
modulating glucocorticoid signalling since the current studies demonstrate the
predominant regeneration of glucocorticoids within the vessel wall. Moreover, in
pathological conditions associated with intense cell proliferation, such as vessel
injury or atheroma, it remains possible that lipHSDl is up-regulated. Acute
systemic variations in glucocorticoid availability do not impair endothelial cell
function, although it remains to be seen whether intracellular changes in
glucocorticoids cause endothelial cell dysfunction.
These studies have provided a basis, for future studies to establish the influence of
glucocorticoid regeneration on the proliferative and inflammatory responses within
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the blood vessel. Unexpected differences between the effects of cytokines on
11 piISDl activity in cultured cells and in intact vessels highlighted by the present
studies deserve further exploration, and, to exclude the possibility that there are
species differences in the inflammatory regulation of 11(3HSD1, future work should
include attempts to recapitulate published data showing cytokine-mediated
upregulation of 11 (3HSD1 in human smooth muscle cells. Also, it will be important
to examine the significance of alterations in smooth muscle cell proliferation or
differentiation, and endogenous glucocorticoid tone, on the responsiveness of
11PHSD1 to inflammatory mediators. Studies using models of accelerated
atherosclerosis and femoral artery injury are already underway in our laboratories to
ascertain the effects of inflammatory mediators on vascular lipHSD activity under
pathological conditions. Also, the possibility that inflammation alters glucocorticoid
metabolism and paracrine signalling from perivascular adipose tissue will be
examined. Finally, with the development of selective inhibitors of human 1 lpHSDs,
there is the opportunity to examine the effects of local manipulation of
glucocorticoid metabolism on endothelial cell function.
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Angiogenesis restores blood flow to healing tissues, a process that
is inhibited by high doses of glucocorticoids. However, the role of
endogenous glucocorticoids and the potential for antiglucocorti-
coid therapy to enhance angiogenesis is unknown. Using in vitro
and in vivo models of angiogenesis in mice, we examined effects
of (/) endogenous glucocorticoids, (/#) blocking endogenous glu¬
cocorticoid action with the glucocorticoid receptor antagonist
RU38486, and (Hi) abolishing local regeneration of glucocorticoids
by the enzyme 11 /J-hydroxysteroid dehydrogenase type 1
(110HSD1). Glucocorticoids, administered at physiological concen¬
trations, inhibited angiogenesis in an in vitro aortic ring model and
in vivo in polyurethane sponges implanted s.c. RU38486-enhanced
angiogenesis in s.c. sponges, in healing surgical wounds, and in the
myocardium of mice 7 days after myocardial infarction induced by
coronary artery ligation. 110HSD1 knockout mice showed en¬
hanced angiogenesis in vitro and in vivo within sponges, wounds,
and infarcted myocardium. Endogenous glucocorticoids, including
those generated locally by 110HSD1, exert tonic inhibition of
angiogenesis. Inhibition of 11 0HSD1 in liver and adipose has been
advocated to reduce cardiovascular risk in the metabolic syndrome:
these data suggest that 110HSD1 inhibition offers a previously
uncharacterized therapeutic approach to improve healing of isch¬
emic or injured tissue.
myocardial infarction | wound healing
Angiogenesis, the formation of new vessels from existingones, is a key factor in many common diseases (1-4), and
manipulation of angiogenesis is an important therapeutic target
(5,6). Supraphysiological concentrations ofglucocorticoids have
been used in vitro and in vivo to inhibit angiogenesis (7-11). It is
unknown, however, whether physiological concentrations of
endogenous glucocorticoids (principally Cortisol in humans and
corticosterone in mice) regulate angiogenesis.
The influence of glucocorticoids on their target tissues is
regulated in a tissue-specific manner by the isozymes of 110-
hydroxysteroid dehydrogenase (110HSD) (12). 110HSD type 1
functions predominantly as an 11-oxidoreductase converting
inactive 11-keto metabolites (cortisone in humans; 11-
dehydrocorticosterone in mice) into active 11-hydroxy glucocor¬
ticoids (Cortisol and corticosterone) (13). 110HSD-1 is highly
expressed in liver, adipose tissue, and regions of the central
nervous system, where it amplifies intracellular glucocorticoid
concentrations and thereby maintains glucocorticoid receptor
activation (13). 110HSD type 2 is an exclusive 110-dehydroge-
nase, inactivating Cortisol or corticosterone in distal nephron,
colon, and sweat glands, thus preventing inappropriate access of
glucocorticoids to mineralocorticoid receptors (12). Both
110HSD isozymes are expressed in the blood vessel wall (14—18).
In mouse and rat aorta, 110HSD-2 is localized in endothelial
cells and 110HSD-1 in vascular smooth muscle (15, 16).
Glucocorticoids have diverse effects on vascular function,
altering vasoconstrictor responses (19), impairing endothelium-
www.pnas.org /cgi /doi /10.1073/pnas.0500641102
dependent vasodilatation (19), and inhibiting inflammation and
cell proliferation (20, 21). We recently reported studies of
vascular function in knockout mice deficient in either 110HSD
isozyme (22). In aortae from 110HSD-2 -/- mice, endotheli-
um-dependent vasodilatation was impaired, suggesting that
110HSD-2 protects endothelial cell receptors from glucocorti¬
coids. However, there was no abnormality of vascular tone in
110HSD-1 -/- mice, so the role of the type 1 isozyme in the
vessel wall remained unclear. At that time, Cai et al. (23)
demonstrated that 110HSD1 expression in vascular smooth
muscle is up-regulated in response to proinflammatory cyto¬
kines, raising the possibility that increased local generation of
glucocorticoids contributes to feedback regulation of vascular
inflammation.
Given that inflammatory cytokines can promote angiogenesis
(24) and pharmacological doses of glucocorticoids have antian-
giogenic activity, we hypothesized that 110HSD-1 modulates
angiogenesis by determining the local regeneration of active
glucocorticoid in the vessel wall. If so, then manipulation of
110HSD-1 may provide a novel therapeutic tool to alter angio¬
genesis. Here, we have tested this hypothesis by using in vitro,
in vivo, and pathological models of angiogenesis in mice.
Methods
Mice. Male, C57B16J wild-type and 110HSD-1 homozygous
null (—/—) mice aged 8-10 weeks were used (Charles River
Laboratories). Genetic inactivation of 110HSD-1 has been
described in MF-1/129 mice (25); for the current experiments,
mice were backcrossed over >10 generations onto a C57B16J
background (26).
Aortic Ring Preparations. Mice were killed, and thoracic aortae
were removed, washed in serum-free MCDB 131 medium
(Invitrogen), cleaned of periadventitial tissue, and divided into
1- to 3-mm rings.
110HSD activities were measured by incubating wild-type
aortic rings for 24 h at 37°C in 1 ml of DMEM-F12 medium
(Invitrogen) containing 3H-steroid supplemented with FBS
(1%), streptomycin (100 /ag/ml), penicillin (100 units/ml), and
amphotericin (0.25 /xg/ml) (27). 110-Reductase activity was
determined by adding 10 pmol pFLj-ll-dehydrocorticosterone
[synthesized in-house from l,2,6,7-[3H4]-corticosterone (Amer-
sham Pharmacia Biosciences) by using rat placental homoge-
nate]. Mouse liver (28 ± 5 mg) and medium alone were used as
positive and negative controls, respectively. 110-Dehydrogenase
activity was determined by adding 10 pmol 1,2,6,7-[3H4]-
corticosterone. Mouse kidney (13 ± 3 mg) and medium alone
served as positive and negative controls. After incubation,
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Time In culture in (days)
Fig. 1. Angiogenesis in aortic rings in vitro. (A) Light micros-
ropy of new vessels shown sprouting from aortic rings. (/)
Aortic ring incubated for 7 days without glucocorticoid. (//)
Aortic ring incubated for / days in the presence of glucocor¬
ticoid. Thick white arrows indicate the aortic ring; thin white
arrows indicate new vessels. (Scale bar: 0.2 mm.) {Hi) Uptake of
low-density lipoprotein (LDL) is shown by fluorescence micros¬
copy. This ring was incubated for 7 days without steroids.
Thick white arrows indicate the aortic ring; thin white arrows
indicate uptake of fluorescent labeled LDL in endothelial cells
in new vessels; black arrows indicate uptake in endothelial
cells of the aortic ring. (Scale bar: 0.2 mm.) (/V) High power
view of new vessels; thick white arrows indicate the aortic ring
and thin white arrows indicate uptake of fluorescent labeled
low density lipoprotein in endothelial cells (Scale bar: 0.02
mm.) (Bi) Time course and effect of corticosterone on angio¬
genesis. O, results from vessels incubated without steroids; ♦,
results from vessels incubated with corticosterone (600 nM).
Results are mean ± SEM for n = 4 per group. Comparison was
by repeated measures ANOVA; *, P < 0.02. (8/7) Effects of
corticosterone and 11-dehydrocorticosterone. Vessels were
counted after 7-day incubation with steroids. Results are
mean ± SEM. #, P < 0.01 versus vehicle by 2-way ANOVA and
least squares difference post hoc test. (C) Influence of receptor
antagonism. (/) Effects of the mineralocorticoid receptor an¬
tagonist spironolactone. Aortic rings from C57BI6J mice were
incubated with (filled bars) and without (open bars) spirono¬
lactone (10-6 M) and glucocorticoids (600 nM). Results are
mean ± SEM for n = 6 experiments. #, P < 0.02 versus corre¬
sponding vehicle. Spironolactone alone had no effect. (/'/)
Effects of the glucocorticoid receptor antagonist RU38486.
Aortic rings from C57BI6 mice were incubated with (filled
bars) andwithout (open bars) RU38486 (10~6M) and glucocor¬
ticoids (600 nM). Results are mean ± SEM for n = 4-6 exper¬
iments. # P < 0.01 versus corresponding vehicle. ***,P< 0.001
for the effect of RU38486 in the presence of glucocorticoid.
RU38486 alone had no effect. (D) Effects of 11 /3HSD inhibition
(/) Pharmacological inhibitor carbenoxolone. Aortic rings
from C57BI6J mice were incubated with (filled bars) and with¬
out (open bars) carbenoxolone (10 6 M) and glucocorticoids
(600 nM). Results are mean ± SEM for n = 5 experiments. #, P<
0.01 versus corresponding vehicle. *, P < 0.04 for the effect of
carbenoxolone in the presence of 11-dehydrocorticosterone.
Carbenoxolone had no effect in the presence of corticoste¬
rone or vehicle alone. (//) Transgenic deletion of 11/3HSD1.
Effects of corticosterone and 11-dehydrocorticosterone on
angiogenesis in vessels from 11 /3HSD1 -/- mice. Aortic rings
from C57BI6J wild-type (open bars) or 11/3HSD1 —/— (filled
bars) mice were incubated with and without glucocorticoids
(600 nM). Results aremean ± SEM for n = 7 experiments. #, P<
0.01 versus corresponding vehicle. **, P < 0.01 for differences in angiogenesis between wild-type and 11/3HSD1 -/- mice. Angiogenesis was not different
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steroids were extracted from media by using Sep-Pak Cis col¬
umns (Waters Millipore). Aortic rings, which contain only 2-3%
of the added radioactivity, were not included in the extraction
(27). pHUj-Corticosterone and pPLtJ-l 1-dehydrocorticosterone
were separated by HPLC and quantified by on-line liquid
scintillation counting (16). Enzyme activity was expressed as
conversion after subtraction of apparent conversion in negative
control wells. Both 11/3-reductase (0.65 ± 0.24 pmol/mg) and
11/3-dehydrogenase (0.66 ± 0.28 pmol/mg) activities were de¬
tected in aortic rings with similar conversion rates as in positive
controls: liver for 11/3HSD-1 (0.18 ± 0.03 pmol/mg) and kidney
for 110HSD-2 (2.13 ± 1.65 pmol/mg).
To quantify angiogenesis, aortic rings were embedded in 200
p.1 of steroid-free Matrigel (Becton Dickinson) (Fig. 1) and
incubated at 37°C in serum-free MCDB 131, with heparin,
ascorbic acid, and GA1000 (Cambrex Biosciences) in the pres¬
ence and absence of corticosterone (3, 30, 300, and 600 nM),
11-dehydrocorticosterone (300 and 600 nM), the glucocorticoid
receptor antagonist RU38486 (10-6 M), the mineralocorticoid
receptor antagonist spironolactone (10 6 M), and/or the non¬
selective llj3HSD inhibitor carbenoxolone (10 6 M). All drugs
(Sigma-Aldrich) were dissolved in ethanol and diluted in aque¬
ous solution; final ethanol concentration 1-3% vol/vol. Media
were changed every 48 h. Experiments were performed in
triplicate. In initial experiments, new vessels were counted daily
by using light microscopy (ref. 8 and Fig. 1). From these studies,
day 7 was selected as the appropriate time point to examine the
effects of glucocorticoids (Fig. IB).
To confirm the nature of apparent new vessels, endothelial
cells were identified by uptake of fluorescent-labeled acety-
lated low-density lipoprotein (Biogenesis, Poole, U.K.)
(Fig. 1,4).
s.c. Sponge Implant Assay. Micewere anesthetizedwith halothane,
and a sterilized sponge cylinder (0.5 cm X 1 cm) (Caligen Foam,
Accrington, Lancashire, U.K.) was implanted s.c. on each flank.
Sponges contained a silastic insert (Silastic 20 medical grade,
Dow Corning) impregnated with vehicle, 2 mg of Cortisol or
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cortisone, or 5.25 mg of RU38486. Each animal had an inter¬
vention-impregnated sponge (steroid or RU38486) on one side
and a placebo-impregnated sponge (silastic only) on the other.
Such inserts release their impregnated compounds in vivo at a
constant rate for 3 weeks (28). Human steroids (Cortisol and
cortisone, equivalent to corticosterone and 11-dehydrocortico-
sterone) were used to allow distinction from endogenous ste¬
roids. In separate experiments (data not shown), angiogenesis in
placebo-impregnated sponges was not altered by the presence or
absence of a contralateral steroid-treated sponge.
A further cohort of wild-type mice underwent adrenalectomy
or sham surgery as described (29) at the time of implantation of
untreated sponges. These mice were then maintained on 0.9%
saline in place of drinking water.
Twenty days after implantation (10), mice were killed, sponges
were excised, and inserts were removed. Sponges were bisected;
one half was fixed in 10% formalin and embedded in paraffin
wax. Sections (8 pm) were stained with hematoxylin/eosin for
identification of blood vessels, as described in ref. 30. The second
half of the sponge was weighed, homogenized in 2 ml of sterile
PBS at 4°C, and centrifuged (2,000 x g for 30 min). Steroids were
extracted from the supernatant by using ethyl acetate and
Cortisol quantified by using a specific RIA (Amersham Phar¬
macia Biotech). Sponge vessel density was determined by using
the mean of triplicate Chalkley counts on two sections per
sponge (31, 32).
Chronic Coronary Artery Ligation. Wild-type and 11/3HSD-1 — /—
mice were anesthetized with an i.p. injection of xylazine (0.018
mg/kg), ketamine (100 mg/kg), and atropine (600 mcg/kg) (33).
Surgery was performed as described in ref. 34. Briefly, after
endotracheal intubation and mechanical ventilation (MiniVent,
Harvard Apparatus, Holliston, MA), superficial tissues were
dissected, an incision was made in the fourth intercostal space,
the pericardium was divided, and the left main descending artery
was ligated with 6.0 prolene suture (Ethicon). In sham operated
animals, the suture was not ligated. The thoracic wall was closed
by layered suturing; the skin was stitched with a continuous
suture by using 5-0 Mersilk with a 10-mm 3/8c round-bodied
needle (Ethicon). At the time of surgery completion, animals
received i.p. atipamazole (5 mg/kg) and s.c. buprenorphine (0.05
mg/kg).
A further cohort of wild-type mice received a s.c. 10 mg
implant (28) containing either vehicle or 5.25 mg of RU38486 1
week before coronary artery surgery.
In preliminary experiments, mice were killed on days 1, 3, 5,
7, and 14 after surgery by cervical dislocation. The angiogenic
response was well established 7 days after infarction (see Fig.
3B), so this interval was selected for comparisons between the
groups above. Excised hearts and surgical thoracotomy wounds
were fixed in 10% formalin, paraffin embedded, and sectioned
at 8 p,m. Sections were stained with an anti-von Willebrand
factor antibody (DakoCytomation, Cambridgeshire, U.K.) to
label endothelial cells and quantify angiogenesis. Hematoxylin
and eosin was used to stain sections from hearts collected at day
7 after coronary ligation to measure the area of the left ventricle
affected by infarction.
Quantification of vessels within the myocardium was achieved
by counting large- and medium-sized vessels as described in ref.
35. Vesselswere identified at X400 magnification (Zeiss) in vWF
(36-38) stained sections. Counting (39) was performed in the
four most vascular fields (two endocardial and two epicardial) by
using a 0.0625-mm2 reticule; the borders of the reticule were
within the infarct. The area of left ventricle affected by infarction
was determined as a percentage of left ventricular wall area (34)
and measured at direct light microscopy; images were captured
by using a Research Systems (Imaging Research, St. Catherine's,
Small et al.
ON, Canada) photometric camera and analyzed by using in-
house scripts.
Wound vessel density was determined in the dermis of vWF-
stained sections at X250 light microscopy by using the mean of
triplicate Chalkley counts on two sections per wound (31).
Statistics. Data are mean ± SEM. Comparisons were made by
ANOVA with least squares difference post hoc tests. Vessel
quantification was performed by investigators "blinded" to the
origin of the sections. Interassay and intraassay coefficients of
variation inwild-type mice were 17% (n = 32) and 22% (n = 18),
respectively, for vessel number in aortic rings after 7 days in
culture; 12% (n = 6) and 12% (n = 6) for vessel density in sponge
implants; 19% (n — 11) and 10% (n = 11) in day-7 infarcts; and
7% (n = 4) and 12% (n = 4) for day-7 wounds.
Results
Effects of Glucocorticoids and 11/3HSD-1 on Angiogenesis in Vitro in
Aortic Rings. Both corticosterone and 11-dehydrocorticosterone
inhibited angiogenesis in wild-type mouse vessels across a range
of physiological concentrations (Fig. IB). The angiostatic effect
is mediated by glucocorticoid receptors because it was prevented
by the antagonist RU38486 (which has no effect in the absence
of steroid) but not by the mineralocorticoid receptor antagonist
spironolactone (Fig. 1C).
Measurement of relevant product generation confirmed both
11/3-reductase (0.65 ± 0.24 pmol/mg) and 11 /3-dehydrogenase
(0.66 ± 0.28 pmol/mg) activities in aortic rings with similar
conversion rates as in positive controls, liver for 11J3HSD-1
(0.18 ± 0.03 pmol/mg), and kidney for 11/3HSD-2 (2.13 ± 1.65
pmol/mg). Pharmacological inhibition of ll/3HSDs in aortic
rings was achieved with the nonselective inhibitor carbenoxolone
(10 6M), which had no direct effect and prevented the antian-
giogenic effect of 11-dehydrocorticosterone but not corticoste¬
rone (Fig. IDi).
To confirm the role of 11 /3HSD-1 , aortic rings were obtained
from homozygous 11/3HSD-1 null (—/—) mice congenic on a
C57B16J genetic background (26) and C57B16J controls. Angio¬
genesis in aortic rings from 11/3HSD-1 —/- mice was similar to
that in wild-type controls in the absence of steroid and inhibited
to a similar degree by corticosterone. However, 11-dehydrocor-
ticosterone did not inhibit angiogenesis in vessels from
1 1/3HSD-1 -/- mice (Fig. 1Dii).
Effect of Endogenous Glucocorticoids and 11/3HSD-1 on Angiogenesis
in s.c. Sponge Implants in Vivo. Placebo-impregnated sponges
excised after 20 days (10) were red on gross inspection with a
lace-like covering of blood vessels. At histology, there was an
inflammatory infiltrate and an abundance of blood vessels (Fig.
2Ai). Sponges from adrenalectomized animals and sponges
impregnated with the glucocorticoid receptor antagonist
RU38486 both exhibited enhanced angiogenesis (Fig. 2Bi) in
wild-type mice.
To test the effects of 11-hydroxy and 11-keto-glucocorticoids
we used the "human" steroids Cortisol and cortisone, which
allowed measurement of steroid concentrations within the
sponge independently of endogenous murine corticosterone and
11-dehydrocorticosterone (Table 1). In wild-type C57B16J mice,
both Cortisol and cortisone inhibited angiogenesis in vivo (Fig. 2
Aii and Bii). In 110HSD-1 null mice, angiogenesis was increased
in placebo-impregnated sponges. Impregnation with Cortisol
produced similar Cortisol concentrations in wild-type and
11/3HSD-1 null mice (Table 1) and inhibited angiogenesis to a
similar degree (Fig. 2Bii). However, impregnation with corti¬
sone, in contrast with its effects in wild-type controls, did not
elevate sponge Cortisol concentrations in 11 /3HSD-1 null mice
(Table 1) and did not inhibit angiogenesis (Fig. 2Bii).
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Fig. 2. Angiogenesis in s.c. implanted sponges. (A) Light
microscopy of hematoxylin/eosin stained sponge 8-/xm sec¬
tions from wild-type mice: vehicle (/) and cortisol-treated (/'/)
sponge (Scale bar: 400 fim) and vehicle-treated sponge at high
power (iii) (Scale bar: 50 /xm.) Sponges were covered with a
fibroblast-rich fibrous coat and were infiltrated with inflam¬
matory neutrophils and lymphocytes. Placebo-treated
sponges alone were also infiltrated with an organized matrix
and an abundance of blood vessels (black arrows). S denotes
sponge matrix. (Bi) Sponges from C57BI6J wild-type (n = 6)
mice. Exposure to RU38486 or adrenalectomy (filled bars)
compared with placebo or sham surgery (open bars). Results
are mean ± SEM. #, P < 0.01 versus vehicle; *, P < 0.02 versus
sham. New vessel formation was greater in RU38486-
impregnated sponges or sponges from adrenalectomized
mice versus their relevant controls. (6/7) Sponges from C57BI6J
wild-type (open bars, n = 12) or 11/3HSD1 —/— (filled bars,n =
6) micewith and without glucocorticoids. Results are mean ±
SEM. #, P < 0.001 versus corresponding vehicle. ***, P < 0.001
for differences betweenwild type and 11/3HSD1 -/-.Placebo-
impregnated sponges exhibited an increased angiogenic re¬
sponse in 11 j3HSD1 -/- compared towild-type mice. Cortisol
inhibited angiogenesis in both strains, but cortisone inhibited
angiogenesis only in wild-type mice.
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Effect of Endogenous Glucocorticoids and 11/3HSD-1 on Myocardial
Revascularization After Coronary Artery Ligation. At day 7, the
proportional area of the left ventricular myocardium affected by
coronary artery ligation was similar in all treatment groups
(41.8 ± 6.2% in vehicle versus 45.5 ± 4.8% in RU38486 and
44.2 ± 3.4% in wild types versus 44.2 ± 2.6% in 11/3HSD-1~''~).
RU38486 increased angiogenesis in the left ventricle after
infarction in wild-type mice (Fig. 3Bii).
There was no difference in myocardial vascularity between
sham-operated wild-type and 110HSD-1 null mice. In contrast,
7 days after coronary artery ligation, 11/3HSD-1 null mice
exhibited enhanced revascularization in the infarcted myocar¬
dium (Fig. 3Bii),
Effect of Endogenous Glucocorticoids and 11/3HSD-1 on Angiogenesis
in Cutaneous Surgical Wounds. New vessel formation was examined
in cutaneous surgical wounds in mice that underwent thoracot¬
omy for the coronary artery ligation studies (Fig. 3c). The dermal
angiogenic response was greater in RU38486-treated mice
(4.8 ± 0.29 Chalkley count versus vehicle 3.5 ± 0.21; P < 0.01)
and in 11/3HSD-1 null mice (5.1 ± 0.27 Chalkley count; P < 0.01)
in comparison to wild-type controls (3.5 ± 0.25 Chalkley count).
Discussion
Folkman et al. described the angiostatic effects of pharmaco¬
logical glucocorticoids in vitro >20 years ago (11), and these
effects have been confirmed in vivo (3, 10). Flere, we show that
the angiostatic effect occurs at physiological concentrations of
Table 1. Cortisol concentration in sponge homogenates from
wild-type and 11/3HSD1 —/— homozygous null mice
Cortisol level (ng/g sponge)
Ipsilateral Contralateral
Steroid steroid-treated placebo-treated
Strain impregnated sponge sponge
Wild type Cortisol 4,271 ± 186" 161 ± 18
Cortisone 295 +■ 25#** 98 ± 19
11 pHSD-1 -/- Cortisol 3,775 ± 1,703# 135 ± 46
Cortisone 87 ± 11 90 ± 30
Results are mean ± SEM for n = 3-6 experiments. #, P < 0.01 versus contralat¬
eral placebo. **, P < 0.01 for comparison of wild type and 110HSD1 -/-.
glucocorticoids and is mediated by glucocorticoid receptors, and
that endogenous glucocorticoids tonically repress angiogenic
responses. Moreover, we show that 11/3HSD1, by regenerating
active glucocorticoids locally, amplifies the angiostatic effect of
glucocorticoids and, thereby, constrains the angiogenic response
after ischemia and injury.
These observations raise the intriguing possibility that local
variations in Cortisol levels or in tissue sensitivity to Cortisol are
key determinants of angiogenesis in disease. It is well recognized
that, in Cushing's syndrome, glucocorticoid excess is associated
with impaired wound healing (40). More recently, we showed
that exogenous glucocorticoid therapy is associated not onlywith
increased incidence of myocardial infarction but also with an
unexpected increase in prevalence of heart failure (41, 42),
suggesting an impact on the outcome and the incidence of
cardiovascular disease. More subtle variations in Cortisol secre¬
tion and action, including variations in responses to stress, have
been described in many populations and have been related to risk
factors for occlusive vascular disease, mood, development in
early life, gender, age, etc. (43-45). We now suggest that effects
ofCortisol on angiogenesis could explain the links between these
quantitative traits in the population and the health outcomes
from vascular disease and, perhaps, from other diseases involv¬
ing angiogenesis, including neoplasia. If so, then therapies, which
reduce glucocorticoid action within ischemic tissue, may be
valuable in improving collateral perfusion. This result cannot be
achieved safely with systemic antiglucocorticoid therapy that is
likely to lead to Addisonian crisis after a severe stressor such as
myocardial infarction. The role of 11/3HSD-1 described here
offers an opportunity for tissue-specific targeting of therapy.
We described the presence of 11/3HSD-1 in the vessel wall >10
years ago (16), but its importance has remained obscure. The
observations that nonselective 11/3HSD inhibitors influence
vascular tone (27, 46) can be attributed to effects on the
11/3HSD-2 isozyme that catalyses inactivation of glucocorticoids
within endothelial cells (15,22). Here, we show that regeneration
of glucocorticoids by lljSHSD-l in isolated aortae amplifies
their angiostatic effect. We found no evidence that dehydroge¬
nase 11 /3HSD-2 influences angiogenesis in vitro because the
nonselective 11)3HSD inhibitor carbenoxolone did not potenti¬
ate the angiostatic effect of corticosterone.
In vivo 110HSD-1 null mice have no obvious difference in
vascular structure in healthy tissues. Normal vascular devel¬
opment occurs in other models of altered angiogenesis in
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Fig. 3. Effect of injury on angiogenesis in mouse myocar¬
dium and skin. 04) Light microscopy (X50) of anti-von Wille-
brand factor immunostaining with fast red chromogen sub¬
strate in day 7 wild-type sham (/) and infarcted (/"/) hearts.
Scattered medium and large vessels were detected in sham
hearts. In contrast, many more vessels were observed in the
healing myocardium after infarction. Black arrows, vessels; Iv,
left ventricle, es, endocardial surface. (Scale bar: 100 /cm.) {iii)
Medium power (x 100) lightmicroscopy of hematoxylin/eosin
staining in day-7 wild-type infarcted heart. (Scale bar: 100
pm.) {iv) High power (X400) light microscopy of anti-von
Willebrand immunostaining in day-7 wild-type infarcted
heart; (Scale bar: 100 fim.) The vascularity of the infarcted
myocardium was increased and multiple vessels containing
erythrocytes were observed (black arrows indicate vessels).
(Br) Vascularity of myocardium of wild-type mouse hearts
after ligation (filled bars, n = 3-11) or sham surgery (open
bars, n = 1-6). Sham-operated animals show a constant vas¬
cularity in contrast to CCL animals in which vessel counts
increase with time, achieving a maximum at day 7. (Bii) Day-7
hearts from wild-type and 11 (3HSD1 -/- mice. Ligation (filled
bars) in wild-type and 11/3HSD1 -/- increased angiogenesis
in comparison to sham (open bars) (wild type, n = 6 sham and
n = 11 ligations; 11 /3HSD1 —/—, n = 5 sham and n = 10
ligations). Ligations in mice that received RU38486 (dark gray
bars, n = 6) induced greater myocardial anqioqenesis in com¬
parison to vehicle-treated ligated controls (light gray bars, n =
3). Results are mean ± SEM. #, P< 0.001 versus corresponding
sham. *«*, P < 0.001 for differences between wild-type and
11HSD1 P < 0.02 for differences between coronary
artery ligated wild-type mice treated with RU38486 orvehicle.
(O Identification of blood vessels in 7-day-old cutaneous
wounds from wild-type mice stained with hematoxylin/eosin
(/) or an antibody against von Willebrand factor (//). (Magni¬
fication: X400; scale bars: 100 p.m.)
which the abnormality is apparent only in adult pathology (47),
thus reflecting the distinct pathways underlying vasculogenesis
and adult angiogenesis. However, when angiogenesis is stim¬
ulated in adult mice, we found that 11/3HSD-1 amplifies the
angiostatic effect of endogenous glucocorticoids. In s.c.
sponge implants, this effect is local, rather than systemic,
because angiogenesis in contralateral sponges was unaffected.
Moreover, Cortisol concentrations in the sponges were lower
after impregnation with cortisone than with Cortisol, suggest¬
ing that it is the generation of Cortisol locally within the cells
that express 11/3-HSD1, rather than levels of Cortisol in the
interstitial fluid of the sponge, which determines the angio¬
static effect. Finally, the relevance of 11/3HSD-1 was con¬
firmed by the demonstration that 11/3HSD-1 null mice exhibit
greater angiogenic responses in wounds and infarcted myo¬
cardium. In these studies, immunohistochemical localization
of vWF enabled quantification of large- and medium-sized
vessels (35) but not the entire population of endothelial cells
in a section. Thus, all of the vessels included in the quantifi¬
cation are likely to be functional.
It is possible that these observations reflect 11|3HSD-1
activity either within the vessel wall or in the inflammatory
infiltrate that accompanies angiogenesis in all of these in vivo
models. llj3HSD-l is expressed in macrophages (48), and
regeneration of glucocorticoids enhances phagocytosis of apo-
ptotic neutrophils (49), hence absence of 11/3HSD-1 may
confer a prolonged and enhanced acute inflammatory re¬
sponse that, in turn, might stimulate angiogenesis. However,
11/3HSD-1 in the inflammatory infiltrate cannot explain the
influence of 11J3HSD-1 in isolated aortic rings. The findings in
the isolated aortic ring model confirm that vessel wall
11/3HSD-1 moderates the angiostatic influence of glucocorti¬
coids and confirms that regeneration of active glucocorticoids
within vascular smooth muscle cell can inhibit angiogenic
processes. Although the in vivo models validated the isolated
aortic ring findings, it is apparent nonetheless that inflamma¬
tory cytokines induce 110HSD-1 expression in a variety of cell
types (13), including in vascular smooth muscle cells (23), so
that the contribution of 11/3HSD-1 within the vessel wall may
be intimately related with the extent of the inflammatory
response.
Angiogenesis is crucially dependent on endothelial cells
producing key factors such as vascular endothelial growth
factor (VEGF) and forming a de novo collagen basement
membrane to allow structured cell proliferation (24). In the
chick chorioallantoic membrane, glucocorticoids alter endo¬
thelial cell morphology and collagen production (7, 9). It has
also been proposed that glucocorticoid effects are mediated by
inhibition of endothelial VEGF transcription and endothelial
nitric oxide production (19, 50). However, in keeping with a
role for 11/3HSD-1, the effect of glucocorticoids may be
mediated within vascular smooth muscle, where inhibition of
matrix metalloproteinase production (51) may alter the effi¬
cacy of endothelium-dependent new vessel formation, and
antiproliferative effects (20) may attenuate formation of vessel
walls around endothelial cell buds.
In contrast to the established effects of supraphysiological
concentrations of glucocorticoids, the influence of endoge¬
nous glucocorticoids on angiogenesis has until now remained
unclear. The current findings in vitro and in vivo confirm a
physiological role for endogenous glucocorticoids to regulate
angiogenesis and highlight the significance of vascular
11/3HSD-1 in modulating this effect. The wider relevance of
these findings to pathology is illustrated in the models of
wound healing and myocardial infarction. These findings may
lead to therapeutic approaches to enhance angiogenesis by
preventing glucocorticoid action. Although systemic glucocor¬
ticoid receptor blockade is unlikely to be successful as a
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treatment in the short term (because of adverse effects of
preventing the normal cortisol-dependent stress response) or
in the long term (because of compensatory activation of the
hypothalamic pituitary adrenal axis), the current data suggest
that manipulation of local 11/3HSD-1 offers a more targeted
approach to the blood vessel wall. 11/3HSD-1 inhibitors are
already being developed for reducing risk factors for cardio¬
vascular disease (45), including in type 2 diabetes mellitus and
obesity. These results suggest that pharmacological inhibition
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Abstract. The ability of glucocorticoids to directly alter
arterial function, structure and the inflammatory re¬
sponse to vascular injury may contribute to their well-es¬
tablished link with the development ofcardiovascular dis¬
ease. Recent studies have emphasised the importance of
tissue-specific regulation of glucocorticoid availability
by the 11 /Thydroxysteroid dehydrogenase (11HSD) iso¬
zymes, which inter-convert active glucocorticoids and
their inactive metabolites. The expression of both type 1
and type 2 1 lFISDs in the arterial wall suggests that pre-
receptormetabolism ofglucocorticoidsmay have a direct
impact on vascular physiology. Indeed there is evidence
that 1 lHSDs influence glucocorticoid-mediated changes
in vascular contractility, vascular structure, the inflam¬
matory response to injury and the growth of new blood
vessels. Hence, inhibition of 11HSD isozymes may pro¬
vide a novel therapeutic target in vascular disease.
Key words. 11 /J-Hydroxysteroid dehydrogenase; inflammation; vascular contractility; angiogenesis; cardiovascular
disease.
Introduction
There is increasing evidence that direct interaction ofglu¬
cocorticoids with the vascular wall [1, 2] contributes to
their association with increased risk of cardiovascular
disease [3,4], Certainly, glucocorticoids can interact both
with endothelial (EC) and with vascular smooth muscle
(VSMC) cells, and furthermore, glucocorticoid-mediated
enhancement of vascular contractility has been impli¬
cated in the development ofhypertension [5]. In addition,
glucocorticoids may directly modify new blood vessel
formation and vascular lesion development by inhibiting
inflammation, proliferation and angiogenic pathways in
the arterial wall [6, 7].
Interaction of glucocorticoids with the vasculature is un¬
likely to be regulated solely by circulating concentrations
of these steroids; pre-receptor metabolism within target
* Corresponding author.
tissues also has a profound influence on glucocorticoid
activity. Such tissue-specific modulation of glucocorti¬
coid activity, regulated by the isozymes of 11 /3-hydroxy-
steroid dehydrogenase (11HSD) [8], has a key role, for
example, in the development ofhypertension, obesity and
the metabolic syndrome [9-11]. It is likely that pre-re-
ceptor metabolism of glucocorticoids influences steroid
action within the vessel wall since both isozymes of
11FISD are expressed in vascular cells [12], This article
reviews the current evidence that vascular 1IHSD ex¬
pression influences glucocorticoid-mediated changes in
vascular growth, function, structure and the inflamma¬
tory response to vascular injury.
Glucocorticoid signalling in the vascular wall
Glucocorticoids (Cortisol in man, corticosterone in ro¬
dents) are predominantly synthesised in, and released
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from, the adrenal cortex. Circulating concentrations of
these steroids are under the control of the hypothalamic-
pituitary-adrenal (HPA) axis, whilst their bioavailability
is regulated by interaction with corticosteroid-binding
globulin (CBG) and albumin in the plasma. The small
proportion of unbound, circulating hormone is able to
cross the cell wall and interact with corticosteroid recep¬
tors. Classically, glucocorticoids interact with the cytoso-
lic glucocorticoid receptor (GR, or corticosteroid recep¬
tor type II). As described below, glucocorticoids may also
activate mineralocorticoid receptors (MR, or corticos¬
teroid receptor type I), but this occurs only in a few tis¬
sues. GR and MR are members of the nuclear hormone
receptor superfamily of ligand-activated transcription
factors [13]. Activation ofGR results in binding of recep¬
tor homodimers to glucocorticoid response elements in
target genes, leading to initiation or repression of tran¬
scription. There is also increasing evidence that gluco¬
corticoids exert specific, non-genomic actions. Examples
exist of rapid glucocorticoid-induced changes to phos-
pholipase A2 (PLA2) and phosphoinositide-3-kinase-me-
diated endothelial nitric-oxide synthase (eNOS) release
that are blocked by GR antagonism but not by inhibition
of transcription [14, 15]. These non-genomic effects are
thought to be mediated by membrane-bound GR [16]
(mGR; although the specific signalling pathways associ¬
ated with these receptors have not been established) or by
cytosolic GR (cGR) without requirement for either nu¬
clear translocation or effects on transcription. In the latter
case, chaperones or co-chaperones (such as Src) act as
signalling components and, therefore, mediators of glu¬
cocorticoid-induced effects [17].
Corticosteroid receptors are present in the cells of the
vascular wall, supporting the idea that glucocorticoids in¬
teract directly with the vasculature. Cytosolic MR and
GR have both been demonstrated in freshly isolated ves¬
sels [18, 19] and in cultured vascular cells (VSMCs [20,
21] and ECs [22-26]) from a variety of species. The dis¬
tribution of these receptors may vary with vascular terri¬
tory, as MR were detected in rabbit aortic and pulmonary
VSMCs but not in small arteries [27]. Vascular GR are
known to be active as antagonism (with RU38486)
blocked dexamethasone-mediated induction ofACE ac¬
tivity in rat aortic ECs [28], Similarly, activity ofMR is
demonstrated by their contribution to angiotensin Il-in-
duced hypertrophy of VSMCs [29] and aldosterone-in-
duced swelling of ECs [22]. It has not been established
whether membrane binding sites for corticosteroids are
present, or have a role, in the vascular wall.
The downstream effects of GR activation within the arte¬
rial wall, and their influence on cardiovascular risk fac¬
tors (such as hypertension), are imperfectly understood
[5]. Glucocorticoids are essential for maintenance of
blood pressure in healthy individuals [1], whilst their
ability to increase peripheral vascular resistance in ani¬
mals devoid of renal mass indicates that a non-renal
mechanism contributes to glucocorticoid-induced hyper¬
tension [30]. A considerable body of evidence suggests
that this non-renal mechanism may involve direct gluco-
corticoid-mediated alteration of EC and VSMC function
[1], Consequently, regulation ofglucocorticoid availabil¬
ity by 11 USDs within the vascular wall may be an impor¬
tant influence on cardiovascular physiology and pathol¬
ogy.
Tissue-specific metabolism of glucocorticoids
by 11 /1-hydroxysteroid dehydrogenases
The 11 HSDs, microsomal enzymes of the short-chain al¬
cohol dehydrogenase superfamily [8], interconvert active
glucocorticoids and their inert 11-keto forms [31]. Two
isozymes, 11HSD1 and 11HSD2, have been identified:
11HSD1 is a low-affinity NADP(H)-dependent, predom¬
inant reductase in vivo. Dehydrogenase activity of this
isozyme is generally not seen in intact cells or organs (in¬
cluding liver [32-34], adipose tissue [35], neurons [36]
and vascular smooth muscle [37]); early suggestions of
11IISD1 dehydrogenase activity in vascular smooth mus¬
cle [38] are probably attributable to 11HSD2 [37].
11HSD1 dehydrogenase activity observed in some prepa¬
rations in vitro [39] is probably attributable to release of
enzyme from damaged or dying cells, with dissociation
from hexose-6-phosphate dehydrogenase, which is
thought to maintain the high NADPH concentrations re¬
quired for reductase activity [40]. 11HSD1 has a Km in
the micromolar range for both Cortisol and corticosterone
[41 ] and is widely expressed in glucocorticoid-target tis¬
sues (including liver, lung, adipose tissue, brain, vascular
smooth muscle, skeletal muscle, anterior pituitary, go¬
nads and adrenal cortex [8]), where its role is to amplify
local glucocorticoid concentrations [42]. Regulatory con¬
trol of 11IISD1 is complex, with its synthesis and activ¬
ity influenced by a variety of factors (such as glucocorti¬
coids [43-45], stress [46, 47], sex steroids [48], growth
hormone [49], cytokines [50] and peroxisome prolifera-
tor-activated receptor agonists [8]) and its activity driven
in the reductase direction through local generation of
NADPII by hexose-6-phosphate dehydrogenase [51],
Other factors that may drive 11HSD1 activity in the re¬
ductase direction include the cellular environment, co-
factor availability, redox potential and substrate concen¬
tration.
11HSD2, by contrast, is a high-affinity NAD-dependent,
exclusive dehydrogenase, which converts active gluco¬
corticoids into inactive 11-ketosteroids and has a Km for
Cortisol and corticosterone in the nanomolar range. It is
found primarily in mineralocorticoid target tissues, such
as the kidney, sweat glands, salivary glands and colon 8],
where it is constitutively active and serves to protect MR
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from illicit occupation by glucocorticoids. Inhibition of
11HSD2 with liquorice or its derivatives results in gluco-
corticoid-dependent 'apparent' mineralocorticoid excess
and hypertension [52]. Similarly, transgenic disruption of
11HSD2 [9] in mice, or congenital deficiency in man
[53], recapitulates the major features of the syndrome of
apparent mineralocorticoid excess (SAME). The impor¬
tance of 11HSD2 in SAME was demonstrated by the de¬
scription of a defect in Cortisol metabolism in children
with this syndrome [54]; this was later shown to be the re¬
sult ofmutations in the 11HSD2 gene [55, 56]. 11HSD2
is also expressed in tissues which are not classic MR tar¬
gets, including the lung, lymph nodes, heart, blood vessel
wall and placenta) [57-59]. In the placenta 11HSD2 acts
to protect the foetus from excessive exposure to maternal
glucocorticoids [60, 61], whereas cardiac 11HSD2 activ¬
ity may have a role in preventing fibrosis resulting from
stimulation ofMR by glucocorticoids [62],
The influence of 11HSD isozyme activity on cardiovas¬
cular physiology and pathophysiology is well recognised
(see Krozowski and Chai for review [63]), but details of
the role of 11 USDs within the vessel wall have emerged
only recently and remain somewhat uncertain.
Intra-vascular glucocorticoid metabolism
Both isozymes of 11HSD are expressed in the blood ves¬
sel wall, suggesting that they could influence vascular
function by regulating local availability of active gluco¬
corticoids [1, 64], The cellular distribution of vascular
11HSD1 and 11HSD2 is not completely clear. Our stud¬
ies using mouse and rat aorta suggest that 11HSD2 is lo¬
calised to ECs, whereas 11HSD1 is predominantly in the
VSMC (fig. 1) [18, 65]. Others, in contrast, have reported
activity of both enzymes in the VSMC [37, 50] and also
in the EC [66], it should be noted that the latter investiga¬
tion [66] demonstrated only 11HSD1 in rat VSMC and
indicated that 11HSD1 was the predominant isozyme in
the endothelium. Direct comparison of studies is often
difficult, given the use of arteries from different species
and anatomical locations combined with a variety of
techniques for detecting llHSDc. The balance of the
literature suggests that cellular distribution of 11 HSD
isozymes differs in vessels from distinct anatomical loca¬
tions and that 11HSD activity increases as artery diame¬
ter diminishes; in the rat 11HSD, activity was greater in
resistance (mesenteric) arteries than in conduit vessels
(aorta) [65] and in the mouse 11 /3-reductase activity was
higher in iliofemoral arteries than in the aorta [A. R.
Dover et al., unpublished data]. These variations in cellu¬
lar distribution and activity suggest that the role of intra¬
vascular glucocorticoid metabolism is not the same in all
blood vessels.
There is increasing evidence that interconversion of ac¬
tive and inactive glucocorticoids by vascular cells may in¬
fluence glucocorticoid-mediated modulation of vascular
function, structure, growth and inflammation.
Glucocorticoids, llHSDs and vascular function
Although it is well established that glucocorticoids con¬
tribute to maintenance ofvascular tone in vivo, the mech¬
anisms have been difficult to establish. A variety of inter¬
actions contribute to homeostasis, including glucocorti¬
coid-mediated regulation of cardiac output and fluid and
electrolyte balance, with salt and water handling modu¬
lated both directly [67] and indirectly by influences on the
production of angiotensinogen (liver), arginine vaso¬
pressin (AVP; hypothalamus) [68] and atrial natriuretic
peptide (ANP; cardiac myocytes) [69]. It is apparent,
however, that these cardiac and renal effects cannot ac¬
count totally for the glucocorticoid-mediated increase in
blood pressure, and there is evidence that a component of
hypertension arises from enhanced contractility of the
vascular wall [70-72]. For example, reversal of adreno-
corticotophin-dependent hypertension by administration
of 1-arginine (the substrate for nitric oxide synthase) sug¬
gests that nitric oxide deficiency contributes to the eleva¬
tion ofblood pressure [73, 74].
Glucocorticoid-dependent potentiation of noradrenaline-





Figure 1. Presence and distribution of 11HSD isozymes in the vas¬
cular wall. In situ hybridisation (Ai) and immunohistochemistry
(AH) confirming both expression and activity of 11HSD1 within the
rat aortic wall; the enzyme was predominantly localised to medial
smooth muscle cells (left-hand panel, sense/control; right hand-
panel, antisense/antibody to 11HSD1). Immunohistochemistry de¬
monstrating (B) 11HSD1 in rat mesenteric artery smooth muscle
and (C) 11HSD2 in human intra-renal artery endothelium [unpub¬
lished], Reproduced from [65] with permission. © The Endocrine
Society, 1991.
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tributed to alterations within the VSMC and the EC (re¬
viewed in Walker and Williams [2] and Ullian [1]). Given
that glucocorticoids can act on both MR and GR, the in¬
creased contractility observed in many studies may be
secondary to increased stimulation of either receptor. Al¬
terations identified within the VSMC (including upregu-
lation of contractile receptors, altered intracellular sec¬
ond messenger activation and modulation of the activity
and synthesis of vasoactive substances) result in a direct
enhancement of contraction [1], In contrast, changes in
the endothelium can increase contractility in two distinct
ways: by increased release of vasoconstrictor compounds
(e.g. angiotensin II, endothelin-1 [75, 76]) from the ECs
and by impaired endothelium-mediated relaxation. Loss
of endothelium-mediated relaxation [77], caused by im¬
paired activity of vasodilators (e.g. prostaglandins, nitric
oxide) [78-80], [reduces the ability of the endothelium to
modulate contraction.
An alternative mechanism through which glucocorticoids
may regulate vascular function is 'foetal programming' of
physiological responses [81]. Exposure of the foetus to
excess maternal glucocorticoid (either by direct infusion
or by inhibition of placental 11HSD2) causes reduced
birth weight [82], an outcome associated with increased
risk of cardiovascular and metabolic disease in adulthood
[83], Two major causes of low birth weight, maternal di¬
etary restriction and maternal stress, may also be gluco-
corticoid-dependent [84, 85]. In the ovine foetus, gluco¬
corticoid infusion elevates blood pressure and alters vas¬
cular contractility in foetal sheep [86]; this may be
significant, as one outcome of foetal programming is el¬
evated blood pressure in adult offspring [87]. However,
although enhanced vascular contractility has been
demonstrated in rats with programmed hypertension, it is
not clear whether this contributes to the elevation of
blood pressure [88, 89]. Furthermore, the mechanisms
through which pre-natal exposure to excess glucocorti¬
coid programme enhance contractility in adult offspring
have not been established.
Influence of llHSDs on vascular function
In SAME, 11HSD2 deficiency results in sodium reten¬
tion and severe hypertension, mediated in part by gluco-
corticoid-dependent activation of MR in the distal
nephron [90], There is, however, a considerable literature
to suggest that changes in 11HSD activity within the vas¬
cular wall also contribute to elevation of blood pressure.
A clear example of this is the demonstration that 11HSD
activity is impaired in arteries taken from rat models of
hypertension [91-93]. A role for altered vascular function
is supported by reports that 11HSD inhibition (with gly-
cyrrhetinic acid) in rats produced an elevation of blood
pressure which, whilst mediated by MR activation, was
blocked by antagonists of the endothelin-1 system [94,
95]. Moreover, studies of dermal vasoconstriction in pa¬
tients exposed to liquorice, and in a single individual with
SAME [53, 96], demonstrated enhanced cortisol-medi-
ated constriction (fig. 2). The possibility that this is due
to changes in glucocorticoid metabolism within the vas¬
cular wall, rather than indirect systemic effects of sodium
retention, gained further credence with in vitro studies
which showed that bile acids (e.g. chenodeoxycholic
acid), which are endogenous inhibitors of 11HSD [97],
pharmacological inhibitors of 11HSD (carbenoxolone,
glycyrrhetinic acid) [98, 99] and isozyme selective anti-
sense oligonucleotides [100] alter corticosterone-medi-
ated enhancement of vasoconstriction. Furthermore,
11 HSD inhibition (with glycyrrhetinic acid) augmented
corticosterone-induced dysfunction in cultured human
ECs, indicating both a role for intra-cellular 11HSD and
independence from blood pressure elevation in vivo [95].
Care is required in interpreting these results, however,
as some 11HSD inhibitors can directly alter contractile
function by damaging the endothelium [101].
These pharmacological studies have been extended by the
use of arteries from 11HSD knockout mice. Aortic func¬
tion (and blood pressure) are unaltered in 11HSD1
mice suggesting that intravascular regeneration of active
glucocorticoids has no effect on vascular contractility
[102, 103]. This indicates that despite the ability of glu¬
cocorticoids to enhance vascular contraction, impaired
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Figure 2. The effect of congenital and acquired 11HSD deficiency
on dermal vasoconstrictor sensitivity to Cortisol and beclometha¬
sone dipropionate. Inhibition of 11 HSD activity with liquorice-en¬
hanced dermal vasoconstriction (measured by skin blanching) in re¬
sponse to Cortisol but not to beclomethasone diproprionate. A sim¬
ilar result was obtained in a patient (GB) with the syndrome of
apparent mineralocorticoid excess type 1 (11HSD2 deficiency).
These data indicate that local regulation of glucocorticoid activity
in the vascular wall contributes to contractile tone. Bars are s.e. NS,
not significant. Reproduced from [53] with permission. © The Bio¬
chemical Society, 1992.





Figure 3. Effect of (a) transgenic deletion of 11HSD2 and (b) ex¬
posure to glucocorticoids on mouse aortic endothelial cell function.
In aortic rings isolated from control mice (squares), release of en-
dothelium-derived nitric oxide acts as a physiological antagonist of
noradrenaline-mediated contraction; thus, removal of the endothe¬
lium (open symbols) results in enhanced contraction. In aortae from
11HSD2^ mice (a; triangles) this ability of the endothelium to
modulate contraction has been lost, suggesting glucocorticoid-me-
diated impairment of endothelial cell function. This is contested,
however, by the demonstration that (b) in vitro incubation (24 h, 37
°C; 10~7M corticosterone) ofaortic rings from control animals with
glucocorticoids (circles) did not produce a similar endothelial cell
dysfunction. Values are mean ± s.e. mean; n=8. Adapted with per¬
mission from [103] and [18]. © Lippincott, Williams and Wilkins.
duce contractile function. In contrast, enhanced contrac¬
tility was demonstrated in thoracic aortae from mice lack¬
ing 11HSD2 as a result of impaired endothelium-derived
NO activity [103], rather than changes in the VSMC
(fig. 3a). This suggests that 11HSD2 activity in the en¬
dothelium may serve to protect endothelium-dependent
relaxation from the detrimental effects of glucocorti¬
coids. This appears to be consistent with in vivo studies
which suggest that non-selective inhibitors of both iso¬
zymes of 11 USDs, such as liquorice derivatives, potenti¬
ate rather than impair the vascular actions of glucocorti¬
coids, suggesting inhibition of inactivation rather than re¬
activation of steroids within the vessel wall. More recent
data, however, suggest that the concept of protection of
ECs by 11HSD2 may be an oversimplification. In mouse
aortic rings, we could not induce EC dysfunction by in¬
cubating isolated rings with glucocorticoids (fig. 3b),
even in the absence of 11HSD2 [18]; whether dehydroge¬
nase activity of 11HSD1 [38] served to protect the en¬
dothelium is not clear, although our data suggest that
11HSD1 does not act as a dehydrogenase in intact arteries.
This raises the possibility that in vivo differences in vas¬
cular function in 11HSD2 knockout mice are dependent
on indirect mechanisms, e.g. related to hypertension or
sodium retention. Cell-specific manipulation of llHSDs
would be the most attractive means to dissect this biology
further, but has yet to be reported for vascular cells.
Glucocorticoids, llHSDs and vascular inflammation
Whereas studies in transgenic mice have suggested that
11HSD2 activity may influence vascular function, whilst
11HSD1 does not, a much clearer role for 11HSD1 has
been identified in regulation of vascular inflammation.
The anti-inflammatory and immunosuppressive effects of
glucocorticoids, which account for their most common
therapeutic applications, are due to GR-mediated interac¬
tions with blood vessels, inflammatory cells and media¬
tors of inflammatory responses [104]. For example, glu¬
cocorticoids decrease expression of adhesion factors, cy¬
tokines and chemokines, and so alter the recruitment of
immune cells such as neutrophils and macrophages to
sites of inflammation. This also results in a decrease in
leukocyte activation and proliferation. Furthermore, the
glucocorticoid receptor mediates lymphocyte apoptosis
[105] and suppresses the synthesis of inflammatory me¬
diators (e.g. prostanoids), and hydrocortisone stimulates
the synthesis of anti-inflammatory mediators (e.g. lipo-
cortins) [106]. Glucocorticoids, but not mineralocorti-
coids, can also promote the phagocytosis of apoptotic
leukocytes [107], and so contribute to the resolution of
inflammation. The expression of 11HSD1 inVSMCs [50]
and in activated macrophages [ 108] suggests that genera¬
tion ofglucocorticoid within these cells may contribute to
regulation of inflammation.
Influence of 1 lHSDs on vascular inflammation
The demonstration that pro-inflammatory cytokines se¬
lectively upregulate 11HSD1 activity in human VSMCs
suggests that glucocorticoid generation within the vascu¬
lar wall provides a mechanism for local feedback regula¬
tion of inflammation [50]. However, this has not been ex¬
amined in vivo. The ability of inflammatory mediators to
regulate 11FISD activity in VSMCs may be dependent
upon the phenotypic state of the cells (with enzyme ac-
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tivity upregulated in actively proliferating, but not in qui¬
escent, cells), the anatomical origin of a particular vessel,
the prevailing local glucocorticoid concentrations and the
modulation of the inflammatory response by neighbour¬
ing tissues [A. R. Dover et al., unpublished data]. Further
work is required to clarify the significance of cytokine-
mediated regulation of 11HSD1 in arterial cells, particu¬
larly given the importance of inflammation in the vascu¬
lar response to injury [109],
Alternatively, 11HSD1 may regulate inflammation by
controlling generation of glucocorticoids within the in¬
flammatory cells. Certainly, the ability of inflammatory
cytokines to upregulate 11HSD1 activity in activated hu¬
man macrophages [108] suggests, as in human VSMC
[50], a means of feedback regulation of inflammation
within these cells.
Glucocorticoids and vascular remodelling
The term 'vascular remodelling' has been used to cover a
range of structural changes in the arterial wall, and its
correct definition is the subject of debate (for review see
Bund and Lee [110]). In this review, the term 'vascular re¬
modelling' encompasses medial hypertrophy (thickening
of the vessel wall caused by increase in cell size) and hy¬
perplasia (thickening of the cell wall caused by an in¬
crease in cell number), as well as the intimal remodelling
seen in neointimal proliferation and the development of
atherosclerotic lesions. It has also been extended to in¬
clude angiogenic growth of new blood vessels.
The relationship between glucocorticoids and arterial re¬
modelling is well-established; for example, one year fol¬
lowing remission, patients with Cushing's syndrome
show reduced intimal/medial thickness and increased lu¬
men diameter in the carotid artery [111]. It should be
noted, however, that remodelling may be the indirect re¬
sult of systemic changes (e.g. increased blood pressure)
rather than direct interactions ofglucocorticoids with the
vessel wall. Glucocorticoids may induce vascular remod¬
elling by altering expression of genes for relevant growth
factors or by inhibiting processes that modulate growth
factor activity. For example, dexamethasone induces a
GR-dependent upregulation of endothelin-1 expression
[76], and Cortisol attenuates the activity of nitric oxide
[77] (itself a potent inhibitor of cell growth). Similarly,
dexamethasone- and hydrocortisone-mediated increases
in ACE activity in VSMCs [112] and ECs [75] may en¬
hance local generation of angiotensin II (a stimulant of
VSMC growth both in vitro [113] and in vivo [114]).
Hypertrophy
Vascular hypertrophy in rats exposed to mineralocorti-
coids, predominantly deoxycorticosterone acetate, and
salt [115] has been attributed to upregulation of the en-
dothelin-1 gene [116]. Similarly, glucocorticoids (dex¬
amethasone, hydrocortisone) have the ability to induce
vascular hypertrophy by augmenting the production of
[112, 117], and hypertrophic response to [118, 119], an¬
giotensin II. The significance of this hypertrophy is un¬
clear, however, as many investigations that demonstrate
enhanced vascular contractility in response to corticos-
terone involved a duration of exposure that would be in¬
sufficient for vascular hypertrophy to occur [120]. Fur¬
thermore, glucocorticoid-mediated stimulation of growth
in the vascular wall is counterintuitive given that dexam¬
ethasone inhibits VSMC growth in culture [121-123] and
glucocorticoids prevent neointimal hyperplasia (see be¬
low). Thus, the direct influence ofglucocorticoids on vas¬
cular hypertrophy/hyperplasia is unclear, and any role of
local glucocorticoid metabolism by llHSDs in the pro¬
cess has yet to be investigated.
Neointimal proliferation
The development of neointimal lesions (e.g. in athero¬
sclerosis and in restenosis following revascularisation) is
a consequence of an excessive wound healing response in
the vessel wall [124,125]. Vascular injury results in infil¬
tration by inflammatory cells and subsequent migration
and proliferation ofVSMCs [109]. Consequently, inhibi¬
tion of either the inflammatory response [126] or VSMC
proliferation/migration [127] inhibits lesion development
in a variety of models. Since glucocorticoids (dexam¬
ethasone) can inhibit inflammation and VSMC prolifera¬
tion [121-123] and migration [128], it is not surprising
that their potential as anti-atherosclerotic [129] and anti-
restenotic agents [130] has been investigated [6]. It is also
possible, however, that the action of glucocorticoids on
the vessel wall is deleterious in patients with vascular dis¬
ease. For example, given that ACE inhibition limits
neointima formation following balloon injury [131, 132],
stimulation ofACE activity by dexamethasone [75, 112]
could exacerbate lesion development. Also, inhibition of
endothelium-derived nitric oxide activity by glucocorti¬
coids could increase bothVSMC proliferation and vascu¬
lar contraction. Further, the systemic effects of glucocor¬
ticoids on cardiovascular risk factors (glucose, insulin,
lipids and blood pressure) may offset beneficial effects
within the vessel wall.
Dexamethasone reduces cholesterol ester accumulation
in the aorta [133], and glucocorticoids (dexamethasone,
hydrocortisone) inhibit neointimal lesion formation in
rats [134, 135], rabbits [136-138] and dogs [139] (with a
few contradictory reports [140, 141]). Clinical trials in
humans, by contrast, have proved disappointing (with no¬
table exceptions [130]): methylprednisolone did not in¬
hibit restenosis after coronary angioplasty [142] or stent
implantation [143], whilst the combination of a glucocor-
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ticoid with colchicine increased the risk of coronary
aneurysm following stent placement [144], Discrepan¬
cies between clinical studies and animal models could be
attributed to species differences or, more probably, to
methodological variation (e.g. small sample size; inap¬
propriate patient selection, dose, duration of treatment,
route of administration). Exacerbation of lesion develop¬
ment by glucocorticoids could be explained by systemic
effects (e.g. weight gain with elevated blood pressure and
plasma lipids, which may be more prominent in humans
than in other species) or by a net stimulation of vascular
cell proliferation. Alternatively, changes in plasma lipids
could influence the ability of glucocorticoids to interact
with vascular cells. Lipoprotein(a) can downregulate GR
gene expression in human VSMCs, thus inhibiting any
protective actions of glucocorticoids and, possibly, repre¬
senting a novel atherogenic mechanism [145].
Angiogenesis
Angiogenesis, in which new blood vessels are formed
from an existing vascular network, is a complex process
regulated by a balance between counteracting endoge¬
nous activators and inhibitors [146]. Physiological angio¬
genesis is an essential component of reproduction and
embryonic development. In postnatal and adult life, it is a
discrete process (e.g. in the reproductive tract, wound
healing and exercised skeletal muscle) of relatively short
duration [147]. In contrast, pathological angiogenesis is
usually persistent and unabated and often continues for
months or years [147]. Numerous disorders are charac¬
terised by excessive angiogenesis, including neoplasia,
rheumatoid arthritis and diabetic retinopathy [148], Con¬
sequently, modulation of angiogenesis is regarded as an
attractive therapeutic goal in a variety of conditions.
A comprehensive review of the mechanisms of angiogen¬
esis is beyond the scope of this article (for recent reviews
see [146, 149]). For the present purposes it is useful to
consider angiogenesis to be a stepwise process compris¬
ing four distinct phases: (i) basement membrane disinte¬
gration, (ii) endothelial cell migration, (iii) channel for¬
mation and (iv) maturation. Of the numerous factors that
control this process, vascular endothelial cell growth fac¬
tor (VEGF) is widely considered to be of central impor¬
tance, since it is crucial for vascular development both in
the embryo and in adult tissues and it is EC specific.
Since its first demonstration by Folkman and colleagues,
over 20 years ago [150], the ability of glucocorticoids to
inhibit angiogenesis has been confirmed in vitro, in vivo
and in tumour-bearing animals [150]. It was suggested
that inhibition of angiogenesis in the rabbit cornea
was independent of classical GR and MR activity [151].
For example, 17a-hydroxyprogesterone and tetrahydro-
S, which have no glucocorticoid or mineralocorticoid ac¬
tivity, retained an anti-angiogenic capability equivalent
to, or greater than, that of hydrocortisone. Taken together,
these studies demonstrated a class of steroids for which
inhibition of angiogenesis appears to be the principal
function and hence were named 'angiostatic steroids.'
[151].
Despite considerable research, the mechanisms through
which glucocorticoids inhibit angiogenesis have not been
identified. Indeed, the role of GR is still controversial, as
some of the 'angiostatic steroids' may actually have the
ability to stimulate these receptors. For example, we have
recently shown that inhibition ofangiogenesis by tetrahy-
drocorticosterone, one of the original angiostatic ster¬
oids, is dependent upon GR activation in mouse aortic
ring explants [G. R. Small et al., unpublished]. Some in¬
dication of mechanism was provided by early studies
which demonstrated, using nude mice or the non-antico¬
agulant hexasaccharide fragment of heparin, that the
combination of glucocorticoid and heparin was indepen¬
dent of an immune response and anti-coagulant function,
respectively [150]. At present, however, there are still sev¬
eral possible pathways through which glucocorticoids
may inhibit angiogenesis: (i) Degradation of extracellular
matrix, (ii) modification of cytokine production, (iii) in¬
hibition of protease activity, (iv) impairment of vessel
maturation and stabilisation, (v) inhibition ofgrowth fac¬
tor activity, (vi) inhibition of the arachidonic acid cas¬
cade, (vii) inhibition of EC-leukocyte interactions and
(viii) non-transcriptional effects. The relative signifi¬
cance of these pathways has not been established.
llHSDs and vascular remodelling
Although the initial focus was on 11HSD2 and vascular
function, the most recent work in the field of intra-vascu-
lar glucocorticoid metabolism has highlighted novel roles
for 11FISD1 in influencing vascular structure and remod¬
elling.
Neointimal remodelling and atherogenesis
The potential link between atherosclerosis and tissue-
specific generation of glucocorticoids by llHSDs has
been underlined by recent demonstrations that selective
upregulation of 11HSD1 in the adipose produces features
of the metabolic syndrome, including central obesity, hy¬
pertension and hypertriglyceridaemia [10,152]. This sup¬
ports the concept that similarities between the metabolic
syndrome and Cushing's syndrome are explained by tis¬
sue-specific increases in 11HSD1 activity resulting in tis¬
sue-specific elevation ofglucocorticoid generation [153].
This link between 11HSD1 activity in glucocorticoid-tar-
get tissues and atherosclerotic risk factors is not limited
to the adipose, as hepatic overexpression of 11FISD1 also
results in elevated blood pressure and dyslipidaemia
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[154]. It has been proposed, therefore, that 11HSD1 inhi¬
bition may reduce atherogenesis. Very recently, systemic
administration of a selective 11HSD1 inhibitor was re¬
ported to virtually abolish lipid accumulation in the aorta
of atherosclerotic (apolipoprotein E/_) mice. However,
inhibition of 11HSD1 in ApoE ' mice produced only a
relatively modest reduction in serum triglycerides and
cholesterol [155], suggesting that mechanisms over and
above amelioration of systemic cardiovascular risk fac¬
tors may be responsible. It may be that inhibition of
11HSD1 within the vessel wall orwithin invading macro¬
phages [156] is crucial, but these mechanisms require
further clarification.
111 ISD2-dependent protection ofMR from inappropriate
occupation by glucocorticoidsmay also influence athero¬
genesis. The role ofMR activation in the pathogenesis of
atherosclerosis [157] is demonstrated by aldosterone-in-
duced enhancement of lesion development in atheroscle¬
rotic (apolipoprotein E ') mice (probably by increasing
oxidative stress in macrophages and cells of the vascular
wall [157, 158]). This potentiation of lesion development
by aldosterone, which is largely independent of blood
pressure, is attenuated by MR antagonists [157], as is
constrictive remodelling following angioplasty [159].
The potential importance of 11HSD activity to the devel¬
opment of atherosclerotic lesions was recently extended
by the demonstration that, in addition to glucocorticoid
metabolism, llHSDs catalyse the conversion of the
atherogenic oxysterol 7-ketocholesterol to 7/S-hydroxy-
cholesterol [160]. 7-Ketocholesterol is present in micro-
molar concentrations in human atherosclerotic lesions
and in nanomolar concentrations in the plasma [161]. Its
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Figure 4. The influence of 11HSD1 on glucocorticoid-mediated angiogenesis. (A) Inmouse aortic rings cultured in Matrigel, corticosterone
and its inactive metabolite 11-dehydrocorticosterone attenuated new vessel growth. Glucocorticoid receptor antagonism (with RU38486,
filled columns) abolished the angiostatic response to both compounds (Ai), but 11HSD1 deletion (hatched columns) selectively prevented
11-dehydrocorticosterone-mediated angiostasis (Aii). Similar results were obtained in vivo, using subcutaneous sponge implants (B), with
11HSD1 deletion (hatched columns) increasing angiogenesis under basal conditions and abolishing cortisone-, but not Cortisol-, mediated
inhibition of vessel growth. This mechanism contributed to regulation ofmyocardial angiogenesis following coronary artery ligation (Q
with increased vessel growth in 11HSD l"'"mice (coronary artery ligation, shaded bars; sham, open bars), "p < 0.05 compared with relevant
vehicle-treated control; **p<0.01 compared with wild-type mice; ***p<0.001 compared with relevant wild-type control or sham-oper¬
ated mouse. Reproduced with permission from [168]. © The National Academy of Sciences of the USA, 2005.
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association with atherosclerosis is demonstrated in the
condition cerebrotendinous xanthomatosis, in which pa¬
tients who have normal circulating cholesterol levels but
increased 7-ketocholesterol develop atherosclerosis pre¬
maturely [162], Conversion of 7-ketocholesterol to 7/3-
hydroxycholesterol by 11 /3-IISD1 may represent the rate-
limiting step in a clearance pathway: in vivo inhibition of
11HSD1 in rats resulted in an accumulation of 7-ketoc-
holesterol in the liver and increased concentrations in the
plasma [163]. In addition to these hepatic effects, reduc¬
tion of 7-ketocholesterol by 11HSD1 within the vascular
wall may also be important. 7-Ketocholesterol and 7p-hy-
droxycholetserol are both toxic to cells of the vascular
wall [164] and are potent inhibitors of endothelium-de-
pendent relaxation [165-167]. Consequently, reduction
of 7-ketocholesterol, and subsequent clearance of 7/?-hy-
drocholesterol, by protecting the vascular wall from dam¬
age may have a role in preventing lesion development.
The influence of 11-HSD activity on angiogenesis
Since inflammatory cytokines can promote angiogenesis,
we hypothesised that 11 /2-HSD1 in the vessel wall may
regulate new vessel formation by controlling the local re¬
generation of active glucocorticoids. This possibly was
addressed using a combination of in vitro, in vivo and
pathological models of angiogenesis [168]. Using a
model oftube formation from mouse aortic rings cultured
in Matrigel [169], we demonstrated (fig. 4A) that angio¬
genesis was inhibited by physiological concentrations of
active glucocorticoid (corticosterone) but also by its in¬
active metabolite (11-dehydrocorticosterone). Both these
responses were blocked by RU38486, but not by spirono¬
lactone, indicating GR dependence. However, whereas
11HSD1-inhibition (with carbenoxolone) or deletion
(aortic rings from 11HSD1 ' mice) had no effect on
the response to corticosterone, they abolished the ability
of 11-dehydrocorticosterone to inhibit angiogenesis
(fig. 4B). This indicated that 11HSD1-dependent regen¬
eration of active glucocorticoid within the vascular wall
regulates new vessel growth. Application of a model
of angiogenesis in sub-cutaneous sponge implants, con¬
firmed this role for 11HSD1 in vivo, showing that
11HSD1 deletion produced increased angiogenesis in un¬
treated sponges and blocked the ability of cortisone (but
not Cortisol) to inhibit new vessel formation. The patho¬
physiological significance of these observations was em¬
phasised in healing cutaneous wounds and in the myocar¬
dial response to coronary artery ligation (fig. 4C). In both
cases, 11HSD1 deletion resulted in increased angiogene¬
sis, demonstrating that 11HSD1 regulates the growth of
new blood vessels in healing tissues.
Altered angiogenesis in 11IISD1^[168] mice could,
conceivably, be the result of changes in macrophage ac¬
tivity. Given that 11HSD1 is expressed in macrophages
[170], and regeneration of glucocorticoids enhances pha¬
gocytosis of apoptotic neutrophils [107], absence of
11HSD1 may confer a prolonged and enhanced acute in¬
flammatory response, thus stimulating angiogenesis. The
use of ex vivo models such as isolated aortic rings cul¬
tured in extracellular matrices [171] has made it possible
to differentiate between these two intimately related path¬
ways, angiogenesis and inflammation, and specifically
address the effects of glucocorticoids on angiogenesis in
the absence of a systemic response. This has produced ev¬
idence that glucocorticoids regulate angiogenesis by di¬
rect interaction with the vessel wall [168],
Conclusions
It is apparent that glucocorticoids have the ability to regu¬
late both the structure and the function of the artery wall,
with significant implications for vascular physiology and
pathophysiology. Emerging evidence suggests that pre-re-
ceptormetabolism ofglucocorticoids within vascular ECs
andVSMCs provides amechanism for regulating these in¬
teractions. Relatively few studies have addressed the role
of intravascular 11HSD activity, and most of those avail¬
able have focussed on vascular function. There is, how¬
ever, a growing body of evidence to suggest that 11HSD
isozymes within the arterial wall modulate vascular con¬
tractility the angiogenic growth ofnew blood vessels, and
the atherosclerotic process. Whether these isozymes also
influence the inflammatory response to vascular injury
and the inter-conversion of atherogenic oxysterols in vas¬
cular smooth muscle has still to be determined. Further
clarification of the role of llHSDs in vascular cells is
likely to increase our understanding of the link between
glucocorticoids and a variety of vascular diseases, and to
demonstrate their potential as therapeutic targets for treat¬
ment of these conditions.
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